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Abstract
This Comment argues that the parties to the International Conference on Harmonization of
Technical Requirements for Regulation of Pharmaceutical Drugs (ITCH) should adopt more spe-
cific guidelines for pediatric research than those included in its Good Clinical Practice Guidelines
(ICH GCP), and analyzes their attempt to do so in the Draft Guideline on Pediatric Trials. Part
I of this Comment outlines the genesis of the current international guidelines for human research
and how they relate to pediatric subjects. Part I also explains the human research guidelines of the
three principal members of the ICH. Part II describes the function of the ICH and the provisions of
the ICH GCP. Part II also discusses how the ICH GCP addresses pediatric medical research issues,
and the provisions of the new Draft Guideline on Pediatric Trials. Part III argues that the Draft
Guideline on Pediatric Trials represents a significant improvement in pediatric research guidelines,
and should be accepted by the parties to the ICH with some modifications regarding the subject’s
consent and the role and composition of international review boards.
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INTRODUCTION
In the early 1990s, thirty-six healthy children between the
ages of six and ten years old participated in a research study in
New York City.1 This study exposed its subjects to a drug that
had been removed from the market by the U.S. Food and Drug
Administration2 ("FDA") for causing death in adult patients.3 In
the course of this three-year study, researchers forced children
to fast for eighteen-hour periods and drew multiple blood sam-
ples from catheters inserted in their veins.4 This process left
some of the children feeling nauseous and complaining of head-
aches.5
Researchers exposed the children in this study6 to doses of
the diet drug fenflouramine, to help measure a hormone in
their brains that may be linked to antisocial behavior.' The sub-
jects agreed to participate only after they were offered US$25 gift
certificates to a popular toy store, and their parents gave permis-
sion after they were offered US$100 for their children's partici-
* J.D. Candidate, May 2000. The author would like to thank her family and
friends for their continual support, encouragement, and patience while she was writing
this Comment. She would also like to thank Sanu Thomas, Joshua Warmund, Robin
Gise, Jessica Garmise, and the rest of the Editors and Staff of the Fordham International
Law Journal for their invaluable advice and assistance with this piece.
1. Rick Weiss, Volunteers at Risk in Medical Studies; Complex Research Projects Strain
System of Safeguards, WASH. PosT, Aug. 1, 1998, at Al.
2. See Food and Drug Administration: An Overview, (visited Mar. 8, 2000) <http://
www.fda.gov/opacom/hpview.html> (on file with the Fordham International Law Journal)
(explaining that U.S. Food and Drug Administration ("FDA") is public health agency
charged with protecting U.S. consumers by ensuring that only wholesome food, and
safe and effective cosmetics and pharmaceuticals are marketed in United States).
3. See Weiss, supra note 1, at A12 (explaining that fenflouramine has not been
approved for use in children and was pulled from market as diet drug for adults).
4. See id. (explaining that blood samples were taken over several hours).
5. See id. (stating that trial methods left children feeling sick).
6. See id. (noting that all subjects were younger siblings of juvenile delinquents).
7. See id. (describing purpose of study).
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pation.8 Accordingly, the researchers proceeded with the study
in the manner approved by an institutional review board (or
"IRB") .9
This case is only one example of a long history of abuses of
pediatric research subjects, both in the United States and
around the world.10 The fact that this study was conducted in
the United States, which is recognized as a leader in human re-
search protections,11 indicates that more protections are needed
both nationally and globally to safeguard vulnerable pediatric
subjects. 12  Particular areas of concern when conducting re-
search on pediatric populations include the level of risk to which
children may be exposed 3 and finding an age-appropriate sub-
8. Id.
9. See id. (describing institutional review board (or "IRB") approval of this study).
An IRB is "any board, committee, or other group formally designated by an institution
to review biomedical research involving humans as subjects, to approve the initiation of
and conduct periodic review of such research." 21 C.F.R. § 50.1 (1999).
10. See Susan E. Lederer & Michael A. Grodin, Historical Overview: Pediatric Experi-
mentation, in CHILDREN AS RESEARCH SUBJECTS, 3, 19 (Michael A. Grodin & Leonard H.
Glantz, eds., 1994) (stating that history of pediatric research is, essentially, history of
abuses).
11. See Ileana Dominguez-Urban, Harmonization in the Regulation of Pharmaceutical
Research and Human Rights: The Need To Think Globally, 30 CORNELL INT'L L.J. 245, 24546
(1997) (stating that United States has very advanced and comprehensive laws regarding
drug research and marketing); see also Keith Epstein & Bill Sloat, U.S. Medical Researchers
Flout Rules Around the World, PLAIN DEALER, Nov. 8, 1998, at Al (remarking that "[a]
legacy of medical exploitation," including radiation experiments and syphillis studies
on African-Americans "has led the United States to adopt some of the world's toughest
protections for people on whom scientists test new drugs, devices and vaccines").
12. See THE INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL RE-
QUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE, TRIPARTITE GUIDE-
LINE FOR GOOD CLINICAL PRACTICE (International Conference on Harmonisation of
Technical Requirements for Registration of Pharmaceuticals for Human Use) (1996),
also available in <http://www.ich.org> (on file with the Fordham International Law Jour-
nal) [hereinafter ICH GCP]. The ICH GCP defines vulnerable populations as
Individuals whose willingness to volunteer in a clinical trial may be unduly
influenced by the expectation, whether justified or not, of benefits associated
with participation, or of retaliatory response from senior members of a hierar-
chy in case of refusal to participate. Examples are members of a group with a
hierarchical structure, such as medical, pharmacy, dental, and nursing stu-
dents, subordinate hospital and laboratory personnel, employees of the phar-
maceutical industry, members of the armed forces, and persons kept in deten-
tion. Other vulnerable subjects include patients with incurable diseases, per-
sons in nursing homes, unemployed or impoverished persons, patients in
emergency situations, ethnic minority groups, homeless persons, nomads, ref-
ugees, minors, and those incapable of giving consent.
Id. art. 1.61.
13. See William G. Bartholome, Ethical Issues in Pediatric Research, in THE ETHICS OF
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stitute for informed consent. 4
While most countries have already enacted national legisla-
tion addressing human research,15 the international nature of
the medical, and particularly the pharmaceutical industry, which
is responsible for a large percentage of medical research world-
wide,16 has created a call for stronger international guidelines on
this issue. 17 A new opportunity to address this issue as a global
concern has arisen with the International Conference on
Harmonisation of Technical Requirements for Regulation of
Pharmaceutical Drugs ("ICH"), its Good Clinical Practice Guide-
lines is ("ICH GCP"), and its Draft Consensus Guideline on
Clinical Investigation of Medicinal Products in the Pediatric Pop-
ulation (or "Draft Guideline on Pediatric Trials").1
This Comment argues that the parties to the ICH should
adopt more specific guidelines for pediatric research than those
included in the ICH GCP, and analyzes their attempt to do so in
the Draft Guideline on Pediatric Trials. Part I of this Comment
outlines the genesis of the current international guidelines for
human research and how they relate to pediatric subjects. Part I
also explains the human research guidelines of the three princi-
pal members of the ICH. Part II describes the function of the
ICH and the provisions of the ICH GCP. Part II also discusses
how the ICH GCP addresses pediatric medical research issues,
RESEARCH INVOLVING HuMAN SUBJECTS: FACING THE 21ST CENTURY, 339, 349-56 (Harold
Y. Vanderpool, ed. 1996) (describing debate over regulation of risks in U.S. regula-
tions).
14. See Michael A. Grodin & Leonard H. Glantz, Preface, to CHILDREN AS RESEARCH
SUBJECTS at i, vii (Michael A. Grodin & Leonard H. Glantz, eds., 1996) (explaining
problems caused by pediatric subjects' inability to give legal consent).
15. See Dominguez-Urban, supra note 11, at 268 (stating that national regulations
have little effect on international community).
16. See id. (noting that "[p]harmaceutical research is the predominant type of re-
search using human subjects").
17. See id. at 273 (stating that because there are no international treaties on re-
search, other international documents have been ineffective).
18. See ICH GCP, supra note 12, at Introduction (explaining that this document
will create "international ethical and scientific quality standard for designing, con-
ducting, recording and reporting trials").
19. DRAFT CONSENSUS GUIDELINE ON CLINICAL INVESTIGATION OF MEDICINAL PROD-
UCTS IN THE PEDIATRIC POPULATION, released for Consultation Oct. 7, 1999 (Interna-
tional Conference on Harmonisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use 1999) (visited Dec. 28, 1999) <http://www.ifpma.org/
ich5e.htm> (on file with the Fordham International Law Journal) [hereinafter DRAFT
GUIDELINE ON PEDIATRIC TRIALS.
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and the provisions of the new Draft Guideline on Pediatric Tri-
als. Part III argues that the Draft Guideline on Pediatric Trials
represents a significant improvement in pediatric research
guidelines, and should be accepted by the parties to the ICH
with some modifications regarding the subject's consent and the
role and composition of IRBs.
I. DEVELOPMENT OF PEDIATRIC MEDICAL RESEARCH,
INTERNATIONAL CONVENTIONS, AND
DOMESTIC REGULATIONS
Abuses of clinical trial subjects, particularly children, has
plagued human research." These abuses led the international
human rights and medical communities to create regulatory
controls, although until recently, none of these attempts have
resulted in binding international agreements.2' Although there
is only one binding international convention addressing human
research 2 2 many countries, including the parties to the ICH,
have created their own regulations or guidelines addressing pe-
diatric research.25
A. Overview of Children in Medical Research
Pediatric research subjects have endured abuses in medical
research settings for hundreds of years.24 Despite these abuses,
however, pediatric testing cannot be banned because of the sci-
entific need to test drugs and other treatments on children. 5
20. See Lederer & Grodin, supra note 10, at 19-20 (stating that throughout history,
convenience led scientists to exploit child subjects to further medical science).
21. See Dominguez-Urban, supra note 11, at 268 (explaining international scheme
for regulation, but stating that there are still no binding regulations on human re-
search).
22. See Peter Leuprecht, Innovations in the European System of Human Rights Protec-
tion: Is Enlargement Compatible with Reinforcement?, 8 TRANSNAT'L L. & CONTEMP. PROBS.
313, 325 (1998) (stating that Council of Europe Convention on Human Rights and
Biomedicine is first binding international document on human rights in biomedicine).
23. See Dominguez-Urban, supra note 11, at 269 (noting that most industrialized
nations have some ethical review standards or mechanisms for human research).
24. See Lederer & Grodin, supra note 10, at 3-4 (explaining that medical studies on
children in past would not comply with current standards of ethical research).
25. See American Academy of Pediatrics, Committee on Drugs, Guidelines for the
Ethical Conduct of Studies to Evaluate Drugs in Pediatric Populations, PEDIATmCS, Feb. 1995,
286, 286 (explaining that "[g]rowth, differentiation, and maturation can alter the kinet-
ics, end organ responses, and toxicities of drugs in the newborn, infant, child, or ado-
lescent as compared to the adult").
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To conduct-this research in an ethical manner, researchers and
governmental actors regulating research must be cognizant of
children's special physical and emotional vulnerabilities, as well
as their liberty interests and dignity as human beings.26
1. History of Pediatric Research
Historically, children were exposed to a great deal of risky
medical research.27 The amount of pediatric research increased
dramatically in the nineteenth century, along with the growth of
pediatric medicine, in an attempt to improve children's health
through superior vaccinations and inoculations. 28 The research-
ers conducting these trials made significant oncological contri-
butions by curing serious childhood diseases. 29 They also, how-
ever, often placed pediatric research subjects at considerable
risk.3°
Similar high-risk experiments continued in the late nine-
teenth century, even as general recognition grew that children
deserve special social protections.31 During this period, re-
searchers focused their experiments upon children who were in-
stitutionalized in asylums and orphanages32 as control groups for
26. See id. at 287 (stating that because children are particularly vulnerable, they
must be provided added protection against violations of their rights and against risk,
necessitating special considerations when soliciting participants, assessing risks and ben-
efits, and ensuring equal representation of population and equal benefits).
27. See Leonard H. Glantz, Research with Children, 24 Am. J. L. & MED. 213, 215
(1994) (stating that "children have been particularly subjected to abuses by researchers
and 'those who do research with children today have inherited the legacy of researchers
who have come before them"').
28. See Lederer & Grodin, supra note 10, at 6 (explaining that poor social condi-
tions in late 19th century led to further investigation into child health problems).
29. See id. at 4-5 (describing pediatric trials that led to smallpox vaccinations); see
also id. at 7-8 (describing how pediatric research led to anti-toxins for diptheria, which
was main cause of death in 19th century children).
30. See Glantz supra note 27, at 215 (explaining that Edward Jenner, creator of
smallpox vaccine, tested vaccine on his one-year-old son, and another eight-year-old
boy, who was then exposed to smallpox virus). When the smallpox vaccine was shipped
to the United States, it was tested on 48 children in a home for indigents. Id.
31. SeeLederer & Grodin, supra note 10, at 6 (mentioning that "[c]hildren became
a focus of social reform in the nineteenth century," and describing creation of Ameri-
can Pediatric Society to "establish pediatrics as a branch of the medical sciences"). The
American Academy of Pediatrics (or "AAP") was established "to benefit the health and
welfare of children." Id. During this time period, children were increasingly regarded
as distinct from adults, and "childhood became a period of life worthy of being recog-
nized and extended." Id.
32. David N. Weisstub, et al., Biomedical Experimentation with Children: Balancing the
2000] THE RIGHTS -OF PEDIATRIC RESEARCH SUBJECTS 853
research on measles,33 the germ theory,34 and other diseases,
theories, and medical treatments. 35 The dangers inherent in
these trials were manifested in several cases,3 6 particularly in one
North Carolina orphanage where children were administered an
experimental tuberculosis vaccine in 1912.37  The children
tested in this trial were later found to have a greater tendency to
contract the disease than the children who had not received the
experimental treatment.31
In the twentieth century, newer, more sophisticated drugs
and medical tools, such as the x-ray, prompted continued medi-
cal research on children, focusing in particular on metabolism
and digestion.39 Some of these experiments caused their sub-
jects to undergo unnecessary medical procedures, and endure a
great deal of discomfort.4" Due to the negative publicity sur-
rounding these trials, however, experiments that abused chil-
dren began to face increased scrutiny from members of the med-
ical community and society-at-large. 4'
Need for Protective Measures with the Need To Respect Children's Developing Ability To Make
Significant Life Decisions for Themselves, in REsEARCH ON HUMAN SUBJECTS 380, 381 (David
N. Weisstub, ed., 1998) (citing one New York pediatrician who commented that chil-
dren in asylums were ideal research subjects because of researcher's ability to control
subjects).
33. See id. at 380-81 (noting that trials similar to smallpox trials were conducted for
measles).
34. See Glantz, supra note 27, at 216 (describing how germ theory was tested by
injecting children and adults with various diseases).
35. See id. at 216 (explaining trial where doctor performed spinal raps on 29 chil-
dren to determine if they are harmful, along with trials involving x-rays).
36. See Lederer & Grodin, supra note 10, at 7 (explaining that medical interest in
diseases like cancer, leprosy, syphilis, gonorrhea, tuberculosis, and yellow fever
prompted researchers to infect children and other research subjects deliberately); see
also id. (describing Japanese experiments with scarlet fever in three to seven-year-old
children).
37. See id. at 8 (describing tuberculosis study where 262 children at North Caro-
lina orphanage were injected with experimental tuberculosis vaccine in 1912).
38. See id. (noting that when Public Health service tested North Carolina subjects
in 1914, "guinea pigs who had received the [tuberculosis] vaccine yielded more quickly
to tubercular infection than those not vaccinated").
39. See id. at 9 (explaining that doctors used x-rays to study normal development of
children and fetuses in utero, and that there was great interest in studying digestion
using stomach tubes in children and infants).
40. See id. at 10 (describing gastrointestinal tests that caused subjects to become ill
and other studies where children had to be sedated and restrained to achieve compli-
ance with protocol requirements).
41. See Glantz, supra note 27, at 216 (describing 1941 incident where editor of
Journal of Experimental Medicine refused to publish study in which 12 healthy infants were
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Despite this increased scrutiny,42 pediatric subjects contin-
ued to endure abuses well into the second half of the twentieth
century.43 One of the most infamous examples of this exploita-
tion was the hepatitis testing conducted at the Willowbrook State
School beginning in 1955 and continuing through the early
1970s.4' Even though researchers conducting this study ob-
tained the subjects' parents' permission, the parents were not
fully apprised of the risks involved in the protocol.45 The head
of the Willowbrook research team defended the study by ex-
plaining that research subjects were at no greater risk, and were,
in fact, at lower risk of serious illness than the school's other
students due to the poor conditions that existed at the school.46
Despite this researcher's defenses, critics continued to question
the merits of this study.4 7 Even though this study and others sim-
ilar to it48 heightened awareness of pediatric research, abuses
inoculated with herpes, even though these children were volunteered by parents for
study).
42. See Lederer & Grodin, supra note 10, at 11-13 (explaining that groups opposing
animal research began to oppose pediatric research subject abuse in late 19th century,
and were later joined by members of medical community and journalists).
43. See Epstein & Sloat, supra note 11, at A12 (describing recent trials on pediatric
subjects conducted by U.S. researchers in Slovak Republic and Egypt without proper
informed consent).
44. Robert M. Nelson, Children as Research Subjects, in BEYOND CONSENT: SEEKING
JUSTICE IN RESEARCH 47, 49 (Jeffrey P. Kahn, et al., eds., 1998). In this study, a group of
mentally challenged students were exposed to a strain of the hepatitis virus intention-
ally, so that researchers could "understand the natural history and prevention" of this
disease. Id.
45. See Lederer & Grodin, supra note 10, at 17 (explaining that researchers told
parents that participants would be placed in special ward where they would be pro-
tected from other diseases running rampant in facility, and that there were questions
regarding whether parents had been given adequate information regarding hepatitis
risks); see also Nelson, supra note 44, at 51 (observing that "'consent forms that parents
signed to allow their children to be infected with the virus' read as though their chil-
dren were to receive a vaccine").
46. See Nelson, supra note 44, at 50 (citing interviews with Saul Krugman, head of
Willowbrook research team, in which Krugman states that because subjects were pro-
tected from common diseases at Willowbrook, including shigellosis and respiratory in-
fections, participation in hepatitis study was safer than school's ordinary living condi-
tions, and therefore ethical).
47. See id. at 50 (explaining that commentators questioned whether parents were
coerced into consenting by promise of better conditions for their children, why similar
tests were not conducted on adult staff members of facility, and why other sanitation
and prevention measures were not taken to control spread of disease).
48. See id. at 52 (stating that U.S. Federal Regulations were designed to prevent
abuses such as those occurring at Willowbrook and Fernald Schools). Circumstances
similar to those existing at the Willowbrook School existed in radiation experiments
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continue throughout the world.49
2. The Problem of Therapeutic Orphaning
Even though medical studies that are conducted on chil-
dren may be controversial, the scientific need for such experi-
mentation is apparent.5" A child's physiology is significantly dif-
ferent from that of an adult or a child of a different age group.5'
These differences may have a significant impact on whether and
how a drug can be used on a pediatric patient.5 2 Drug studies
conducted on adults, moreover, may not adequately predict
conducted at the Walter E. Fernald School in Massachusetts, between 1950 and 1953.
Id. at 51. In the course of these studies, 17 children were exposed to radioactive iron,
and 57 were exposed to radioactive calcium. Id. Information letters sent to parents
falsely indicated that this study was intended to benefit the subjects. Id.
49. See Epstein & Sloat, supra note 11, at A12 (describing study conducted by U.S.
researchers in Slovak Republic on allergic diseases that was stopped because research-
ers were drawing blood samples from children without informing parents or children
what study was about or asking for permission); see also id. (describing study conducted
in Egypt in 1997 by U.S. researchers assessing blood levels in children, without telling
children or parents blood was being drawn for research).
50. See National Institutes of Health ("NIH"), NIH Policy and Guidelines on the Inclu-
sion of Children as Participants in Research Involving Human Subjects, March 6, 1998, (visited
Feb. 16, 2000) <http://www.nih.gov/grants/guide/notice-files/not98-024.html> (on
file with the Fordham International Law Journal) (stating that NIH concluded that "there
is a need to enhance the inclusion of children in clinical research," after reviewing
"scientific information, demonstrated human need, and considerations of justice for
children in receiving adequately evaluated treatments"); Regulations Requiring Manu-
facturers to Assess the Safety and Effectiveness of New Drugs and Biological Products in
Pediatric Patients, 62 Fed. Reg. 43900, 43901 (1997) (stating that pediatric testing is
necessary to determine appropriate drug dosing guidelines, as incorrect dosing can
lead to "unexpected adverse reactions," and ineffective treatment).
51. See NOTE FOR GUIDANCE ON CLINICAL INVESTIGATION OF MEDICINAL PRODUCTS IN
CHILDREN, CPMP/EWP/462/95, art. 1.2 (European Agency for the Evaluation of Me-
dicinal Products, Committee for Proprietary Medicinal Products ("CPMP") 1997), avail-
able at <http://www.eudra.org/humandocs/PDFs/EWP/046295en.pdf> [hereinafter
GUIDELINE FOR CHILDREN] (on file with the Fordham International Law Journal) (stating
that "[a]dequate evaluation of medicinal products for use in children cannot be
achieved in adult studies because there are physiological differences between children
and adults, and because children suffer from different diseases from adults, or show a
different natural history for the same disease."). The Note for Guidance on Clinical
Investigation of Medicinal Products in Children ("Guideline for Children") also sets
forth specific pharmokinetic, pharmacodynamic, and pathological differences between
children and adults. Id. art. 1.2 (a)-(d).
52. See id., art. 1.2 (a), (b) (explaining metabolic differences between children of
different ages and differences in organ and tissue function); see also Ralph E. Kauffman,
Scientific Issues in Biomedical Research with Children, in CHILDREN AS RESEARCH SUBJECTS 30,
38 (Michael A. Grodin and Leonard H. Glantz, eds. 1994) (stating that "capacity to
metabolize and excrete drugs changes throughout infancy, childhood, and adoles-
cence").
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whether a drug will be toxic if prescribed to a child.53 Pharma-
ceutical companies' failure to test medicines in children may re-
sult in death or serious illness.54 Without adequate pediatric
testing, doctors encounter a serious ethical dilemma: either pre-
scribe medication or perform a procedure that potentially may
benefit the child, or refrain from this treatment because it has
not been adequately tested on children.55 This problem, com-
monly referred to as therapeutic orphaning,56 hampers the de-
velopment and use of potentially life-saving therapies for pediat-
ric patients."
Pediatric patients are likely to become therapeutic orphans,
as many pharmaceutical companies resist conducting research
on children 58 because of ethical and legal issues involved in per-
forming pediatric trials,59 difficulty recruiting subjects,6" and
strains in raising adequate funds to conduct extra protocols.6"
This situation creates grave dangers and risks for pediatric pa-
53. See GUIDELINE FOR CHILDREN, supra note 51, art. 1.2 (explaining that adult tests
"may not accurately predict the minimal effective dose, maximum titrated dose, thera-
peutic effect or adverse reactions in the child"); see also Committee on Drugs, supra note
25, at 286 (explaining that drug studies in adults cannot accurately predict the
"pharmokinetic, pharmacodyamic, or toxic properties of drugs in children").
54. See Committee on Drugs, supra note 25, at 286 (explaining that when children
were prescribed drugs with insufficient pharmocological studies, they suffered severe
toxic effects, including death).
55. See id. at 286-87 (explaining that using nonvalidated drugs, which does not
create data for future use, may create greater risk than administering drugs in con-
trolled clinical trial).
56. See ROBERT J. LEVINE, ETHICS AND REGULATION OF CLINICAL RESEARCH 239
(1986) (explaining that this term arose from orphaning clauses that appear on many
prescription drugs conveying warnings such as "not to be used in children.").
57. See id. (stating that therapeutic orphaning occurs when drug manufacturers
cannot adequately label drug for use in pediatric patients or other patient populations,
due to absence of appropriate testing).
58. See Robert Pear, FDA Prescribes New Rules for Conducting Pediatric Drug Tests/Com-
panies Say Requirements Impractical, Hous. CHRON., Nov. 28, 1998, at 2 (explaining that
pharmaceutical industry offered strenuous objections to new U.S. regulation requiring
greater testing of drugs on children, calling requirements impractical and burden-
some).
59. See LEVINE, supra note 56, at 239 (noting that "uncertainties about the ethical
propriety of and legal authority to do research on children," have impeded pediatric
testing); see also Pear, supra note 58, at 2 (stating that drug companies stated that newly
required tests on children would be costly and unethical because they may put children
at risk).
60. See Kauffman, supra note 52, at 31 (stating that many protocols are impeded
because researchers are not able to enroll sufficient number of subjects that conform to
study's criteria).
61. See LEVINE, supra note 56, at 240 (explaining that often, pharmaceutical compa-
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tients, as a large number of medications commonly prescribed
for children are not tested on pediatric subjects.62 The problem
is particularly pronounced in medications used to treat serious
illnesses, such as the human immunodeficiency virus ("HIV).63
Certain age groups are also commonly left out of drug trials, re-
sulting in incomplete and unreliable results concerning the
safety and effectiveness of drugs for these patients.64
3. The Need for Greater Protections for Children
When scientists conduct research on pediatric subjects, they
must address special concerns.65 First, they must determine the
degree to which a child can be exposed to risks involved in par-
ticipating in a clinical trial. 6 6 Along with mere physical risks, re-
searchers must also consider a child's psychological and emo-
tional state because the child may be exposed to extreme dis-
comfort, even in situations where physical risk is absent.67 A
child's inability to understand an experiment and his or her
fies are reluctant to invest huge sums of money required by FDA for marketing, esti-
mated at US$70 million per product in 1981).
62. See NIH, supra note 50, at 43899 (stating that AAP has reported that "only a
small fraction of all drugs and biological products marketed in the U.S. have had
clinical trials for use in pediatric patients").
63. See id. at 43900 (noting that less than half of FDA approved drugs used to treat
human immunodeficiency virus ("HIV") and opportunistic infections caused by HIV
are labeled for use in children). According to the AAP, 81% of the drugs listed in the
1991 Physician's Desk Reference disclaimed all use in children, or at least disclaimed
use in children of certain age groups. Id. In 1992, 79% of the 19 new molecular enti-
ties that were approved by the FDA were not labeled for use in pediatric patients. Com-
mittee on Drugs, supra note 25, at 286. In 1996, only 37% of new molecular entities
with potential usefulness in children had some pediatric labeling. NIH, supra note 50,
at 43902. Similar problems exist in Europe, where the British Medical Journal reported
that 36% of children in U.K. hospitals received medications that were not approved for
pediatric use. Unlicensed/Off-Label Use and Testing in Children, MARKETLETTER, June 22,
1998.
64. See NIH, supra note 50 (explaining that there is almost no information for most
classes of drugs for use in children under age two).
65. See GUIDELINE FOR CHILDREN, supra note 51, art. 1.1 (listing risk of injury and
legal dependence on parents to make decisions as "Ethical Considerations").
66. See Committee on Drugs, supra note 25, at 288 (describing determination of
risks and benefits as area of concern).
67. See Barbara Conrad & Sharon Homer, Issues in Pediatric Research: Safeguarding
the Children, 2J. SoC. PEDIATRIC NURSES 163, 166 (1997) (explaining that there are criti-
cal development periods that should be considered in risk analysis, although, generally,
trials involving deception, "induced anxiety, stress, fear of failure, lowered self-esteem,
intrusions of privacy, guilt, embarrassment, or compromised trust present greater risks
to children than adults").
858 FORDHAM INTERNATIONAL LAWJOURNAL [Vol. 23:848
emotional immaturity may affect the way he or she perceives the
experience dramatically. 68  Similarly, physical risks vary accord-
ing to the child's age and developmental level.69 Because a
child's emotional and physical vulnerabilities change with age,
trials must be conducted accordingly."y
In addition to the physical and psychological risks involved
in subjecting children to medical research, there is concern that
children's liberty interests may be compromised because of their
inability to give adequate consent.71 One reason for this con-
cern is that informed consent may be more difficult to regulate
fairly in children than in other decisionally-impaired popula-
tions.72 Any regulations addressing this issue must balance the
child's growing capacity to participate in making important deci-
sions with the child's need for protection. 7 As many children
have not yet exhibited values that would allow others to deter-
mine what the child would decide if legally competent, it is often
68. See id. (explaining that children's cognitive limitations, underdeveloped assess-
ment skills and coping strategies, and lack of maturity may influence perception of trial
experience and explanation of cause and effect).
69. See GUIDELINE FOR CHILDREN, supra note 51, art. 2 (outlining specific risks that
must be considered when conducting trials in various age groups, such as body compo-
sition, potential hazards, increased rate of drug penetration in brain for infants, growth
rate, absorbtion rates, and sexual maturation).
70. See Conrad & Homer, supra note 67, at 167 (noting psychological differences
between children of different age groups). Researchers conducting studies involving
pre-school age children must be sensitive to the fact that these children have underde-
veloped coping strategies and assessment skills, and may be made particularly uncom-
fortable by changes in their every day routine and exposure to unfamiliar environ-
ments. Id. Consequently, changes in the child's schedule, time restraints, or frighten-
ing themes or environments may be stressful to children in this age group. Id.
Children between the ages of 6 and 11 tend to be uncomfortable in situations that
challenge their independence, or comparisons, especially unfavorable comparisons,
with their peers. Id. These children are sensitive to peer group tensions, and being
assigned names with negative connotations, such as "special needs." Id. Adolescents
are also susceptible to studies that may damage their self-esteem, particularly those that
affect the subject's appearance, or that deal with sexuality or sexual attractiveness. Id.
71. See Glantz, supra note 27, at 218 (explaining that because children may not be
competent to volunteer to participate, child may be participating in study
nonvoluntarily or involuntarily); see also LEVINE, supra note 56, at 235 (expressing view
of those who believe that involving subjects who cannot give legal consent is objectiona-
ble, "[b]ecause the Nuremberg Code identifies voluntary consent as absolutely essen-
tial, it is clearly problematic to involve subjects who lack free power of choice.").
72. See Weisstub, supra note 32, at 384 (stating that two major problems are "the
need to obtain substitute consent" with "need children have to develop their own capac-
ity to give consent").
73. See id. at 383-84 (expressing difficulties assessing child's desire to participate in
research studies).
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difficult for a parent or guardian to provide a true substitute
consent for a minor. 4 Additionally, at least one commentator
believes that complete reliance on proxy consent 75 exposes the
child to the possible ulterior motives of the substitute decision-
makers or researchers, who may not always prioritize the child's
best interests.76
Some commentators suggest that involving the child in the
research participation decision is necessary in order to show re-
spect for the child as an autonomous human being.77 Although
some commentators believe that proxy consent is sufficient for
non-therapeutic, low risk experiments,78 others believe that fail-
ing to respect a child's decision not to participate in a research
protocol may affect the child's future ability to trust adults and
74. See id. (noting reasons why substituted consent presents unique problems for
research on minors as opposed to other incompetent populations). David Weisstub
lists the differences as:
The "universality of childhood dependency," making the need to establish and
maintain mechanisms for others to make health care decisions for children
universally accepted.
1. As opposed to other vulnerable groups, children have "a clearly de-
fined class of persons" to make medical and other decisions for them.
2. The need for substitute decision making changes with the child's age
and maturity.
3. Many children have not expressed values to enable a substitute deci-
sion-maker to "assess what the child would do if competent."
Id.
75. See, e.g., Eric T. Juengst, Protecting Human Subjects in Genome Research: A Prelimi-
nary Policy Agenda, in THE ETHics OF RESEARCH INVOLVING HuMAN SUBJEcrs: FACING THE
21sT CENTURY 401, 410 (Harold Y. Vanderpool, ed., 1996) (explaining problems caused
by proxy consent, or when family members or authorized representatives give consent
for incompetent subjects).
76. See Glantz supra note 27, at 219 (observing that parents are not obligated to
make decisions in child's best interests, and that they may make "idiosynchratic deci-
sions for their children for personal or religious reasons").
77. See Sanford Leikin, Minors' Assent, Consent, or Dissent to Medical Research, 15
I.R.B. 1, 1 (1993) (explaining that principle of respect for persons extends not only to
respect for those capable of making autonomous decisions, but also to those who are
not legally competent to make autonomous decisions).
78. See Willard Gaylin, The Competence of Children: No Longer All or None, HASTINGS
CR. Ryr., Apr. 1982, 33, 37 (arguing that child's right to refuse participation in low
risk/low gain experiments should be overridden if child's parent agrees to child's par-
ticipation). Willard Gaylin espouses the view that parents and doctors should be able to
ignore a child's refusal to participate in a low risk study to teach the child "moral re-
sponsibility." Id.; see also Lainie Friedman Ross, Children as Research Subjects: A Proposal to
Revise the Current Federal Regulations Using a Moral Framework, 8 STAN. L. & POL'Y REv. 159,
171 (1997) (expressing view that parental permission alone is sufficient for minimal
risk, non-therapeutic research, if parents feel that participation will "guide her develop-
ment according to their vision of the good life").
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members of the medical community negatively.79 Some com-
mentators also believe that respecting the child's decision may
contribute to the trial's success, since it reduces the child's level
of stress and anxiety, and increases the child's willingness to co-
operate in the elements of the protocol.80 There is also evidence
indicating that participation in this type of decision making
helps to develop a child's psychological well-being, and positive
feelings of self-esteem and self-image.8 l Participation also gives
the child access to making important life decisions in a con-
trolled environment.8 2
These theories on why children should be given the oppor-
79. See Bartholome, supra note 13, at 358-59 (arguing that ignoring child's refusal
to participate may undermine child's trust of adults and sense of control over his or her
life); see also Leikin, supra note 77, at 5 (stating that not only is failure to accept child's
dissent disrespectful, but it may also undermine child's trust of people involved in pro-
tocol and compromise future relationships with health care providers); Committee on
Drugs, supra note 25, at 298 (stating that all children over age seven should have right
to refuse to participate in non-therapeutic research).
80. See Lois A. Weithorn & David G. Scherer, Children's Involvement in Research Par-
ticipation Decisions: Psychological Considerations, in CHILDREN AS RESEARCH SUBJECTS 133,
135 (Michael A. Grodin & Leonard H. Glantz, eds., 1994) (stating that involving child
in research decisions creates positive psychological benefits including, "greater feelings
of competence and effectiveness, increased sense of self-esteem, reduced depression,
decreased anxiety, and generally less psychopathology"). Additionally, involving chil-
dren in research decision making, "may increase the child's compliance with the re-
search endeavor, may improve their performance in the required tasks (including pro-
moting their compliance with treatment regimens), and may lead to an improved treat-
ment outcome."). Weisstub, supra note 32, at 394. Weisstub states that
To the child, rather than serving as an obstacle to participation in research,
the process of consent may instead present an opportunity to develop the abil-
ity to evaluate the potential benefits to others and to medical science against
the potential harm to herself, and to place this evaluation in the context of
her own personal priorities.
Id.
81. See Weithorn & Scherer, supra note 80, at 133, 134 (stating that "it is in the
interests of children, parents, and researchers to maximize the children's involvement
in research participation decisions to the greatest extent to which the children are capa-
ble"); see also Bartholome, supra note 13, at 358 (arguing that "[riespect for the child as
a moral agent requires respect for the developing capacity of the child for autonomy,"
and that participation in this type of decision-making is essential to fostering develop-
ment of children's self-esteem and self-image, and contribute to the child's psychologi-
cal and moral growth); Weisstub, supra note 32, at 394 (stating that "considerable bene-
fits may be derived from the dynamic involvement of the child in the consent process").
82. See Weithorn & Scherer, supra note 80, at 135 (describing benefits that chil-
dren accrue by enabling them to practice decision-making skills that may be helpful in
later determinations, such as whether to use illegal drugs). Participation in this type of
decision-making helps develop a child's sense of responsibility and general decision-
making abilities. Id. at 394.
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tunity to participate in research decisions are strengthened by
further evidence that even young children have the capacity to
make rational choices concerning their involvement in research
trials.83 These studies have shown that children over the age of
nine years old have the cognitive capacity to participate in mak-
ing this decision.84 The child's ability to make a rational choice,
however, may vary depending on the type of research and inter-
ventions involved85 and the child's own psychology.86 Accord-
ingly, factors other than age must be considered when determin-
ing whether a child is old enough to consent to participation,
such as intellectual capacity, reasoning ability, life experience,
the environment in which the research is to be conducted, and
the child's personality.87
B. International Conventions and Their Effect on Pediatric Research
The long history of human research abuses has led to nu-
merous national and international human research regulations.
The first major document setting forth guidelines in this field
was the Nuremberg Code88 (or "Code") in 1947.89 Although the
83. See Leikin, supra note 77, at 2 (stating that "[a]lthough most experts still be-
lieve that the cognitive systems of early childhood, middle childhood, and adolescence
are qualitatively different from one another, there is growing doubt that the differences
between them are as radical as formerly thought."); see Conrad & Horner, supra note 67,
at 166 (stating that children 7 to 12 years old can generally express preference regard-
ing participation and understand risk and benefit and provide assent).
84. See Leikin, supra note 77, at 4 (stating that generally, children over age nine
have sufficient cognitive capacity to provide assent to research participation). Many
researchers and professional groups have asserted that children over the age of seven
can be involved in deciding whether to participate in a research study. Id.; see also
Weisstub, supra note 32, at 400-01 (citing studies suggesting that children between ages
of 7 and 14 are capable of providing assent and consent, respectively, but stating that, as
individual capacities differ, capacity must take into account functional criteria more
than mere age). But see Committee on Drugs, supra note 25, at 290 (stating "[a] ssent
must be obtained from any child with the intellectual age of 7 years or more. The
protection provides the opportunity for a child 7 years or older to refuse participation
in studies or procedures done for research purposes.").
85. See Leikin, supra note 77, at 4 (explaining that where research involves simple
interventions, such as weighing child, very young child would be able to provide assent,
however, in research involving more complex risks and interventions, such as drug tri-
als, greater cognitive ability may be required). Id.
86. See id. at 2-4 (stating that child should be able to understand research, reason
about research, and express their will without undue influence from outside sources).
87. See Weithorn & Scherer, supra note 80, at 165-71 (detailing factors that should
be considered when determining whether child may provide meaningful assent).
88. See Sharon Perley, et al. The Nuremberg Code: An International Overview, in THE
NAZI DocroRs AND THE NUREMBERG CODE, 149, 150 (George J. Annas & Michael A.
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Nuremberg Code was significant in promoting informed con-
sent, its shortcomings, including its lack of guidance on consent
for incompetent subjects, caused the World Medical Association
(or "WMA") to develop the Helsinki Declarations in 1964, with
continual revisions through 1996.90 The Helsinki Declarations
represented a significant step forward in the area of pediatric
research, by introducing the concept of proxy consent,9' and al-
lowing incompetent subjects to be involved in research participa-
tion decisions.92 The World Health Organization ("WHO") and
Grodin, eds., 1992) (stating that while Nuremberg Code (or "Code") was "almost cer-
tainly the first international code" it had several significant national and ancient prede-
cessors).
89. Id.
90. See DECLARATION OF HELSINKI I (18th World Medical Assembly 1964), reprinted
in THE NAZI DoCToRS AND THE NUREMBERG CODE 331 (George J. Annas & Michael A.
Grodin, eds. 1992) [hereinafter HELSINKI I]. The World Medical Association ("WMA")
doctors that formulated the Helsinki Declaration realized that the Code did not pro-
vide adequate guidance for many populations, including minors, and attempted to
ameliorate this problem by adding proxy consent in the first Helsinki Declaration.
RobertJ. Levine, International Codes and Guidelines for Research Ethics: A Critical Appraisa
in THE ETHICS OF RESEARCH INVOLVING HUMAN SUBJECTS, 235, 236 (Harold Y. Vander-
pool, ed. 1996).
91. HELSINKI I, supra note 90, art. 11 (1), art. III (3a). Article II, "Clinical Research
Combined with Professional Care," states
If at all possible, consistent with patient psychology, the doctor should obtain
the patient's freely given consent after the patient has been given a full expla-
nation. In the case of legal incapacity consent should also be procured from
the legal guardian; in the case of physical incapacity the permission of the
legal guardian replaces that of the patient.
Id. art. 11 (1). Similarly, Article III, "Non-Therapeutic Clinical Research," paragraph 3a,
states "[c]linical research on a human being cannot be undertaken without his free
consent, after he has been legally informed; if he is legally incompetent, the consent of
the legal guardian should be procured." Id. art. III (3a). Article II, paragraph 3(b)
however, limits proxy consent in non-therapeutic trials by stating that the "subject of
clinical research should be in such a mental, physical, and legal state as to be able to
exercise fully his power of choice." Id. art. III (3b). Proxy Consent is consent to re-
search given by a proxy consenter, who is "an individual authorized to exercise parental
rights on behalf of or a spouse or guardian of the trial subject, or a person equivalent
thereto." GUIDELINE FOR GOOD CLINICAL PRACTICE Ordinance No. 28 (Ministry of
Health and Welfare 1997) [hereinafter NEW JAPANESE GCP].
92. See DECLARATION OF HELSINKI III, (35th World Medical Assembly 1983), re-
printed in THE NAZI DOCTORS AND THE NUREMBERG CODE 336 (George J. Annas &
Michael A. Grodin, eds., 1992) [hereinafter HELSINKI III]. Although the concept of
involving minors in research participation decisions, at least in therapeutic trials, may
be implied in Article II, paragraph 1, in the case of a psychologically incompetent per-
son, informed consent should also be obtained from the legal guardian. Id. This idea
is specifically enumerated in Article I, paragraph 11 of Helsinki III, which states,
In the case of legal incompetence, informed consent should be obtained from
the legal guardian in accordance with national legislation. Where physical or
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the Council for International Organizations of Medical Science
("CIOMS") further developed these concepts in its International
Ethical Guidelines for Biomedical Research Involving Human
Subjects9" ("CIOMS/WHO Guidelines" or "Guidelines") in
1993, devoting an entire section to research on children.94
Although the Code, the Helsinki Declarations, and the CIOMS/
WHO Guidelines are not legally binding, the Council of Europe
recently passed the first binding international document that
discusses human research.95 The rights and protections out-
lined in these documents embody the growing international
movement for children's rights exemplified by the United Na-
tions Convention on the Rights of the Child (or "CRC").96
Although there are many challenges incumbent in international
research regulation,97 the growing multinationalism of the phar-
mental incapacity makes it impossible to obtain informed consent, or when
the subject is a minor, permission from the responsible relative replaces that
of the subject in accordance with national legislation. Whenever the minor
child is in fact able to give a consent, the minor's consent must be obtained in
addition to the consent of the minor's legal guardian.
Id. art. 1 (11).
93. INTERNATIONAL ETHICAL GUIDELINES FOR BIOMEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS (Council for International Organizations of Medical Science (CI-
OMS) in collaboration with the World Health Organization ("WHO") 1993) [hereinaf-
ter CIOMS/WHO GUIDELINES].
94. Id.
95. See Innovations in the European System of Human Rights Protection: Is Enlargement
Compatible with Reinforcement?, 8 TRANSNAT'L L. & CONTEMP. PROBS. 313, 325 (1998) (not-
ing that Convention on Human Rights and Biomedicine ("Biomedical Convention")
was first binding international document on bioethics).
96. See United Nations Convention on the Rights of the Child, G.A. Res. 44/25, U.N.
GAOR, 44th Sess., Supp. No. 49, at 174, U.N. Doc. A/44/736 (1989), 28 I.L.M. 1448
(1989) [hereinafter CRC].
97. See Dominguez-Urban, supra note 11, at 253 (explaining that divergent cultural
and regulatory systems impede harmonization efforts). Varying cultural values, with
regard to the manner in which clinical testing is conducted, and the testing require-
ments themselves, have caused a significant barrier to regulatory harmonization. Id.; see
also id. at 260 (explaining differences in regulatory ideals, stating that while United
States requires randomized testing, France considers such testing "cruel and inhu-
mane"); id. at 270 (describing different priorities placed on informed consent in Euro-
pean Union, United States, and Japan); Carel B. Ijsselmuiden & Ruth R. Fadden, Medi-
cal Research and the Principle of Respect for Persons in Non-Western Cultures, in THE ETHICS OF
RESEARCH INVOLVING HUMAN SUBJECTS 281, 287-88 (Harold Y. Vanderpool, ed., 1996)
(describing anthropological reasons why individual informed consent may not be best
model for certain non-Western Countries). In past attempts at international regula-
tion, as ultimately recognized by the International Ethical Guidelines for Biomedical
Research Involving Human Subjects ("CIOMS/WHO Guidelines"), a major problem
was achieving consensus on informed consent. Perley, supra note 88, at 161. In many
tribal cultures, and particularly in developing nations, individual informed consent may
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maceutical and medical industries has created a demand for
stronger and more cogent guidelines in pediatric research.98
1. The Nuremberg Code
The Nuremberg Code9 9 was one of the first international
instruments to define ethical standards for conducting medical
research."° Although it has no concrete legal authority, the
Code has served as a moral guide for researchers since its pro-
mulgation in 1947101 by a panel of U.S. judges 10 2 at the conclu-
sion of the Nuremberg Medical Trial.' The Nuremberg Medi-
cal Trial began on December 9, 1946, as a trial against twenty-
three Nazi physicians for war crimes and crimes against human-
ity.10 4 In the course of this trial, the judges received detailed
information regarding the atrocities that Nazi physicians com-
not be as important as achieving consent from a tribal leader, family member, or com-
munity at large. See Dominguez-Urban, supra note 11, at 280 (explaining group consent
mentality in non-Western cultures).
98. See Dominguez-Urban, supra note 11, at 245-46 (explaining how growth of har-
monization of pharmaceutical regulation and mutual acceptance of clinical data has
led to greater need for "regulations extending beyond national borders to protect
human subjects").
99. United States v. Karl Brandt, et al., 2 TRIALS OF WAR CRIMINALS BEFORE THE
NUREMBERG MILITARY TRIBUNALS UNDER CONTROL COUNCIL LAW 10, Case 1, Oct.
1946-Apr. 1949, 181-82 (1949) [hereinafter Nuremberg Code].
100. SeeJonathan D. Moreno, The Dilemmas of Experimenting on People; Striking a Bal-
ance Between Human Rights and Medical Progress, MASS. INST. TECH. ALUMNI ASS'N TECH.
REv., July, 1997, at 31 (stating that Nuremberg Trial prosecutors faced absence of interna-
tionally recognized codes of medical ethics regarding experimentation); see also Weithorn &
Scherer, supra note 80, at 132 (describing absence of universal principles for human
experimentation during Nuremberg Trials).
101. See Moreno, supra note 100 (calling Code powerful moral force, despite its
lack of legal authority); see also Harold Y. Vanderpool, Introduction and Overview: Ethics,
Historical Case Studies, and the Research Enterprise, in THE ETHICS OF RESEARCH INVOLVING
HUMAN SUBJECTS: FACING THE 21ST CENTURY 501 (Harold Y. Vanderpool, ed., 1996) (re-
marking that some regard Nuremberg as fundamental standard for research in compe-
tent adults).
102. SeeJonathan Moreno, Reassessing the Influence of the Nuremberg Code on American
Medical Ethics, 13J. CONTEMP. HEALTH L. & POL'Y 347, 348 (1997) (noting that Nurem-
berg panel was composed of three U.S. judges).
103. Id. The Nuremberg Medical Trial is another name for Trials of War Criminals
Before the Nuremberg Military Tribunals Under Control Council Law 10, Case 1 United States v.
Karl Brandt, et al., Oct. 1946-Apr. 1949, 1-1004; 2 id. [hereinafter Nuremberg Medical
Trial].
104. See Evelyne Shuster, The Nuremberg Code: Hippocratic Ethics and Human Rights,
351 LANCET 974 (1998) (explaining that Nuremberg Medical Trial involved U.S. judges
sitting in judgment of 23 Nazi physicians and doctors for murder and torture in con-
ducting medical experiments).
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mitted on human subjects in the name of medical research.1 °5
Although these experiments left the Nuremberg judges pro-
foundly disturbed,1"6 they found themselves at a loss for interna-
tional guidelines by which to judge the defendants' behavior. 7
To resolve the dilemma caused by the absence of universally
accepted guidelines, the judges adopted their own set of stan-
dards, known as the Nuremberg Code.0 8 The judges sought in-
formation from a variety of sources in order to form a consensus
on the appropriate limits for human research. 0 9 By using these
resources, the judges created a Code that represents not only the
opinion of a single war crime tribunal, but also serves as a state-
ment of universally-accepted principles of medical ethics."0
105. See Telford Taylor, Opening Statement of the Prosecution, December 9, 1946, 1, Tri-
als of War Criminals Before the Nuremberg Military Tribunals Under Control Council Law 10,
27-74 (detailing concentration camp experiments). Children, particularly twins, were
subjected to numerous experiments in concentration camps. Eva Mozes-Kor, The
Mengele Twins and Human Experimentation: A Personal Account, in THE NAZI DOCTORS AND
THE NUREMBERG CODE 53 (George J. Annas & Michael Grodin, eds. 1992). These trials
included germ experimentation where one twin would be injected with a germ, and
then, if that twin died, the other would be killed as well, to compare the autopsies of the
infected child with the uninfected child. Mozes-Kor, supra, at 56. Among others, chil-
dren were also engaged in tests to see how much blood a person could lose before they
died, genetic studies involving cross-transfusions to try to "make boys into girls," and
studies trying to create "Siamese twins" by joining a set of twins together. Id. at 57.
106. See Judgement and Aftermath, in THE NAzI DocroRs AND THE NUREMBERG CODE
94, 104 (GeorgeJ. Annas & Michael Grodin, eds. 1992) (describing evidence of revolt-
ing physical conditions to which prisoners were exposed, and extreme pain or torture
experienced by prisoner research subjects).
107. See Moreno, supra note 102, at 348 (explaining how Nuremberg judges had
no preexisting international frame of reference by which to evaluate defendants' behav-
ior, as defense attorneys were able to use ambiguity of human research protocol in
defense arguments).
108. See GeorgeJ. Annas & Michael Grodin, Introduction, in THE NAZI DOCTORS AND
THE NUREMBERG CODE, 3, 4 (GeorgeJ. Annas & Michael Grodin, eds., 1992) (explaining
that 10 point code was enumerated at end of judgment in Nuremberg Medical Trial).
109. See Michael A. Grodin, Historical Origins of the Nuremberg Code, in THE NAZI
DocroRs AND THE NUREMBERG CODE, 121, 139 (George J. Annas & Michael A. Grodin,
eds., 1992) (explaining that Code was based on combination of testimony and memo-
randa prepared by representatives of American Medical Association ("AMA"), doctors
Andrew Ivy, M.D., and Leo Alexander, M.D., Hippocratic Oath, writings of several med-
ical ethicists, and notably, human research regulations promulgated in pre-war Ger-
many and Third Reich).
110. See Moreno, supra note 102, at 348-49 (describing how Nuremberg judges be-
lieved that they were codifying pre-existing moral values among doctors); see also Nu-
remberg Medical Trial, supra note 103 at 181 (stating that "all agree, however, that cer-
tain basic principles must be observed in order to satisfy moral, ethical and legal con-
cepts"). There is, however, some debate on whether the Code truly represented a
universal set of guidelines. See LEVINE, supra note 56, at 240 (arguing that content of
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a. The Principles Embodied in the Code
The principle of informed consent is the most significant
element of the Code,111 and is outlined in its first principle. 1 2
The first principle of the Code states that all subjects must give
voluntary, informed consent to participate in medical trials.113
This principle also defines the requirements for informed con-
sent, stating that an experiment should be explained to a subject
in a manner that is free from duress, force, or deception.1 14 Sim-
ilarly, the subject must be at liberty to withdraw from the trial at
any time.115
In addition to the informed consent provisions, the Code
contains limitations on the degree of risk to which subjects can
Code was heavily influenced by fact that medical trial was heard by U.S. judges, relying
heavily on testimony of two U.S. physicians, and is therefore product of Western ideas
and culture).
111. See, e.g. George Annas, Mengele's Birthmark: The Nuremberg Code in United States
Courts, 7J. CONTEMP. HEALTH L. & POL'Y 17, 21 (1991) (describing Code as "most com-
plete and authoritative statement of the law of informed consent to human experimen-
tation").
112. See id. (stating that although informed consent is included in paragraph one,
Code's other requirements regarding trial design must be satisfied before trial gets to
consent stage).
113. Nuremberg Code, supra note 99, para. 1. The first principle states that "[t]he
voluntary consent of the human subject is absolutely essential". Id.
114. Id. para. 1. The first principle of the Nuremberg Code states in full:
The voluntary consent of the human subject is absolutely essential. This
means that the person involved should have legal capacity to give consent;
should be so situated as to be able to exercise free power of choice, without
the intervention of any element of force, fraud, deceit, duress, over-reaching,
or other ulterior form of constraint or coercion; and should have sufficient
knowledge and comprehension of the elements of the subject matter involved
as to enable him to make an understanding and enlightened decision. This
latter element requires that before the acceptance of an affirmative decision
by the experimental subject there should be made known to him the nature,
duration, and purpose of the experiment; the method and means by which it
is to be conducted; all inconveniences and hazards reasonably to be expected;
and the effects upon his health or person which may possibly come from his
participation in the experiment.
The duty and responsibility for ascertaining the quality of the consent
rests upon each individual who initiates, directs, or engages in the experiment.
It is a personal duty and responsibility which may not be delegated to another
with impunity.
Id.
115. See id. para. 9. (stating that "[d]uring the course of the experiment the
human subject should be at liberty to bring the experiment to an end if he has reached
the physical or mental state where continuation of the experiment seems to him to be
impossible.").
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be exposed.' 16 Under the Code, the level of risk must be pro-
portional to the trial's expected benefits, and no trials should be
conducted where death or disabling injury may result.1 7 The
judges also provided adequate provisions in the event that the
subject is injured or becomes ill as a result of the trial." 8
b. The Code and Pediatric Research
Although the Code pioneered international human re-
search regulation, it has several widely recognized weaknesses." 19
Foremost among these weaknesses, the Code fails to provide for
conducting research on subjects who are incapable of providing
legal informed consent.120 This omission led to widespread de-
bate among members of the medical and ethical communities
on whether research should be conducted on children at all. 12 1
116. See id. para. 6. (explaining that "[the degree of risk to be taken should never
exceed that determined by the humanitarian importance of the problem to be solved
by the experiment.").
117. See id. para. 5. (instructing that "[nlo experiment should be conducted
where there is an a priori reason to believe that death or disabling injury will occur;
except, perhaps in those experiments where the experimental physicians also serve as
subjects."). The level of risk is to be determined through prior animal experimentation
and knowledge of the disease. Id. para. 3.
118. See id. para. 7 (stating that laboratory in which study takes place should also
be inspected to "protect the experimental subject against even remote possibilities of
injury, disability, or death.").
119. See Annas, supra note 111, at 24 (explaining physician's groups' complaints
that Code was too legalistic and was irrelevant to normal medical experimentation).
120. See Nuremberg Code, supra note 99, para. 1 (stating that "the person involved
should have legal capacity to consent."). There are no statements in the Code that
allow for proxy consent, or any type of legal permission for subjects who are not person-
ally capable of providing legal, voluntary consent. See Ross, supra note 78, at 159 (ex-
plaining that Code makes no mention of proxy consent and that subject must person-
ally consent to research participation, thereby implying that children who are not capa-
ble of informed consent cannot participate).
121. See Ross, supra note 78, at 159-60 (describing problem created by Code's man-
date that voluntary consent is absolutely essential when children are involved). Leading
figures in this debate, beginning in the 1970s, were two Christian theologians, Paul
Ramsey and Richard McCormick. Id. Ramsey posited that under the Code, children
and other legal incompetents could never legally consent to participation in non-bene-
ficial research. Paul Ramsey, The Enforcement of Morals: Nontherapeutic Research on Chil-
dren-A Reply to Richard McCormick, HASTINGS CTR. REP., Aug. 1976, at 21. Ramsey fur-
ther believed that because the Code never mentioned proxy consent, a parent's con-
sent on behalf of a minor child is ethically invalid, and is, in fact, a breach of the
fiduciary duty that a parent owes to his or her child. Ross, supra note 78, at 159. He
calls research conducted under these conditions "offensive touching." Richard McCor-
mick, Experimentation in Children: Sharing in Sociality-A Reply to Paul Ramsey, HASTINGS
CTR. REP., Dec. 1976, at 41. McCormick, on the other hand, used a natural law argu-
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In this regard, critics have and continue to view the Code as
too restrictive to allow for human experimentation using any
subjects other than competent adults.' 22 Commentators felt that
the limitations imposed by the Code would significantly hinder
the study of childhood disease and conditions arising in the
mentally ill. 123 Additionally, many doctors and researchers
shared the view that the Code was inapplicable to their re-
search. 124 These doctors felt that the extreme circumstances sur-
rounding the Nuremberg Medical Trial and the atrocities com-
mitted in concentration camps had little relevance to their daily
practices. 125 Consequently, although the Code formed the basis
for modern regulations, the international medical community
recognized the need for more practical and comprehensive
guidelines. 126
ment to suggest that parental consent for a child's participation is valid because, pre-
sumably, the child would want to participate. Ramsey, supra, at 21. McCormick argues
that as a social being, the child would want to participate in non-beneficial research that
poses no harm to him because he ought to for the good of society as a whole. Ramsey,
supra, at 22. Ramsey rebuts this argument, stating that a child's primary interest is his
or her own physical well-being and to force a child to participate in this type of research
amounts to compulsory altruism, which would be unacceptable if imposed on adults.
See id. at 23 (stating that child's main interest is "preservation of [an] unimpaired life").
Ramsey's second argument is based on the Canteen theory that to use children as sub-
jects in non-beneficial research is to use them solely as a means, rather than as an end.
Ross, supra, at 160. McCormick replies to this argument by stating that the child is
treated as an end, even in non-beneficial research, as the child benefits through help-
ing society as a whole. Id.
122. See Harold Y. Vanderpool. Introduction and Overview: Ethics, Historical Case
Studies, and the Research Enterprise, in THE ETHICS OF RESEARCH INVOLVING HUMAN Sun-
JEcrs: FACING THE 21sT CENTURY 1, 8 (Harold Y. Vanderpool, ed., 1996) (stating that
Code has been viewed as "politically naive and unduly restrictive with respect to re-
search involving children and other populations of patients").
123. See Perley, supra note 88, at 155 (noting that U.S. researcher Henry Beecher
asserted that Code would "effectively curtail the study of mental illness and children's
diseases").
124. See Moreno, supra note 102, at 349 (explaining that many doctors felt that
Code only applied to Nazi doctors, not to them).
125. See id. at 349 (listing four rationales that explain why many doctors do not
think that Nuremberg applies to them: that conduct of Nazi doctors was so extreme
that Code would have no relevance to civilized, moral physicians; that concentration
camps were far removed from normal circumstances attending medical research; that
Hippocratic Oath was sufficient to guide doctors in everyday practice and research ac-
tivities; and that requirement of "absolute consent" was unreasonable and inapplicable
to important research protocols on children and other cognitively impaired popula-
tions); see also Shuster, supra note 104, at 976 (explaining that Code's link to Nazi atroci-
ties, murder, and torture led average physicians to believe that Code was only relevant
to Nazi Doctors).
126. See Perley, supra note 88, at 150-51 (stating that many believe that Nuremberg
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2. The Helsinki Declarations
The criticisms surrounding the Code led physicians to call
for a set of research guidelines that would be more relevant to
their daily practices.1 27 The World Medical Association's Com-
mittee on Medical Ethics ("Ethics Committee") first undertook
this challenge in 1953128 by creating the Resolution on Human
Experimentation: Principles for Those in Research and Experi-
mentation 129 ("Resolution")."' The five principles embodied in
this document placed primary ethical responsibilities on the re-
searcher. 13 1 Furthermore, it clarified that personal informed
consent was necessary for healthy subjects, while proxy consent
was sufficient for those who were too ill to give consent.
13 2
After the Resolution, the Ethics Committee continued to
study medical research issues. 133 In 1964, the WMA's General
Assembly in Helsinki adopted the result of the Ethic's Commit-
tee's efforts, the Declaration of Helsinki13 1 ("Helsinki I") .135
provided "starting point" for examining ethical issues regarding experimentation and
brought "issue of human experimentation to the forefront of public debate"); Kevin M.
King, Note, A Proposal for the Effective International Regulation of Biomedical Research Involv-
ing Human Subjects, 34 STAN. J. INT'L L. 163, 179 (1998) (stating that Nazi experiments
highlighted need for more comprehensive guidelines to deal with human research).
127. See Robert J. Levine, International Codes and Guidelines for Research Ethics: A
Critical Appraisal in THE ETHICS OF RESEARCH INVOLVING HUMAN SUBJECTS 235, 242
(Harold Y. Vanderpool, ed., 1996) (citing WMA's Committee on Medical Ethics 1953
statement recognizing "need for professional guidelines designed by physicians for phy-
sicians" and that Code was not merely legal document created for use in specific trial).
128. See Perley, supra note 88, at 157 (explaining that WMA Committee on Medical
Ethics began to deal with human experimentation in 1953, realizing need for profes-
sional guidelines to cure Code deficiencies, such as failure to recognize difference be-
tween therapeutic and non-therapeutic research).
129. Resolution on Human Experimentation: Principles for Those in Research and Experi-
mentation, adopted by the WMA General Assembly 8th Sess. (Rome, 1954).
130. Id.
131. See Perley, supra note 88, at 157 (stating that Resolution on Human Experi-
mentation placed primary responsibility for ethical conduct on researcher).
132. See id. (describing fourth principle as stating that researchers must attempt to
obtain fully informed, free consent from healthy subjects, but may obtain consent of
incompetent patient's next of kin, after informing subject or legal guardian of nature,
reason, and risks involved in trial).
133. See id. at 158 (stating that between 1954 and 1960 Ethics Committee contin-
ued to study human experimentation, and presented first draft of Helsinki Declaration
to WMA's 15th Assembly in 1961).
134. See id. at 158 (stating that after first draft was presented at 15th Assembly,
Code underwent several revisions, and was adopted at WMA's 18th Assembly in Hel-
sinki, Finland, in 1964); see also Zbigniew Bankowski, International Ethical Considerations
for Research on Human Subjects, in ETHICAL ISSUES IN RESEARCH, 177, 181 (Darwin Cheney,
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Although Helsinki I was influenced by the Code, it included sev-
eral significant differences. 3 6 First, Helsinki I distinguished be-
tween therapeutic research 3 7 and non-therapeutic research, 38
ensuring the rights of patients receiving experimental therapeu-
tic care, as well as the rights of volunteers. 3  Additionally, Hel-
sinki I required that the level of risk inherent in the medical trial
must be proportional to the trial's expected benefits. 40 More-
over, with regard to pediatric research, Helsinki I permitted
proxy consent for all subjects who were legally incompetent."'
Thus, Helsinki I enabled researchers to conduct trials on sub-
jects who were not able to give legally competent consent, in-
cluding pediatric and other vulnerable populations. 42
Although many physicians praised Helsinki I as providing an eth-
ed. 1993) (explaining that need for ethical guidelines created by physicians was realized
at 18th WMA Assembly in 1964, when Declaration of Helsinki was adopted).
135. Id.
136. See Perley, supra note 88, at 158 (mentioning that although Code is never
explicitly mentioned in Helsinki I, Executive Director of WMA confirmed that Helsinki
drafters consulted text of Code and Code was discussed at WMA Assembly meetings).
137. See Shuster, supra note 104, at 976 (distinguishing "therapeutic research" as
that which benefits patient and which "[saves] life, re-establish[es) health or alleviat[es]
suffering" from nontherapeutic research, which is defined as purely scientific.)
138. HELSINKI I, supra note 90, at Introduction. The Introduction to Helsinki I
states, "a fundamental distinction must be recognized between clinical research in
which the aim is essentially therapeutic for a patient, and clinical research the essential
object of which is purely scientific and without therapeutic value to the person sub-
jected to the research." Id.
139. See Perley, supra note 88, at 158 (stating that Helsinki I's distinction between
therapeutic and non-therapeutic research is important because it emphasized that pa-
tients who are receiving experimental therapies must be afforded same rights and re-
spect as healthy patients).
140. HELSINKI I, supra note 90, art. 1.3. Paragraph 3 of the Basic Principles states,
"[c]linical research cannot legitimately be carried out unless the importance of the
objective is in proportion to the inherent risk to the subject." Id.
141. Id. art. II (1). Article II, "Clinical Research Combined With Professional
Care," states in paragraph 1,
If at all possible, consistent with patient psychology, the doctor should obtain
the patient's freely given consent after the patient has been given a full expla-
nation. In case of legal incapacity consent should also be procured from the
legal guardian; in case of physical incapacity the permission of the legal guard-
ian replaces that of the patient.
Id. Regarding non-therapeutic research, article III (3a) states, " [c]linical research on a
human being cannot be undertaken without his free consent, after he has been fully
informed; if he is legally incompetent the consent of the legal guardian should be pro-
cured." Id. art. III (3a).
142. See Lederer & Grodin, supra note 10, at 16 (stating that Helsinki "recognized a
place in medical research for experimentation in special populations and called for
some protection for these groups, including a process of surrogate decision-making").
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ical, rather than a legal, solution to the problems facing medical
researchers, 143 others found that it was too paternalistic and
vague. 144
As a result, Helsinki I was revised at the twenty-ninth annual
WMA meeting in Tokyo in 1975, creating the Declaration of Hel-
sinki I115 ("Helsinki II").141 Several major concepts were intro-
duced in this revision, such as an independent committee review
requirement for all research protocols. 47 Further, Helsinki II
supplemented Helsinki I's risk protections, as it emphasized pro-
tecting both the subject's physical148 as well as psychological well-
being. 4 Helsinki II also placed greater emphasis on the princi-
ple of informed consent by devoting three paragraphs of the Ba-
sic Principles to this topic,' 50 instead of merely placing it among
143. See Annas & Grodin, supra note 109, at 26 (citing U.S. physician Henry
Beecher, President of Council for International Organizations of Medical Sciences,
praising Helsinki I). Beecher summarized the feelings of the international medical
community in relation to Helsinki when he stated, "[t]he Nuremberg Code presents a
rigid set of legalistic demands . . . The Declaration of Helsinki, on the other hand,
presents a set of guides. It is an ethical, as opposed to a legalistic document, and is thus a
more broadly useful instrument than the one formulated at Nuremberg." Id.
144. See id. at 26 (citing Jay Katz's statement that Codes are "painfully vague").
145. DECLARATION OF HELSINKI II (29th World Medical Assembly, 1975), reprinted
in, THE NAZI DOcTORs AND THE NUREMBERG CODE, 333 [herinafter HELSINKI II]. See
Perley, supra note 88, at 159 (stating that Helsinki I was largely unrevised for more than
10 years).
146. HELSINKI II, supra note 145.
147. See id. art. I (2) (stating that all experiments involving human subjects should
be "transmitted to a specially appointed independent committee for consideration,
comment and guidance").
148. See id. art. I (7) (stating that "[dloctors should abstain from engaging in re-
search projects involving human subjects unless they are satisfied that the hazards in-
volved are believed to be predictable. Doctors should cease any investigation if the
hazards are found to outweigh the potential benefits.").
149. See id. art. I (6) (stating that "[elvery precaution should be taken to respect
the privacy of the subject and to minimize the impact of the study on the subject's
physical and mental integrity and on the personality of the subject.").
150. Id. art. I, (9)-(11). Paragraph 9 of the Basic Principles defines the general
requirements of informed consent under Helsinki II, stating
In any research on human beings, each potential subject must be adequately
informed of the aims, methods, anticipated benefits and potential hazards of
the study and the discomfort it may entail. He or she should be informed that
he or she is at liberty to abstain from participation in the study and that he or
she is free to withdraw his or her consent to participation at any time. The
doctor should then obtain the subject's freely -given informed consent, pref-
erably in writing.
Id. Paragraph 10 provided further informed consent requirements for subjects with a
special relationship to the investigator. Id. para. 10. Paragraph 11 enumerates in-
formed consent requirements for incompetent adults and children. Id. para. 11.
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the guidelines for specific types of research.'-" Furthermore,
Helsinki II sets incompetent subjects apart from other groups by
devoting an entire paragraph to substituted consent.152 This
paragraph specifically mentioned minors as a distinct class of le-
gally incompetent subjects. 153  Helsinki II's provisions allowed
researchers to conduct trials after obtaining permission from a
responsible relative, as permitted by national legislation.' 54
Following Helsinki II, the WMA revised the Helsinki Decla-
ration three more times, in 1983,151 1989,156 and 1996.1'5 The
Declaration of Helsinki III ("Helsinki III"), further developed
the notion of informed consent in pediatric subjects by advanc-
ing the idea that children can share in the decision-making pro-
cess.' 58 The Basic Principles of Helsinki III specified that when
dealing with a subject who is legally incompetent, the researcher
must obtain not only the consent of the legal guardian, but also
the consent of the child to the extent that he or she is able to
provide such consent.'59 The Declaration of Helsinki IV ("Hel-
151. Id. art. I (11). Unlike Helsinki I, which listed the informed consent require-
ment in Article II and Article III and which specifically dealt with requirements for
therapeutic and non-therapeutic trials, Helsinki II places informed consent in Article I,
paragraph 11, which states:
In the case of legal incompetence, informed consent should be obtained from
the legal guardian in accordance with national legislation. Where physical or
mental incapacity makes it impossible to obtain informed consent, or when
the subject is a minor, permission from the responsible relative replaces that
of the subject in accordance with national legislation.
Id.
152. Id. art. I (11). Paragraph 11 of the Basic Principles states that
In the case of legal incompetence, informed consent should be obtained from
the legal guardian in accordance with national legislation. Where physical or
mental incapacity makes it impossible to obtain informed consent, or when
the subject is a minor, permission from the responsible relative replaces that
of the subject in accordance with national legislation.
Id.
153. Id.
154. Id. art. I (11). Section 1.11 states, "permission from a responsible relative
replaces that of the subject in accordance with national legislation." Id.
155. HELSINKI III, supra note 92.
156. DECLARATION OF HELSINKI IV (41st World Medical Assembly, 1989) [hereinaf-
ter HELSINKI IV].
157. DECLARATION OF HELSINKI V (48th World Medical Assembly, 1996) [hereinaf-
ter HELSINKI V].
158. See HELSINKI III, supra note 92, art. I (11).
159. Id. Article I states,
In case of legal incompetence, informed consent should be obtained from the
legal guardian in accordance with national legislation. Where physical or
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sinki IV') and the Declaration of Helsinki V ("Helsinki V")
largely retained this language, although the provision regarding
consent of a capable minor was further emphasized by turning
this sentence into a separate paragraph in Helsinki IV. 6'
The Helsinki Declarations, like the Code, are not legally-
binding documents.16 1 Like the Code, the Helsinki Declarations
have significantly impacted later international, national, and re-
gional regulations. 62 The Helsinki Declaration also stressed the
importance of allowing children to participate in medical re-
search decision making,163 and of including the medical commu-
mental incapacity makes it impossible to obtain informed consent, or when
the subject is a minor, permission from the responsible relative replaces that
of the subject in accordance with national legislation. Whenever the minor
child is in fact able to give a consent, the minor's consent must be obtained in
addition to the consent of the minor's legal guardian.
Id. (emphasis added). It should be noted that the child's consent, when the child is
able to provide such consent, is mandatory, as opposed to other provisions of Helsinki
that are permissive. Compare with id. art. I (10). Article I, paragraph 10 states
When obtaining informed consent for the research project the physician
should be particularly cautious if the subject is in a dependent relationship to
him or her or may consent under duress. In that case the informed consent
should be obtained by a physician who is not engaged in the investigation and
who is completely independent of this official relationship.
Id. art. I (10) (emphasis added).
160. HELSINKI IV, supra note 156, art. I (11). Article I, paragraph 11 finds that
In case of legal incompetence, informed consent should be obtained from the
legal guardian in accordance with national legislation. Where physical or
mental incapacity makes it impossible to obtain informed consent, or when
the subject is a minor, permission from the responsible relative replaces that
of the subject in accordance with national legislation.... Whenever the minor
child is in fact able to give a consent, the minor's consent must be obtained in
addition to the consent of the minor's legal guardian.
Id.
161. See Bankowski, supra note 134, at 182 (stating that similar to Code, Helsinki is
not legally binding).
162. See, e.g., Good Clinical Practice for Trials on Medicinal Products in the European
Community, 111/3976/88, (adopted May 1990), art. 1.1, 1.2. [hereinafter EU GCP]. Arti-
cle 1.1 of the Good Clinical Practice for Trials on Medicinal Products in the European
Community (or "EU GCP") states "It] he current revision of the Declaration of Helsinki
is the accepted bases for clinical trial ethics, which must be fully known and followed by
all engaged in research on human beings." Id. art. 1.1. Article 1.2 of the EU GCP
states, "[t~he personal integrity and welfare of the trial subjects is the ultimate responsi-
bility of the investigator in relation to the trial; but independent assurance that subjects
are protected is provided by an Ethics Committee and freely obtained informed con-.
sent." Id. art. 1.2.
163. See HELSINKI IV, supra note 156, art. I (11) (stating that child must agree to
participation if able to do so).
874 FORDHAMINTERNATIONAL LAWJOURNAL [Vol. 23:848
nity's opinion in formulating human research regulations. 16 4
3. The CIOMS/WHO International Ethical Guidelines for
Biomedical Research Involving Human Subjects
In 1983, the CIOMS and WHO produced the CIOMS/
WHO Guidelines.'65 The authors of the CIOMS/WHO Guide-
lines intended to clarify Helsinki TV, and to make its provisions
more easily applicable.' 66 They also sought to assist developing
countries in formulating guidelines for human research. 67 Be-
cause the Guidelines address research conducted in developing
countries, its drafters were forced to recognize divergent inter-
cultural ethical standards. 68 The document was drafted in three
CIOMS Round Table Conferences, in consultation with health
ministries and medical schools from more than sixty coun-
tries."' The Guidelines were first introduced in 1982,170 and
later revised and reissued in 1993.171
The authors of the Guidelines sought to create protections
164. See Levine, supra note 90, at 243 (stating that Helsinki recognized need for
professional guidelines drafted for and by physicians).
165. See CIOMS/WHO GUIDELINES, supra note 93.
166. See Sev S. Fluss, The Regulation of Human Experimentation: Historical and Contem-
porary Perspectives, in RESEARCH ON HUMAN SUBJECTS 222, 229 (David Weisstub ed., 1998)
(explaining that CIOMS/WHO Guidelines were intended to "amplify and give effect"
to Helsinki IV).
167. See Perley, supra note 88, at 161 (citing WHO/CIOMS PROJECT PROPOSAL FOR
THE DEVELOPMENT OF GUIDELINES FOR ESTABLISHMENT OF ETHICAL REVIEW PROCEDURES
FOR RESEARCH INVOLVING HUMAN SUBJECTS 4 (WHO & CIOMS, 1978). The CIOMS/
WHO's objectives were to
develop the guidelines for the establishment of ethical review procedures for
research involving human subjects [so as to] enable countries to: (a) define a
national policy on the ethics of medical and health research and to adopt
ethical standards appropriate to their specific local needs; and (b) to establish
adequate mechanisms for ethical review of research activities involving human
subjects.
Id.
168. See CIOMS/WHO GUIDELINES, supra note 93, at Guideline 8 (stating that in-
vestigators must seek review from ethical review boards that are "thoroughly familiar
with the customs and traditions of the community").
169. See Perley, supra note 88, at 161 (explaining that CIOMS sent out more than
100 questionnaires to Health Ministries and medical schools in developing nations, and
more than 60 responses were received).
170. See Bankowski, supra note 134, at 182 (stating that CIOMS and WHO first
released Proposed International Guidelines for Biomedical Research Involving Human
Subjects in 1982 for comment and revision).
171. Id.
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for vulnerable subjects, including children.172 In fact, the Guide-
lines devote an entire section to informed consent and risk is-
sues pertaining to pediatric subjects both in therapeutic and
non-therapeutic trials. 173  Guideline Five spends three
paragraphs explaining that a parent must give proxy consent,
that the child must consent to the extent he or she is able, and
that the child's refusal to participate in non-therapeutic research
must always be respected.1 7 ' Furthermore, Guideline Five ex-
plains that the level of risk in pediatric trials must be low and, at
the very least, in proportion to the knowledge that the research
is likely to yield.' 75 Indeed, despite early concerns that interna-
tional guidelines must be general to accommodate varying opin-
ions, 1 7 6 the CIOMS/WHO Guidelines recognized that research
on children and other vulnerable groups required specialized at-
tention. 177
172. See id. at 183 (describing how CIOMS/WHO Guidelines drafters attempted to
clarify when experimentation on vulnerable populations was ethical).
173. CIOMS/WHO Guidelines, supra note 93, at Guideline 5. Guideline 5 states:
Before undertaking research involving children, the investigator must ensure
that:
" Children will not be involved in research that might equally well be
carried out with adults;
" The purpose of the research is to obtain knowledge relevant to the
health needs of children;
" A parent or legal guardian of each child has given proxy consent;
* The consent of each child has been obtained to the extent of the
child's capabilities;
* The child's refusal to participate in research must always be respected
unless according to the research protocol the child would receive ther-
apy for which there is no medically-acceptable alternative;
* The risk presented by interventions not intended to benefit the individ-
ual child-subject is low and commensurate with the importance of
knowledge to be gained; and
* The interventions that are intended to provide therapeutic benefit are
likely to be at least as advantageous to the individual child-subject as any
available alternative.
Id.
174. Id.
175. Id.
176. See Perley, supra note 88, at 160 (quoting March 1978 WHO document,
WHO/CIOMS Project Proposal for the Development of Guidelines for the Establish-
ment of Ethical Review for Research Involving Human Subjects, stating that "by their
very nature, international declarations can only be general.").
177. See id. at 163 (noting that CIOMS/WHO Guideline paid particular attention
to children, pregnant and nursing women, and mentally ill).
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4. The Council of Europe and the Biomedical Convention
The Council of Europe Convention on Human Rights and
Biomedicine 178 ("Biomedical Convention") represents the first
binding international instrument protecting human rights in bi-
omedicine. 179 The long process culminating in the Biomedical
Convention began in June 1990, with recommendations from
both the European Ministers of Justice and the Parliamentary
Assembly.180 In response to these recommendations, the Com-
mittee of Ministers instructed the Steering Committee on
Bioethics ("CAHBI") to create a general framework convention
protecting human rights in the biomedical field.' 81 The Bi-
omedical Convention was adopted by the Committee of Minis-
ters on November 19, 1996,12 and opened for signature on
178. Council of Europe, Convention on Human Rights and Biomedicine and Ex-
planatory Report, Apr. 4, 1997, 36 I.L.M. 817 [hereinafter Biomedical Convention].
179. See Leuprecht, supra note 22, at 325 (stating that Council of Europe Conven-
tion on Human Rights and Biomedicine ("Biomedical Convention") is "the first bind-
ing legal instrument ever drafted on an international scale with a view to safeguarding
human dignity and fundamental rights against any improper applications of medicine
and biology").
180. See Biomedical Convention, supra note 178, at 827 (stating that idea for Bi-
omedical Convention originated in European Ministers of Justice adoption of Resolu-
tion No. 3 on Bioethics). Recommendation No. 3 suggested that the Council of Europe
should instruct the Steering Committee on Bioethics ("CAHBI") to formulate a frame-
work convention to express general standards for protecting people in light of continu-
ing biomedical developments. Id. CAHBI was to be instructed to "examine the possibil-
ity of preparing a framework convention 'setting out common general standards for the
protection of the human person in the context of the development of the biomedical
sciences.'" Id. In June 1991, the Parliamentary Assembly promulgated Recommenda-
tion 1160, set forth a similar recommendation for a framework convention with general
provisions in its main text, and additional protocols regulating specific areas of bi-
omedicine. Id.
181. Id. In September 1991, Mr. Vincent Tabone, chair of the Committee of Min-
isters, instructed the group to create a document
to prepare, in close cooperation with the Steering Committee for Human
Rights (CDDH) and the European Health Committee (CDSP) ... a frame-
work Convention, open to non-member states, setting out common general
standards for the protection of the human person in the context of the bi-
omedical sciences and Protocols to this Convention, relating to, in a prelimi-
nary phase: organ transplants and the use of substances of human origin;
[and] medical research on human beings.
Id. The Biomedical Convention was open to signature by both member and non-mem-
ber states. Id.
182. See id. (explaining that draft Biomedical Convention was modified according
to Parliamentary Assembly recommendations contained in Opinion No. 184, and re-
ports issued by Committee on Science and Technology, Committee on Legal Affairs
and Human Rights, and Social, Health and Family Affairs Committee, and adopted on
2000) THE RIGHTS OF PEDIATRIC RESEARCH SUBJECTS 877
April 4, 1997.183
The Biomedical Convention is based on a variety of pre-ex-
isting international and European human rights controls18 4 that
consider respect for human dignity as their primary themes.18
Each party to the Biomedical Convention must give effect to its
provisions through domestic legislation."' Although the negoti-
ating process diluted some of the provisions of the Biomedical
Convention, 18 7 this document makes significant progress in uni-
fying certain areas of biomedical regulation. 8  The Biomedical
Convention addresses issues relevant to human research in its
chapters regarding consent and research. 8 9
The chapter on consent mandates that every person must
November 19, 1996). Belgium, Germany, and Poland abstained from the vote. Anne
Lawton, Regulating Genetic Destiny: A Comparative Study of Legal Constraints in Europe and
the United States, 11 EMORY INT'L L. REV. 365, 383, n.53 (1997).
183. See Lawton, supra note 182, at 383 (stating that Biomedical Convention was
opened for signature on April 4, 1997).
184. See Biomedical Convention, supra note 178, at Preamble (stating that Bi-
omedical Convention contains principles embodied in U.N. Universal Declaration of
Human Rights, Convention for the Protection of Human Rights and Fundamental Free-
doms, European Social Charter, International Covenant on Civil and Political Rights,
International Covenant on Economic, Social, and Cultural Rights, Convention for the
Protection of Individuals with regard to Automatic Processing of Personal Data, and
Convention on the Rights of the Child),
185. See Lawton, supra note 182, at 384-85 (stating that first principle is embodied
in Article one of Biomedical Convention, which states, "parties to this Convention shall
protect the dignity and integrity of all human beings," and second theme is represented
in Article 2, which echoes Helsinki in stating that "[the interests and welfare of the
human being shall prevail over the sole interest of society or science."); see also Eibe
Riedel, Global Responsibilities and Bioethics: Reflections on the Council of Europe's Bioethics
Convention, 5 IND. J. GLOBAL LEGAL STUD. 179, 182 (1997) (stating that Biomedical Con-
vention used European Convention on Human Rights and Fundamental Freedoms' ap-
proach to bring "the inherent value of the human being into the bioethics debate").
186. See Biomedical Convention, supra note 178, art. 1.2. (stating that "[elach
party shall take in its internal law the necessary measures to give effect to the provisions
of this Convention.").
187. See Maurice A.M. de Wachter, The European Convention on Bioethics; Includes
Related Information, HASTINGS CTR. REP., Jan.-Feb. 1997, at 13, 15 (conveying story of
Parliamentary Assembly president when Assembly gave its first opinion on Biomedical
Convention, stating that Biomedical Convention provisions resulted from "com-
promises in harmonizing the interests of the individual human being, society, and sci-
ence").
188. See Riedel, supra note 185, at 183 (explaining Biomedical Convention's six
main focal points). The main focal points of the Convention are: (1) questions of con-
sent to interventions in the health field; (2) protection of the human genome and
scientific research; (3) research on embryos; (4) transplantation medicine; (5) data
protection issues; and (6) economic consequences of biogenetics. Id.
189. Biomedical Convention, supra note 178, at Chap. II & V. Chapter Two of the
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give free and informed consent before undergoing any type of
medical intervention. 9 ° This provision is satisfied if the patient
is provided with appropriate information regarding the purpose,
nature, consequences, and risks of the intervention. 9' The pa-
tient's consent can be written or verbal, express or implied, de-
pending on the nature of the intervention. 92 A person may
withdraw consent for treatment at any time.1 93
The Biomedical Convention also directly addresses individ-
uals who lack the legal capacity to consent, such as children.1 94
Although the Biomedical Convention does not explicitly define
the inability to consent, 95 it states that a minor's opinion must
be considered proportional to his or her age and maturity
level.'9 6 If the patient is determined to be incompetent under
Biomedical Convention is entitled "Consent" and Chapter Five addresses "Scientific Re-
search." Id.
190. See id. art. 5 ("[a]n intervention in the health field may only be carried out
after the person concerned has given free and informed consent to it"). This provision
is intended to secure the patient's autonomy in his or her relationship with the health
care provider, and affirm the well-established international rule that no person should
be forced to undergo a medical procedure without his or her express consent. Id. at
Explanatory Report, para. 34.
191. See id. art. 5 (stating "[tlhis person shall beforehand be given appropriate
information as to the purpose and nature of the intervention as well as on its conse-
quences and risks"). The information required in this paragraph, however, is not an
exhaustive list; other information may be required, depending on the intervention, and
must include information regarding alternative treatments. Id. at Explanatory Report,
para. 35. Any information imparted on the patient must be clear and worded in a
manner suited to the person who is to undergo the intervention, must be objective, and
must be given in a way that does not exert any pressure on the patient to participate in
the intervention. Id. at 35-36.
192. See id. at Explanatory Report, para. 37 (stating that express consent would be
inappropriate with regard to routine medical acts). Providing the patient with suffi-
cient information is suitable in these situations. Id.
193. See id. art. 5. ("[t]he person concerned may freely withdraw consent at any
time.").
194. See id. art. 6 (discussing "protection of persons not able to consent").
195. See id. art. 6.2 (stating that "[w] here, according to law, a minor does not have
capacity to consent. . ."). The Explanatory Report elaborates on this position, stating
that "it is for domestic law in each country to determine, in its own way, whether or not
persons are capable of consenting to an intervention and taking account of the need to
deprive persons of their capacity for autonomy only where it is necessary in their best
interests." Id. at Explanatory Report, para. 42.
196. See id. art. 6.2 (stating that "[t]he opinion of the minor shall be taken into
consideration as an increasingly determining factor in proportion to his or her age and
degree of maturity."). The Explanatory Report states that obtaining the minor's opin-
ion is necessary to preserve the concept of individual autonomy, in accordance with
Article 12 of the Convention on the Rights of the Child. See id. at Explanatory Report,
para. 45 (explaining that minor's opinion should be taken into account to degree that
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national law, then the health care provider must obtain the con-
sent of the patient's legal representative before performing the
experiment. 1
97
The provisions for consent are further modified in the
chapter addressing scientific research. 9 8 This chapter specifies
that research on incompetent individuals can only be performed
if: (1) the subject will receive direct medical benefit from the
protocol; (2) the research cannot be carried out on adults; (3)
the subject's legal representative gives consent; and (4) the sub-
ject does not object.'99 Unlike the provisions for informed con-
sent in medical treatment, consent for medical research from a
legal representative must be specific and written. 20  This provi-
sion also requires the researcher to consider the patient's opin-
ion on whether to participate in the protocol.201 Research that
does not directly benefit the research subject can only be carried
out if it will contribute to a greater understanding of the individ-
ual's condition and if it will benefit patients in the subject's age
group.20 2 Although this provision would appear to exclude re-
depends on "nature and seriousness of the intervention as well as the minor's age and
ability to understand").
197. Id. art. 6.2.
198. Id. at Chap. V.
199. Id. art. 17 (1) (i). Article 17 (1) (i) states that research on subjects who do
not have capacity to consent can only be undertaken where:
(i) the conditions laid down in Article 16, sub-paragraphs i to iv, are
fulfilled [general provisions for medical research];
(ii) the results of the research have the potential to produce real and
direct benefit to his or her health;
(iii) research of comparable effectiveness cannot be carried out on
individuals capable of giving consent;
(iv) the necessary authorisation provided for under Article 6 has been
given specifically and in writing;
(v) the person concerned does not object.
Id. The Explanatory Report states that potential benefit under this Article means that
"[the benefit must be real and follow from the potential results of the research." Id.
Explanatory Report, para. 103. It also states with regard to objections that "the wish of
the person concerned prevails and is always decisive." Id. para. 108.
200. Id. at Explanatory Report, para. 105 (explaining that Article 6 authorization
must be specific and in writing, and can be withdrawn at any time).
201. See id. at Explanatory Report, para. 106 (stating "[tihe rule prohibiting the
carrying out of research against the wish of the subject reflects concern, in research, for
the autonomy and dignity of the person in all circumstances, even if the person is con-
sidered legally incapable of giving consent.").
202. Id. art. 17 (2) (i), (ii). Article 17 (2) states:
Exceptionally and under the protective conditions prescribed by law, where
the research has not the potential to produce results of direct benefit to the
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search in healthy children, the Biomedical Convention's Explan-
atory Report notes that research in healthy children under this
definition is per se ethical, as it may eventually benefit the
child.2 °3
With regard to the level of risk exposure in a non-therapeu-
tic trial, the Biomedical Convention imposes greater restrictions
for children than those imposed for adults. 214 Instead of merely
mandating that the benefits of the research outweigh the risks,
the Biomedical Convention states that non-therapeutic research
may only be conducted on children if it involves minimal risk
and minimal burden to the subject.20 5 Although the term mini-
mal risk is not defined, the Explanatory Report further discusses
this term and gives concrete examples of what constitutes mini-
mal risk in incompetent populations.20 6
health of the person concerned, such research may be authorised subject to
the conditions laid down in paragraph 1, subparagraphs i, ii, iii, iv, and v
above, and to the following additional conditions:
i. the research has the aim of contributing, through significant improve-
ment in the scientific understanding of the individual's condition, dis-
ease or disorder, to the ultimate attainment of results capable of con-
ferring benefit to the person concerned or to other persons in the
same age category or afflicted with the same disease or disorder or
having the same condition.
ii. The research entails only minimal risk and minimal burden for the
individual concerned.
Id.
203. See id. at Explanatory Report, para. 109 (explaining that although research in
healthy children is clearly for benefit of other children, "such research may well be of
ultimate benefit to healthy children taking part in this research."). Paragraph 110 also
states that the phrase "individual's condition" may also refer generally to aspects of
normal child development, relevant to childhood abnormalities or diseases. Id. para.
110.
204. See id. art. 16 (ii) (mandating that risk may not outweigh benefits in trials
involving human subjects).
205. See id. art. 17 (2) (ii) (stating that research is permissible if it "entails only
minimal risk and minimal burden for the individual involved).
206. Id. at Explanatory Report, para. 113 (a). Paragraph 113 (a) of the Explana-
tory Report states with regard to minimal risk,
in respect of children: replacing x-ray examinations or invasive diagnostic
measures for children by ultrasonic scanning; analyses of incidental blood
samples from newborn infants without respiratory problems in order to estab-
lish the necessary oxygen content for premature infants; discovering the
causes and improving treatment of leukaemia in children (e.g. by taking a
blood sample).
Id. Paragraph 114 notes that non-therapeutic interventions described in paragraph 113
(a), "may be ethically acceptable if the above highly protective conditions, resulting
from the combined effect of Articles 6, 7, 16, and 17, are fulfilled." Id. para. 114.
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Due to differences in national regulations, the drafters of
the Biomedical Convention faced some problems.2 °7 In particu-
lar, they encountered difficulties creating a uniform set of regu-
lations that place a different emphasis on codified law.2°" Gen-
eral cultural and religious differences also made drafting the Bi-
omedical Convention more difficult, as varied religious values
throughout the Council of Europe created divergent views on
bioethical issues.20 9
The Biomedical Convention's provisions regarding non-
therapeutic research in subjects who are unable to give informed
consent caused a significant amount of debate among the mem-
bers of the Council of Europe.210 This provision drew a particu-
larly negative response from Germany, whose government re-
fused to sign the final draft of the Biomedical Convention. 211
Despite these controversies, however, the Biomedical Conven-
tion is binding, as it has been signed and ratified by more than
the requisite number of member states. 12
207. See Arthur Rogers, Europe: Ethical Diversity, 339 LANCET 861 (1992) (noting
difficulties at Workshop discussions in Madrid, stating that "national approaches to
bioethics [were] more divergent than had been suspected and that similarities [were]
largely superficial").
208. See id. (stating that countries with more codified legal systems were more
open to more legislation to control ethical review boards, while others, such as Canada,
Germany, and United Kingdom "view legislation as too confining and difficult to inter-
pret.").
209. See Richard H. Nicholson, One Law for All?, HASTINGS CTR. REP., Mar-Apr.
1995, at 4 (explaining tendency for division in Europe on bioethical issues between
predominantly Catholic South and Protestant North).
210. See Rory Watson, European Bioethics Convention Signed, 314 BRIT. MED. J. 1065
(1997) (quoting Dr. Peggy Norris, secretary of European Doctor's Union, stating,
"[t]he basic rule should be that you cannot do research on someone without their con-
sent").
211. See Bioethics Convention Fails in the Council of Europe; German Opposition Decisive,
WEEK IN GERMANY, Oct. 7, 1994 (noting Germany's opposition to non-therapeutic inter-
ventions on incapacitated persons and embryonic research, and that, accordingly, prior
to Council of Europe vote representatives of Germany's political parties made their
opposition to Biomedical Convention unambiguously clear). It was also upon recom-
mendation of the German Bundestag that the name of the document was changed
from the "Convention on Bioethics" to the "Convention on Biomedicine." de Wachter,
supra note 187, at 16. Germany particularly opposed the informed consent provisions,
as they found that they contradicted German law, which forbids all non-therapeutic
research on children. de Wachter, supra, at 17. This provision met with strong objec-
tions not only from the German government, but also from patient's groups, the Ro-
man Catholic Church, the German Evangelical Church, and major German political
parties. Id. Even after several changes were made to the Biomedical Convention to
appease the German delegation, the Germans still refuse to sign on to it. Id.
212. See Council of Europe Website, Convention on Human Rights and Biomedicine,
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5. The United Nations Convention on the Rights of the Child
The U.N. Convention on the Rights of the Child was
adopted unanimously by the General Assembly of the United
Nations on November 20, 1989.213 Presently, all U.N. members
have signed and ratified the CRC, with the exception of the
United States and Somalia. 4 The primary value expressed by
the CRC is preserving the child's dignity as a human being, de-
fined as the child's identity, self-worth, autonomy, and develop-
ment of self-realization. 215 The CRC working group strove to de-
pict children in a way that illuminates their vulnerability, and as
a group whose evolving capabilities must be respected, and
whose rights should be granted accordingly.21 6 Thus, the CRC
promotes the view that a child should not be denied the oppor-
tunity to participate actively in matters that effect his or her
life.2 17 The CRC Committee did not, however, advocate that
Chart of Signatures and Ratifications (visited Feb. 21, 2000) <http://www.coe.fr/tablconv/
164t.htm> (on file with the Fordham International Law Journal) (listing states that have
signed and ratified Biomedical Convention).
213. See Cynthia Price Cohen, Introductory Note: United Nations: Convention of the
Rights of the Child, 28 I.L.M. 1448 (1998) (noting that this document is outgrowth of
Declaration of the Rights of the Child, issued by United Nations in 1959). In 1979, the
International Year of the Child, a working group was established to draft the Conven-
tion on the Rights of the Child ("CRC"). Id.
214. Id. at 29. See Catherine Langevin-Falcon, Second Class Citizens?, HUMANIST,
Nov. 1, 1998, at 11 (stating that even though United States has signed CRC, it has not
yet ratified it).
215. SeeJudith Karp, Concepts Underlying the Implementation of the Convention on the
Rights of the Child, 4 Loy. POVERTY LJ. 113, 114 (1998) (explaining basic values underly-
ing CRC). The 10 basic concepts underlying CRC are:
1. Respect for human dignity;
2. Rights-based orientation;
3. Holistic and integrated approach;
4. Empowerment and visibility of children;
5. Partnership and society;
6. Implementation and development as a process of empowerment;
7. Proactivity;
8. Maximization of efforts;
9. Sustainability;
10. Transparency and accountability.
Id.
216. See id. at 123-24 (explaining that CRC gives voice to movement that children
should be granted rights in accordance with their developing capacities, not necessarily
according to official age of majority).
217. See id. at 124 (explaining principle of participation and that "basic message of
the Convention is that a child is not a dormant entity, devoid of all capacity until the
age of eighteen.").
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children should be completely independent of parental influ-
ence, but rather, that professionals should be trained to deal
with children in a way that maximizes their empowerment while
respecting their vulnerabilities.218
Although the CRC does not directly address pediatric medi-
cal research or medical informed consent, several articles of the
CRC are relevant to this topic. 219 For example, the CRC entitles
children with the highest standards of health and treatment fa-
cilities, 22° and prohibits any national health care practices that
are prejudicial to children.221 Parties are also encouraged to
take all appropriate measures to provide necessary pediatric
health care, and develop their primary care systems. 22 With re-
spect to a child's participation in research decisions, the CRC
states that a child should generally be able to express his or her
own views according to his or her capacity, and have others re-
spect those views in accordance with his or her age.223 This pro-
vision, however, is mitigated by a provision that requires states to
respect a parent's right to guide the child's decision making.224
218. See id. at 124 (stating that CRC advocates that decision makers should be
subordinate to children, and that children's views should be listened to; this process
could be facilitated by training individuals who work with children to inform them in
age-appropriate manner).
219. See generally CRC, supra note 96.
220. Id. Article 24, paragraph 1 states
States Parties recognize the right of the child to the enjoyment of the highest
attainable standard of health and to the facilities for the treatment of illness
and rehabilitation of health. States Parties shall strive to ensure that no child
is deprived of his or her right of access to such health care services.
Id.
221. See id. art. 24, para. 3 ("States Parties shall take all effective and appropriate
measures with a view to abolishing traditional practices prejudicial to the health of chil-
dren.").
222. See id. art. 24, para. 2 (b) ("States Parties shall pursue full implementation of
this right and, in particular, shall take appropriate measures: ... "t~o ensure the provi-
sion of necessary medical assistance and health care to all children with emphasis on
the development of primary health care.").
223. See id. art. 12 ("States Parties shall assure to the child who is capable of form-
ing his or her own views the right to express those views freely in all matters affecting
the child, the views of the child being given due weight in accordance with the age and
maturity of the child.").
224. See id. art. 14, para. 2 (stating that all parties "shall respect the rights and
duties of the parents and, when applicable, legal guardians, to provide direction to the
child in the exercise of his or her right in a manner consistent with the evolving capaci-
ties of the child"). Article 5 provides that parties
shall respect the responsibilities, rights and duties of parents or, where appli-
cable the members of the extended family or community as provided for by
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Although the CRC has been ratified by 191 countries, mak-
ing it the most widely adopted human rights instrument in such
a short period of time, it does have its detractors, particularly the
United States.225 Some critics denounce the CRC as giving chil-
dren too many rights, thereby separating the child from valuable
familial influence and guidance. 226 Another criticism is that the
CRC is too vague, and leaves room for certain rights to be dimin-
ished.227 For all of the criticism that the CRC has received, how-
ever, even its detractors agree that the CRC symbolizes a growing
movement for more autonomy, independence, and respect for
children and their rights as research subjects.2 28
C. Pediatric Medical Research Regulations in the United States,
European Union, and Japan
The three primary governmental entities involved in the
ICH are the United States, European Union, andJapan.229 Each
of these entities has independent regulatory schemes governing
human research issues.230 These regulations, along with the in-
ternational conventions discussed earlier, comprise the basis for
local custom, legal guardians or other persons legally responsible for the
child, to provide, in a manner consistent with the evolving capacities of the
child, appropriate direction and guidance in the exercise by the child of the
rights recognized in the present Convention.
Id. art. 5.
225. Robert F. Drinan, A Global Revolution for Children, AMERICA, Mar. 27, 1999.
226. See Bruce C. Hafen & Jonathan 0. Hafen, Abandoning Children to Their Own
Autonomy: The United Nations Convention on the Rights of the Child, 37 HARV. INT'L L. J.
449, 458, 478 (1996) (opining that Article 5 of CRC limits parental authority to that
which is compatible with rights of child and that children should not necessarily be
given more autonomy without data showing increased capacity to handle such responsi-
bilities).
227. SeeJamesJ. Kilpatrick, Take a Closer Look at U.N. Children's Treaty: It Bites, NEws
& OBSERVER, May 20, 1991 .(criticizing use of phrase "highest attainable standard" as
describing level of health care that children should be able to enjoy).
228. See Hafen & Hafen, supra note 226, at 457 (noting that CRC exemplifies inter-
national movement toward increased social and legal autonomy for children).
229. See International Conference on Harmonisation Web Site (visited Dec. 2,
1999) <http://www.ich.org> (on file with the Fordham International Law Journal) (ex-
plaining that United States, European Union, and Japan formulated idea for ICH at
WHO Conference on Drug Regulatory Activities).
230. See 45 C.F.R. § 46 (1999) (including U.S. Regulations on human research); see
also Guideline for Children, supra note 51 (including European Community guidelines
on human research on children); GOOD CLINICAL PRACrCE (Japanese Ministry of
Health and Welfare) effective Apr. 1998 [hereinafter NEW JAPANESE GCP] (including
Japanese regulations on human research).
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creating pediatric medical research guidelines in the ICH.2 3 1
1. U.S. Regulations on Assent and Risk
The United States has two separate sets of human research
regulations.232 The first set of regulations was promulgated by
FDA for research on FDA-regulated products including food ad-
ditives, drugs, medical devices, and biological products for
human use. 23 3 The second set of regulations was agreed to by
the other seventeen federal agencies that conduct human re-
search in the United States ("Common Rule").24 Although
both sets of regulations are similar,235 the Common Rule, unlike
the FDA regulations, contains an entire set of rules devoted to
pediatric research.236
The Common Rule arose from the National Research
Act,2 17 which was passed by Congress on July 12, 1974.28 The
231. See Department of Health and Human Services, International Conference on
Harmonisation; Draft Guideline on Good Clinical Practice, 60 Fed. Reg. 42948, 42498 (1995)
[hereinafter Draft GCP] (explaining sources of ICH Guidelines).
232. Jeffrey Cohen, Ph.D., Associate Director of Education, Office for Protection
from Research Risks, Department of Health and Human Services National Institutes of
Health, Presentation at Fordham University School of Law (Feb. 16, 2000) (stating that
FDA has regulations that are distinct from those adopted by all other research-oriented
agencies in U.S. Government).
233. 21 C.F.R § 50.1 (1999). Title 21, section 50.1 states that the FDA regulations
apply to "all clinical investigations regulated by the Food and Drug Administration...
that support applications for research or marketing permits for products regulated by
the Food and Drug Administration, including food and color additives, drugs for
human use, medical devices for human use, biological products for human use, and
electronic products." Id.
234. See Cohen, supra note 232 (stating that 45 C.F.R. § 46 has been adopted to
regulate human research by 17 U.S. agencies, including, among others, Departments of
Agriculture, Energy, Commerce, Housing and Urban Development, Justice, Defense,
Education, Veteran's Affairs, Transportation, Social Security Administration, Central
Intelligence Agency, and Consumer Product Safety Commission). Title 45, section 46
of the C.F.R. is referred to as the Common Rule. Id.
235. See id. (stating that FDA regulations and Common Rule are "utterly the
same").
236. See 45 C.F.R. § 46, Sub. D (1999) (addressing "Protections for Children In-
volved as Subjects in Research"). The FDA Regulations only state that when
[w]hen some or all of the subjects, such as children, prisoners, pregnant wo-
men, handicapped, or mentally disabled persons, or economically or educa-
tionally disadvantaged persons, are likely to be vulnerable to coercion or un-
due influence additional safeguards have been included in the study to pro-
tect the rights and welfare of these subjects.
21 C.F.R. § 56.111 (c) (1999).
237. 45 C.F.R. § 46 (1999).
238. Id.
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National Research Act created the National Commission for the
Protection of Human Subjects in Biomedical and Behavioral Re-
search (the "Commission") .29 The National Research Act em-
powered the Commission with the responsibility for determining
how and under what circumstances research on children and
other groups is appropriate.24 ° In 1977, the Commission issued
its Report and Recommendations on Research Involving Chil-
dren 241 ("Commission Report"), which formed the basis for the
Common Rule provisions regarding pediatric research.242
The Commission Report introduced several key concepts
now embodied in the Common Rule.2 43 The first concept is that
research on children is necessary to promote children's health
and welfare.244 The Commission Report also introduced institu-
tional review boards to evaluate each medical research study's
worth and appropriateness. 245 The Commission further deter-
mined that the best way to achieve effective informed consent
for pediatric medical research would be through a combination
239. Rules and Regulations, Department of Health and Human Services, 48 Fed.
Reg. 9814, 9814 (1983) (stating that National Research Act made Commission responsi-
ble for studying "nature of research on children, the purposes of such research, the
steps necessary to protect children as subjects, and the requirements for informed con-
sent of children, their parents or guardians").
240. Id.
241. NATIONAL COMMISSION FOR THE PROTECTION OF HuMAN SUBJECTS IN BIOMEDI-
CAL AND BEHAVIORAL RESEARCH, REPORT AND RECOMMENDATIONS ON RESEARCH INVOLV-
ING CHILDREN (1977) [hereinafter COMMISSION REPORT].
242. See Nelson, supra note 44, at 52 (stating that Commission Report was founda-
tion for current federal regulations).
243. See Leonard H. Glantz, The Law of Human Experimentation with Children, in
CHILDREN AS RESEARCH SUBJECTS, 103, 121 (Michael A. Grodin & Leonard Glantz, eds.,
1994) (noting that Commission recommendations were largely incorporated into final
rules). The U.S. human research regulations apply to all federally funded pediatric
medical research, except for studies employing educational tests and observations of
public behavior. Id.; see also 45 C.F.R. § 46.401 (a) (stating that Subpart D applies to "all
research involving children as subjects conducted or supported by the Department of
Health and Human Services"). Section 46.402 (b) states that
[t]he exemption at §46.101 (b) (2) regarding educational tests are applicable
to this subpart. However, the exemption at §46.101 (b) (2) for research in-
volving a survey or interview procedures or observations of public behavior
does not apply to research covered in this subpart, except for research involv-
ing observation of public behavior when the investigators do not participate in
the activities being observed.
Id. § 46.402(b).
244. See Glantz, supra note 243, at 123-25 (describing Commission Report's influ-
ence over current regulations).
245. Id.
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of parental permission and child assent.246 The Commission Re-
port also set forth a minimal risk standard to limit parental dis-
cretion to volunteer their children for potentially risky medical
trials. 4 7 Finally, the Commission created the four risk/benefit
categories that appear in the Common Rule.24
The Common Rule, like the Commission Report, does not
use the term informed consent 249 to refer to a subject's agree-
246. See Ross, supra note 78, at 161 (explaining that Commission set forth mini-
mum requirements for guidelines on pediatric research and created IRBs "to ensure
that these safeguards were fulfilled").
247. Nelson, supra note 44, at 54.
248. See Glantz, supra note 243, at 120 (explaining that Commission balanced risks
and benefits of research and current regulations are based on balancing these factors).
249. 45 C.F.R. § 46.116 (1999). Section 46.116 states
Except as provided elsewhere in this policy, no investigator may involve a
human being as a subject in research covered by this policy unless the investi-
gator has obtained the legally effective informed consent of the subject or the
subject's legally authorized representative. An investigator shall seek such
consent only under circumstances that provide the prospective subject or the
representative sufficient opportunity to consider whether or not to participate
and that minimize the possibility of coercion or undue influence. The infor-
mation that is given to the subject or the representative shall be in language
understandable to the subject or the representative. No informed consent,
whether oral or written, may include any exculpatory language through which
the subject or the representative is made to waive or appear to waive any of the
subject's legal rights, or releases or appears to release the investigator, the
sponsor, the institution or its agents from liability for negligence.
(a) Basic elements of informed consent. Except as provided in para-
graph (c) or (d) of this section, in seeking informed consent the fol-
lowing information shall be provided to each subject:
(1) A statement that the study involves research, an explanation of
the purposes of the research and the expected duration of the
subject's participation, a description of the procedures to be fol-
lowed, and identification of any procedures which are experi-
mental.
(2) A description of any reasonably foreseeable risks or discomforts
to the subject.
(3) A description of any benefits to the subject or to others which
may reasonably be expected from the research.
(4) A disclosure of appropriate alternative procedures or courses of
treatment, if any, that might be advantageous to the subject.
(5) A statement describing the extent, if any, to which confidentiality
of records identifying the subject will be maintained.
(6) For research involving more than minimal risk, an explanation as
to whether any compensation and an explanation as to whether
any medical treatments are available if injury occurs and, if so,
what they consist of, or where further information may be ob-
tained.
(7) An explanation of whom to contact for answers to pertinent
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questions about the research and research subjects' rights, and
whom to contact in the event of a research-related injury to the
subject.
(8) A statement that participation is voluntary, refusal to participate
will involve no penalty or loss of benefits to which the subject is
otherwise entitled, and the subject may discontinue participation
at any time without penalty or loss of benefits to which the sub-
ject is otherwise entitled.
(b) Additional elements of informed consent. When appropriate, one or
more of the following elements of information shall also be provided
to each subject:
(1) A statement that the particular treatment or procedure may in-
volve risks to the subject (or to the embryo or fetus, if the subject
is or may become pregnant) which are currently unforeseeable.
(2) Anticipated circumstances under which the subject's participa-
tion may be terminated by the investigator without regard to the
subject's consent.
(3) Any additional costs to the subject that may result from participa-
tion in the research.
(4) The consequences of a subject's decision to withdraw from the
research and procedures for orderly termination of participation
by the subject.
(5) A statement that significant new findings developed during the
course of the research which may relate to the subject's willing-
ness to continue participation will be provided to the subject.
(6) The approximate number of subjects involved in the study.
Id. The FDA Regulation requirements for informed consent are found at 21 C.F.RI
§ 50.25. Title 21, section 50.25 of the Code of Federal Regulations states,
(a) Basic elements of informed consent. In seeking informed consent,
the following information shall be provided to each subject:
(1) A statement that the study involves research, an explanation of
the purposes of the research and the expected duration of the
subject's participation, a description of the procedures to be fol-
lowed, and identification of any procedures which are experi-
mental.
(2) A description of any reasonably foreseeable risks or discomforts
to the subject.
(3) A description of any benefits to the subject or to others which
may reasonably be expected from the research.
(4) A disclosure of appropriate alternative procedures or courses of
treatment, if any, that might be advantageous to the subject.
(5) A statement describing the extent, if any, to which confidentiality
of records identifying the subject will be maintained and that
notes the possibility that the Food and Drug Administration may
inspect the records.
(6) For research involving more than minimal risk, an explanation as
to whether any compensation and an explanation as to whether
any medical treatments are available if injury occurs and, if so,
what they consist of, or where further information may be ob-
tained.
(7) An explanation of whom to contact for answers to pertinent
questions about the research and research subjects' rights, and
[Vol. 23:848
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ment to participate in pediatric studies.25 ° Instead, the Common
Rule uses the term permission 251 to refer to a parent's agree-
ment to allow its child to participate in a study, and assent to
refer to a legally incompetent child's express agreement to par-
whom to contact in the event of a research-related injury to the
subject.
(8) A statement that participation is voluntary, that refusal to partici-
pate will involve no penalty or loss of benefits to which the sub-
ject is otherwise entitled, and that the subject may discontinue
participation at any time without penalty or loss of benefits to
which the subject is otherwise entitled.
(b) Additional elements of informed consent. When appropriate, one or
more of the following elements of information shall also be provided
to each subject:
(1) A statement that the particular treatment or procedure may in-
volve risks to the subject (or to the embryo or fetus, if the subject
is or may become pregnant) which are currently unforeseeable.
(2) Anticipated circumstances under which the subject's participa-
tion may be terminated by the investigator without regard to the
subject's consent.
(3) Any additional costs to the subject that may result from participa-
tion in the research.
(4) The consequences of a subject's decision to withdraw from the
research and procedures for orderly termination of participation
by the subject.
(5) A statement that significant new findings developed during the
course of the research which may relate to the subject's willing-
ness to continue participation will be provided to the subject.
(6) The approximate number of subjects involved in the study.
(c) The informed consent requirements in these regulations are not in-
tended to preempt any applicable Federal, State, or local laws which
require additional information to be disclosed for informed consent
to be legally effective.
(d) Nothing in these regulations is intended to limit the authority of a
physician to provide emergency medical care to the extent the physi-
cian is permitted to do so under applicable Federal, State, or local
law.
Id. at § 50.25.
250. COMMISSION REPORT, supra note 241, at 13. The Commission Report states
that "[t]he commission uses the term parental or guardian permission rather than 'con-
sent,' in order to distinguish what a person may do autonomously (consent) from what
one may do on behalf of another (grant permission)." Id.; see 45 C.F.R. § 46.402 (1999)
(omitting definition of consent in definitions); Glantz, supra note 243, at 120 (stating
that National Commission intentionally avoided consent in its recommendations).
251. 45 C.F.R § 46.402 (c) (1999). Permission is defined in the Common Rule as
"the agreement of parent(s) or guardian to the participation of their child or ward in
research." Id. Although the National Commission suggested that the disclosure re-
quirements for assent should be the same as those for consent, these components must
be modified to allow the child to understand the trial. Glantz, supra note 243, at 144.
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ticipate.25 2 Under the Common Rule, the definition of a child
may vary from one research institution to another, as it defers to
the law of the jurisdiction where the research is conducted on
this point.255 Although the Common Rule requires that a child
provide express assent to participate, 5 4 it does not include the
Commission's recommendation that a child's dissent, or refusal
to participate in research, should be binding.255
The Common Rule also mandates that every research insti-
tution receiving federal funding must have an IRB2 5 6 to protect
252. 45 C.F.R. § 46.402 (b) (1999). The Common Rule defines assent as "a child's
affirmative agreement to participate in research. Mere failure to object should not,
absent affirmative agreement, be construed as assent." Id. The FDA Regulations, on
the other hand, only state, in their section on Exception from general requirements,
that
[t]he obtaining of informed consent shall be deemed feasible unless, before
the use of the test article (except as provided in paragraph (b) of this section),
both the investigator and a physician who is not otherwise participating the in
clinical investigation certify in writing all of the following... (2) Informed
consent cannot be obtained from the subject because of an inability to com-
municate with, or obtain legally effective consent from, the subject.
21 C.F.R. § 50.25 (1999). In these cases, the subject's legally authorized representative
or family member should give consent for the subject's participation in the study. 21
C.F.R. § 50.3 (l)-(m) (1999).
253. Id. § 46.402 (a). The Common Rule defines children as "persons who have
not yet attained the legal age for consent to treatments or procedures involved in the
research, under the applicable laws of the jurisdiction in which the research will be
conducted." Id.
254. See id. § 46.402 (b) (stating that failure to object is not same as assent).
255. See Bartholome, supra note 13, at 347 (quoting National Commission Report,
which states that "a child's objection to participation in research should be binding
unless the intervention holds out a prospect of direct benefit that is important to the
health or well-being of the child and is available only in the context of research").
256. 45 C.F.R. § 46.407 (1999). This section states that
(a) Each IRB shall have at least five members, with varying backgrounds
to promote complete and adequate review of research activities com-
monly conducted by the institution. The IRB shall be sufficiently
qualified through the experience and expertise of its members, and
the diversity of the members, including consideration of race, gen-
der, and cultural backgrounds and sensitivity to such issues as com-
munity attitudes, to promote respect for its advice and counsel in
safeguarding the rights and welfare of human subjects. In addition to
possessing the professional competence necessary to review specific
research activities, the IRB shall be able to ascertain the acceptability
of proposed research in terms of institutional commitments and reg-
ulations, applicable law, and standards of professional conduct and
practice. The IRB shall therefore include persons knowledgeable in
these areas. If an IRB regularly reviews research that involves a vulner-
able category of subjects, such as children, prisoners, pregnant wo-
men, or handicapped or mentally disabled persons, consideration
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the health, privacy, and liberty interests of the research sub-
ject.257 Each IRB is responsible for determining whether the in-
vestigator has obtained appropriate assent and permission for
the applicable category of research. 2 8 Although the American
Academy of Pediatrics ("AAP") has suggested that IRBs that re-
view pediatric research must include or consult with health care
professionals that are knowledgeable in pediatric medicine, psy-
chology, and sociology, neither the Common Rule nor the FDA
regulations have adopted this requirement. 259 Finally, IRBs must
shall be given to the inclusion of one or more individuals who are
knowledgeable about and experienced in working with these sub-
jects.
(b) Every nondiscriminatory effort will be made to ensure that no IRB
consists entirely of men or entirely of women, including the institu-
tion's consideration of qualified persons of both sexes, so long as no
selection is made to the IRB on the basis of gender. No IRB may
consist entirely of members of one profession.
(c) Each IRB shall include at least one member whose primary concerns
are in scientific areas and at least one member whose primary con-
cerns are in nonscientific areas.
(d) Each IRB shall include at least one member who is not otherwise
affiliated with the institution and who is not part of the immediate
family of a person who is affiliated with the institution.
(e) No IRB may have a member participate in the IRB's initial or contin-
uing review of any project in which the member has a conflicting
interest, except to provide information requested by the IRB.
(f) An IRB may, in its discretion, invite individuals with competence in
special areas to assist in the review of issues which require expertise
beyond or in addition to that available on the IRB. These individuals
may not vote with the IRB.
Id. The FDA Regulations have exactly the same requirements for IRB membership. 21
C.F.R. § 56.107.
257. 45 C.F.R. § 46.103 (1999). The Common Rule states that the purpose of the
IRB is to "ensure that risks are minimized, subjects are selected equitably, safety and
privacy are protected, and most importantly, informed consent is obtained from sub-
jects.., and documented." Id.
258. 45 C.F.R. § 46.408 (a) (1999). The Common Rule states that,
In determining whether children are capable of assenting, the IRB shall take
into account the ages, maturity, and psychological state of the children in-
volved. Thisjudgment may be made for all children to be involved in research
under a particular protocol, or for each child, as the IRB deems appropriate.
If the IRB determines that the capability of some or all of the children is so
limited that they cannot reasonably be consulted or that the intervention or
procedure involved in the research holds out a prospect of direct benefit that
is important to the health or well-being of the children and is available only in
the context of the research, the assent of the children is not a necessary condi-
tion for proceeding with the research.
Id.
259. See Committee on Drugs, supra note 25, at 288 (stating that "[a] 11 IRBs that
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determine which children are capable of giving assent, and when
the child's refusal to assent may be overridden.26 °
Although the Commission suggested that children should
be allowed to provide assent at the age of seven,26 1 an age that
was also adopted by the AAP, 26 2 the Common Rule does not
adopt a specific age requirement. 263 Instead, the Common Rule
instructs the IRB to determine whether a child is capable of as-
senting based on the child's age, maturity, and psychological
state, and the trial's importance to the child's health. 264 This
instruction, however, has resulted in great variations among re-
search institutions-as one study found that the age of assent
varied from five to fifteen years of age, depending on the IRB. 2 65
Due to these discrepancies, some bioethicists have called for
clearer regulations in this area. 66
Under certain circumstances, the IRB may determine that
parental permission is not required, such as when waiver is nec-
review proposals for investigations in children must include or seek consultation from
health care professionals who are aware of the special medical, psychological, and social
needs of child research subjects."); see also Weisstub, supra note 32, at 390 (stating that
Australian Academy of Pediatrics recommended that "an ethics committee be estab-
lished in all centres responsible for research in children"); Conrad & Homer, supra
note 67, at 169 (recommending that at least one person on IRB have "solid understand-
ing" of child development, and where this is not possible, that IRB should seek advice
from child expert).
260. 45 C.F.R. § 46.408 (a)-(c) (1999) (making IRBs responsible for ensuring that
"adequate provisions are made for soliciting the assent of the children, when in the
judgment of the IRB the children are capable of providing assent").
261. See Glantz, supra note 243, at 144 (stating that Department of Health and
Human Services did not adopt National Commission recommendation that children
aged seven or older should be able to provide assent).
262. Committee on Drugs, supra note 25, at 290.
263. See Bartholome, supra note 13, at 347 (explaining that Regulations did not
adopt National Commission's recommendations regarding age requirements.)
264. See 45 C.F.R. § 46.408(a) (1999) (listing factors for IRBs to consider when
determining which children are capable of assenting).
265. See Conrad & Homer, supra note 67, at 165 (explaining study showing that
little consensus exists to determine if child is capable of assent); see also Weisstub, supra
note 32, at 399400 (noting that in one survey conducted among U.S. authorities in
field of child development regarding appropriate age of consent for research participa-
tion, responses varied from age 2 to 17, with no modal agreement on age emerging).
266. See Bioethicists Call for New Focus on Clinical Research Ethics, Sheep Get in the Way,
HEALTH LEG. & REG., May 14, 1997 (reporting that bioethicists who testified at House
Governmental Reform and Oversight Human Resources Subcommittee hearing called
for "statutory language to clarify rules of research involving vulnerable populations such
as children and the mentally disabled," among other suggestions).
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essary for the trial's success, 2 6 7 when the child is neglected or
abused,2 68 or when the child can give independent informed
consent.269 When an IRB grants a waiver, however, trial subjects
267. 45 C.F.R. § 46.116 (c), (d) (1999). Section 46.116 (c), (d) states
(c) An IRB may approve a consent procedure which does not include, or
which alters, some or all of the elements of informed consent set
forth above, or waive the requirement to obtain informed consent
provided the IRB finds and documents that:
(1) The research or demonstration project is to be conducted by or
subject to the approval of state or local government officials and
is designed to study, evaluate, or otherwise examine: (i) Public
benefit of service programs; (ii) procedures for obtaining bene-
fits or services under those programs; (iii) possible changes in or
alternatives to those programs or procedures; or (iv) possible
changes in methods or levels of payment for benefits or services
under those programs; and
(2) The research could not practicably be carried out without the
waiver or alteration.
(d) An IRB may approve a consent procedure which does not include, or
which alters, some or all of the elements of informed consent set
forth in this section, or waive the requirements to obtain informed
consent provided the IRB finds and documents that:
(1) The research involves no more than minimal risk to the subjects;
(2) The waiver or alteration will not adversely affect the rights and
welfare of the subjects;
(3) The research could not practicably be carried out without the
waiver or alteration; and
(4) Whenever appropriate, the subjects will be provided with addi-
tional pertinent information after participation.
Id.
268. Id. § 46.408 (c). Section 46.408 (c) states
In addition to the provisions for waiver contained in § 46.116 of Subpart A, if
the IRB determines that a research protocol is designed for conditions or for a
subject population for which parental or guardian permission is not a reason-
able requirement to protect the subjects (for example, neglected or abused
children), it may waive the consent requirements in Subpart A of this part and
paragraph (b) of this section, provided an appropriate mechanism for protect-
ing the children who will participate as subjects in the research is substituted,
and provided further that the waiver is not inconsistent with Federal, state or
local law. The choice of an appropriate mechanism would depend upon the
nature and purpose of the activities described in the protocol, the risk and
anticipated benefit to the research subjects, and their age, maturity, status,
and condition.
Id. The FDA Regulations permit IRBs to waive informed consent requirements for all
research when "it finds that the research presents no more than minimal risk of harm
to subjects and involves no procedures for which written consent is normally required
outside the research context." Id. Where the informed consent requirement is waived,
however, "the IRB may require the investigator to provide subjects with a written state-
ment regarding the research." Id.
269. See Conrad & Homer, supra note 67, at 165 (explaining that "some adoles-
cents may provide full informed consent without parental permission even though they
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must be provided with relevant information at the study's con-
clusion. 270 Despite this provision, if the IRB incorrectly waives
the parental permission requirements, then there may be serious
consequences for the research institution, including the loss of
federal funding.271 Under these circumstances, the IRB may also
be found liable in tort to the subject.272
The elements of adequate permission or assent for a par-
ticular trial depend on which of the Common Rule's four
risk/benefit category are appropriate for the trial.273 The first
category includes research that does not involve greater than
have not yet attained full adult legal status"). The first category of minors who can
make independent medical decisions are emancipated minors. Id. Emancipated mi-
nors live independently, are self-supporting, and are not subject to parental control. Id.
Children in this category are comprised mainly of minors who are married or in the
military. Michelle Oberman, Minor Rights and Wrongs, 24 J.L. MED. & ETHICS 127, 130
(1996). A minor may also give independent consent if he seeks medical treatment for a
condition for which the state has passed statutes waiving the parental permission re-
quirement for public policy reasons, such as treatment for sexually transmitted diseases,
alcohol and substance abuse, and psychiatric problems. Oberman, supra, at 130. Fi-
nally, a mature minor may provide independent consent. Id.; see also Conrad & Homer,
supra. Mature minors are "children who understand their medical condition, the alter-
native treatments and their associated risks and benefits, and can make an informed,
voluntary decision about their medical treatments." Id. All minors who are not emanci-
pated, however, are considered children for the purposes of non-therapeutic research.
Glantz, supra note 27, at 230.
270. See 45 C.F.R. § 46.116 (c)(4) (1999) (stating that "[w]henever appropriate,
the subjects will be provided with additional pertinent information after participa-
tion").
271. See id. § 46.122 (declaring that federal funds may not be used in any research
involving human subjects that does not comply with Common Rule).
272. See Robert J. Katerberg, Note, Institutional Review Boards, Research on Children,
and Informed Consent of Parents: Walking the Tightrope Between Encouraging Vital Experimen-
tation and Protecting Subjects'Rights, 24J.C. & U.L. 545, 575 (1998) (explaining that IRBs
may be found tortiously liable for waiver if plaintiff shows not only that IRB incorrectly
waived permission but also that IRB made waiver decision negligently).
273. See 45 C.F.R. § 46.411 (a)(4), (a)(5) (1999) (making IRBs responsible for re-
viewing risks and informed consent); see generally 45 C.F.R. Sub. D (holding IRBs re-
sponsible for determining level of risk and attaining appropriate assent and permis-
sion). The FDA Regulations do not have risk/benefit categories that are specific to
children, but, instead, IRBs must consider
(a) An IRB shall review and have authority to approve, require modifica-
tions in (to secure approval), or disapprove all research activities cov-
ered by these regulations.
(b) An IRB shall require that information given to subjects as part of in-
formed consent is in accordance with § 50.25. The IRB may require
that information, in addition to that specifically mentioned in
§ 50.25, be given to the subjects when in the IRB'sjudgment the in-
formation would meaningfully add to the protection of the rights
and welfare of subjects.
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minimal risk.274  Research in this category requires both the
(c) An IRB shall require documentation of informed consent in accord-
ance with § 50.27 of this chapter, except as follows:
(1) The IRB may, for some or all subjects, waive the requirement that
the subject, or the subject's legally authorized representative,
sign a written consent form if it finds that the research presents
no more than minimal risk of harm to subjects and involves no
procedures for which written consent is normally required
outside the research context; or
(2) The IRB may, for some or all subjects, find that the requirements
in § 50.24 of this chapter for an exception from informed con-
sent for emergency research are met.
(d) In cases where the documentation requirement is waived under para-
graph (c) (1) of this section, the IRB may require the investigator to
provide subjects with a written statement regarding the research.
(e) An IRB shall notify investigators and the institution in writing of its
decision to approve or disapprove the proposed research activity, or
of modifications required to secure IRB approval of the research ac-
tivity. If the IRB decides to disapprove a research activity, it shall in-
clude in its written notification a statement of the reasons for its deci-
sion and give the investigator an opportunity to respond in person or
in writing. For investigations involving an exception to informed con-
sent under § 50.24 of this chapter, an IRB shall promptly notify in
writing the investigator and the sponsor of the research when an IRB
determines that it cannot approve the research because it does not
meet the criteria in the exception provided under § 50.24(a) of this
chapter or because of other relevant ethical concerns. The written
notification shall include a statement of the reasons for the IRB's de-
termination.
(f) An IRB shall conduct continuing review of research covered by these
regulations at intervals appropriate to the degree of risk, but not less
than once per year, and shall have authority to observe or have a third
party observe the consent process and the research.
(g) An IRB shall provide in writing to the sponsor of research involving
an exception to informed consent under § 50.24 of this chapter a
copy of information that has been publicly disclosed under
§ 50.24(a) (7) (ii) and (a) (7) (iii) of this chapter. The IRB shall pro-
vide this information to the sponsor promptly so that the sponsor is
aware that such disclosure has occurred. Upon receipt, the sponsor
shall provide copies of the information disclosed to FDA.
21 C.F.R. § 56.109 (1999).
274. 45 C.F.R. § 46.404 (1999). The first risk/benefit category states that "HHS
will conduct or fund research in which the IRB finds that no greater than minimal risk
to children is presented, only if the IRB finds that adquate provisions are made for
soliciting the assent of the children and the permission of their parents or guardians, as
set forth in § 46.408." Id. The term minimal risk, as used in the Common Rule, "means
that the probability and magnitude of harm or discomfort anticipated in the research
are not greater in and of themselves than those ordinarily encountered in daily life or
during the performance of routine physical or psychological examinations or tests." 45
C.F.R. § 46.102 (2) (i) (1999). The FDA Regulations' definition of minimal risk is ex-
actly the same as the Common Rule's definition. 21 C.F.R. § 50.3(k) (1999).
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child's assent and the parent's permission to participate in re-
search, 2 75 and confers no therapeutic benefit to the child.276 Re-
search in the second category includes trials that involve greater-
than-minimal risk, but may directly benefit the individual sub-
ject.277 Research in this category is permissible if the potential
benefit of the study justifies the greater-than-minimal risk in-
volved,278 or if the trial may be as beneficial to the subject as
alternative treatments. 279 Although this section requires that
both the child's assent and the parent's permission adequately
be obtained, 8 ° the IRB may waive the assent requirement where
the child's participation is medically necessary. 281 The Common
Rule's third category includes research involving greater than
minimal risk that will not yield a direct benefit to the individual
subject, but is likely to provide general knowledge about the sub-
ject's disorder or condition.282 Research in the third category is
only permissible if it represents a minor increase over minimal
risk,283 or involves an amount of risk that is roughly equal to that
which the child would face in an ordinary medical or dental
check-up. 284 This type of research is permissible if the study is
275. 45 C.F.R. § 46.404 (1999).
276. Conrad & Homer, supra note 67, at 165.
277. 45 C.F.R. § 46.405 (1999). Research in this category includes "[r]esearch in-
volving greater than minimal risk but presenting the prospect of direct benefit to the
individual subjects." Id.
278. Id. § 46.405 (a). The risk in this category must be 'Justified by the anticipated
benefit to the subjects." Id.
279. Id. § 46.405 (b). The second category mandates that "[tihe relation of the
anticipated benefit to the risk is at least as favorable to the subjects as that presented by
available alternative approaches." Id.
280. Id. § 46.405 (c). This category requires that "[a]dequate provisions are made
for soliciting the assent of the children and permission of their parents or guardians, as
set forth in § 46.408." Id.
281. Id. § 46.408 (a). This section states that "[I]f the IRB determines that.., the
intervention or procedure involved in the research holds out a prospect of direct bene-
fit that is important to the health or well-being of the children and is available only in
the context of the research, the assent of the children is not a necessary condition for
proceeding with the research." Id.
282. Id. § 46.406. Section 46.406 includes, "[r]esearch involving greater than min-
imal risk and no prospect of direct benefit to individual subjects, but likely to yield
generalizable knowledge about the subject's disorder or condition." Id.
283. Id. § 46.406 (a). Research in this category is permissible if "[tihe risk repre-
sents a minor increase over minimal risk." Id.
284. Id. § 46.406 (b). This section defines a trial that involves a minor increase
over minimal risk as one where "the intervention or procedure presents experiences to
subjects that are reasonably commensurate with those inherent in their actual or ex-
pected medical, dental, psychological, social, or educational situations." Id.
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likely to yield general knowledge about the subject's condi-
tion, 2 85 the child assents to participation, and the child's parents
give permission. 286 The Common Rule's final category includes
trials that would not ordinarily be approved, but that present an
opportunity to understand, prevent, or alleviate a serious prob-
lem affecting children's health or welfare. 28 7 These trials must
undergo external review to ensure that they meet the safety and
consent standards required by the Common Rule.288
Although these four categories are based on the term mini-
mal risk, there appears to be some confusion regarding this
term's definition.289 In an attempt to apply this standard in a
fair and ethical manner, the Common Rule instructs IRBs to ap-
ply the minimal risk standard to the particular child involved in
the study.290 Under this construction, however, children who
are ill and often endure potentially risky interventions may be
285. Id. § 46.406 (c). The research in this category must be "likely to yield general-
izable knowledge about the subjects' disorder or condition which is of vital importance
for the understanding or amelioration of the subjects' disorder or condition." Id.
286. Id. § 46.406 (d). For research in this category, IRBs must make sure that
"[a] dequate provisions are made for soliciting assent of the children and permission of
their parents or guardians, as set forth in § 46.408." Id.
287. Id. § 46.407. Research in this category includes "[r]esearch not otherwise ap-
provable which presents an opportunity to understand, prevent, or alleviate a serious
problem affecting the health or welfare of children." Id. Section 46.407 (a) requires
that an IRB reviewing trials in this category must find "that the research presents a
reasonable opportunity to further the understanding, prevention, or alleviation of a
serious problem affecting the health or welfare of children." Id. at § 46.407(a).
288. Id. § 46.407 (b). To ensure the ethical nature of these trials,
The Secretary, after consultation with a panel of experts in pertinent disci-
plines (for example: science, medicine, education, ethics, law) and following
opportunity for public review and comment, has determined either: (1) That
the research in fact satisfies the conditions of § 46.404, § 46.405, or § 46.406,
as applicable, or (2) the following:
(i) The research presents a reasonable opportunity to further the un-
derstanding, prevention, or alleviation of a serious problem affect-
ing the health or welfare of children;
(ii) The research will be conducted in accordance with sound ethical
principles;
(iii) Adequate provisions are made for soliciting the assent of children
and the permission of their parents or guardians, as set forth in
§ 46.408.
Id.
289. See Glantz, supra note 27, at 232-33 (explaining that "although the concept of
minimal risk may be alluring, it is quite difficult to define and apply").
290. 45 C.F.R. § 45.102 (2) (i) (1999) (defining minimal risk as level of harm or
discomfort that is commensurate with that "ordinarily encountered in daily life or dur-
ing the performance of routine physical or psychological examinations or tests").
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subjected to studies posing a significant amount of risk.291 In
these situations, researchers must take care not to exceed so-
cially acceptable limitations for levels of risk to which a child may
be exposed.292 To ameliorate this problem, commentators have
suggested that the level of risk in studies should be commensu-
rate with the risk involved in activities with which the child is
both familiar and able to cope, rather than within the realm of
the child's experience. 93
Although the AAP suggests that the term minimal risk
should be construed broadly,294 there are several highly invasive
procedures that some IRBs characterize as posing no more than
minimal risk.29 5 Additionally, aside from the physical risks that
the research entails, experts believe that it is also important that
researchers and IRBs consider psychological risks related to chil-
dren's developmental vulnerabilities, as discussed earlier.29 6 In
the absence of a clear definition of what constitutes a minimal
risk intervention, some experts fear that U.S. IRBs may underes-
timate the risks to which pediatric research subjects are ex-
posed.12 9 7
2. European Union Regulations on Assent and Risk
Europe has led the world in harmonizing pharmaceutical
291. See Ross, supra note 78, at 162 (noting that concept of ordinary risk may in-
crease vulnerability of chronically ill children).
292. See id. (explaining that IRBs owe fiduciary duty to patients to always look after
their best interests).
293. See id. (citing one commentator that suggests that experimental interventions
under minimal risk category should be limited to experiences with which subject is
comfortable, "rather than any activity which a child may have previously experienced").
294. Committee on Drugs, supra note 25, at 288 (explaining that IRBs must re-
member that drugs and other medical interventions may pose risks that have not been
exposed in earlier trials).
295. See Bartholome, supra note 13, at 350 (citing survey of pediatric departmental
chairs and directors of pediatric research programs stating that substantial minority of
those polled "regarded interventions such as arterial puncture, placement of a naso-
gastric tube, and typmanocentesis (aspirating fluid from the middle ear with a needle
placed through the ear drum) to be minimal risk interventions.").
296. See Conrad & Homer, supra note 67, at 167 (explaining vulnerabilities effect-
ing children of different ages).
297. See Ross, supra note 78, at 163 (noting reasons to question IRB decision-mak-
ing on questions of risk). One reason why IRBs may not be reliable is that most IRBs
are largely composed of members of the research community and may be biased by this
affiliation. Id. There is also evidence that IRBs "tend to suffer from typical group
mentality," which generally leads to an increase in risk taking over that of individual
decision making. Id.
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regulations. 298 Their efforts began in 1965, when the European
Community adopted Directive 65/65,299 requiring Member
States to establish regulations and criteria for drug approval."°°
Since 1965, European countries have recognized the need to
create uniform ethical guidelines for pre-market drug approval
and clinical trials.3"1 Although the European Union (or "EU")
has been hesitant to become involved in ethical matters, it has
also recognized the need to have some EU regulation on human
research in its pharmaceutical regulatory scheme. In 1990, the
Committee for Proprietary Medicinal Products0 2 ("CPMP")
promulgated the Good Clinical Practice Guideline 0 3 ("EU
GCP"), which was later replaced when the ICH GCP entered
into force. 04 With regard to pediatric medical research, the
298. See Dan Kidd, Note, The International Conference on Harmonization of Pharmaceu-
tical Regulations, the European Medicines Evaluation Agency, and the FDA: Who's Zooming
Who?, 4 IND. J. GLOBAL LEGAL STUD. 183, 188 (1996) (explaining that Europe under-
stood value of borderless pharmaceutical market before rest of world).
299. Council Directive 65/65 on the Approximation of Provisions Laid Down By
Law, Regulation or Administrative Action relating to Proprietary Medicinal Products,
O.J. L 22/269 (1965).
300. See Richard F. Kingham, et al., The New European Medicines Agency, 49 FoOD &
DRUG L.J. 301, 301 (1994) (stating that Directive 65/65 provided impetus for pharma-
ceutical regulation harmonization in EC).
301. See R. Fears, et al. Life Sciences, R & D, National Prosperity, and Industrial Competi-
tiveness, SCIENCE, May 2, 1997, at 759 (stating that "[cioherence and consistency in sci-
ence policy is essential if the full intellectual capital of Europe is to be harnessed for
societal benefit.").
302. See Kingham, supra note 300, at 302 (stating that Commission created CPMP
in 1975 to coordinate multi-state procedure for recognizing national pharmaceutical
approvals). The CPMP is composed of Member State regulatory agency representatives,
and coordinates multi-state procedures for accepting national drug approvals on a Eu-
ropean level. Id.
303. EU GCP, supra note 162.
304. See Good Clinical Practice, Directive 75/328/EEC, CPMP/ICH 135/95, re-
vised 1996, effective Jan. 1997, at Additional Notes, available at (visited Mar. 8, 2000)
<http://www.eudra.org/humandocs/PDFs/ICH/013595en.pdf> (on file with the Ford-
ham International Law Journal). This directive states that
This note for guidance concerns the application of Part 4, sections B and C of
the Annex to Directive 75/318/EEC as amended with a view to the granting of
a marketing authorisation for a medicinal product. It established the princi-
ples for standards of Good Clinical Practice both within the European Com-
munity and within the ICH regions. It replaces the previous 1990 guideline
entitled Good Clinical Practice for Trials on Medicinal Products in the European Com-
munity (111/3976/88) adopted May 1990."). Shortly after this report was re-
leased, the standard of good clinical practice was later reinforced in an annex
to a Commission directive adopted in July of 1999. See Commission Directive
91/507/EEC, O.J. L 270/32 (1999). Part four of the annex of Commission
Directive 91/507/EEC on the approximation of the laws of the Member States
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CPMP created a separate set of guidelines entitled the Note for
Guidance on Clinical Investigation of Medicinal Products in
Children10 5 (or "Guideline for Children"). °6
a. The European Union Good Clinical Practice Guidelines
In July 1990, the CPMP issued the EU GCP, which set forth
basic guidelines for conducting medical trials on human sub-
jects. 30 7 The purpose of this guideline was to establish systematic
procedures for protecting trial subjects' dignity while preserving
the scientific integrity and reliability of trial results. 3 8 The EU
GCP defined the term good clinical practice as a manner of trial
design that produces credible data and protects the rights and
integrity of trial subjects. 30 9
The EU GCP adopted the general standards for ethical re-
search set forth in the Helsinki Declarations by conferring with
the Ethics Committees on issues of informed consent and risk.310
relating to the analytical, pharmatoxilogical and clinical standards and proto-
cols in respect of the testing of medicinal products, states that all trials shall be
"designed, implemented and reported in accordance with good clinical prac-
tice."
Id.
305. GUIDELINE FOR CHILDREN, supra note 51.
306. Id.
307. See John Gorski, An FDA-EEC Perspective on the International Acceptance of Foreign
Clinical Data, 21 CAL. W. INT'L L.J. 329, 550 (1991) (describing evolution of European
Good Clinical Practice).
308. See id. at 350. The foreword of the EU GCP states that
parties involved in the evaluation of medicinal products share the responsibil-
ity of accepting and working according to such standards in mutual trust and
confidence. Pre-established, systematic written procedures for the organiza-
tion, conduct, data collection, documentation and verification of clinical trials
are necessary to ensure that the rights and integrity of the trial subjects are
thoroughly protected and to establish the credibility of data and to improve
the ethical, scientific and technical quality of trials. These procedures also
include good statistical design as an essential prerequisite for credibility of
data and moreover, it is unethical to enlist the cooperation of human subjects
in trials which are not adequately designed.
Id.
309. EU GCP, supra note 162, at Glossary. The EU GCP defines Good Clinical
Practice as "a standard by which clinical trials are designed, implemented and reported
so that there is public assurance that the data are credible, and that the rights, integrity
and confidentiality of subjects are protected." Id.
310. Id. art. 1.1, 1.2. Article 1.1 of the EU GCP states "[t]he current revision of
the Declaration of Helsinki is the accepted basis for clinical trial ethics, which must be
fully known and followed by all engaged in research on human beings." Id. art. 1.1.
Article 1.2 of the EU GCP states, "[t]he personal integrity and welfare of the trial sub-
jects is the ultimate responsibility of the investigator in relation to the trial; but in-
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Some commentators, however, found fault with the EU GCP's
apparently liberal wording on informed consent, which could
have been construed as not requiring informed consent in in-
convenient situations. 11 With regard to pediatric subjects, the
EU GCP permitted proxy consent for legally incompetent sub-
jects, although minors were not specifically included in this
group.312 This document also appeared to prohibit a child's par-
ticipation in non-therapeutic trials completely, as participation
in non-therapeutic studies required the subject's own signa-
ture. 1 3 In subsequent years, the original EU GCP has been re-
placed by the ICH GCP, which the CPMP adopted in July
1996.14
dependent assurance that subjects are protected is provided by an Ethics Committee
and freely obtained informed consent." Id. art. 1.2. It should be noted, however, that
the EU GCP may be viewed as more permissive than Helsinki, as it allows for oral con-
sent in situations where written consent cannot be obtained, and where there is a wit-
ness to the informed consent. Gorski, supra note 307, at 360 n.150. Additionally, the
EU GCP states that investigators should consider Ethics Committee opinions, making
these group's role more advisory than mandatory. Gorski, supra.
311. EU GCP, supra note 162, art. 1.8. Article 1.8 may be viewed as overly permis-
sive, since it states that, "[t ] he principles of informed consent in the current revision of
the Helsinki Declaration should be implemented in each clinical trial. Id. (emphasis
added).
312. Id. art. 1.13. Article 1.13 states that
If the subject is incapable of giving personal consent (e.g., unconsciousness or
severe mental illness or disability), the inclusion of such patients may be ac-
ceptable if the Ethics Committee is, in principle, in agreement and if the inves-
tigator is of the opinion that participation will promote the welfare and inter-
est of the subject. The agreement of a legally valid representative that partici-
pation will promote the welfare and interest of the subject should be recorded
by a dated signature. If neither signed informed consent nor witness signed
verbal consent are possible, this fact must be documented by the investigator.
Id.
313. Id. art. 1.14. This section states that "[clonsent must always be given by the
signature of the subject in a non-therapeutic study, i.e. when there is no direct benefit
to the subject." Id.
314. See The International Conference on Harmonisation Web Site, at Efficacy
Topics, E6, Good Clinical Practice: Consolidated Guideline (visited Dec. 2, 1999)
<http://www.ich.org> (on file with the Fordham International Law Journal (noting that
ICH GCP was adopted by CPMP in June 1996, and was issued in CPMP report, CPMP/
768/97). In the period following adoption of the ICH-GCP, numerous proposals for
Parliament and Council Directives have been issued regarding the approximation of
national laws to the GCP. Id. Most notably, these proposals suggest that the Member
States must lay down laws to safeguard individuals who are incapable of providing con-
sent. Amended Proposal for a European Parliament and Council Directive on the Ap-
proximation of the Laws, Regulations and Administrative Provisions of the Member
States Relating to the Implementation of Good Clinical Practice in the Conduct of Tri-
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b. The CPMP Note for Guidance on Clinical Investigation of
Medicinal Products in Children
Although the EU GCP did not discuss pediatric research di-
rectly, the CPMP specifically addressed this issue in its Note for
Guidance on Clinical Investigation of Medicinal Products in
Children.315 First, the Guideline for Children stresses the need
to test medicinal products in pediatric subjects, even if the prod-
uct will only be used in a small number of children. 16 It then
emphasizes the fact that while adults can actively take risks with
their bodies, children depend on adults to determine what risks
are appropriate for them.317 Consequently, informed consent
must be obtained from the child's parent or guardian in accord-
ance with national legislation.
Along with parental consent, the Guideline for Children
specifies that the child should be provided information regard-
ing the trial in an age appropriate manner, and if able, sign and
date a written informed consent form.3 19 The child must also be
informed of his or her right not to participate in the trial and,
unlike U.S. regtilations, the investigator must obey the child's
refusal to participate.3"' The Guideline for Children makes no
als on Medicinal Products for Human Use, COM/99/0193 Final-COD 97/0197, O.J. C
160/5 (1999), 3.
315. GUIDELINE FOR CHILDREN, supra note 51.
316. Id. art. 1.1. Article 1.1 states that authorities have a responsibility to ensure
that
children have timely access to safe and effective medicines which have accu-
rate, scientifically justified prescribing information. Applicants are en-
couraged to investigate the safety and efficacy of a product in children, if it is
likely to be of therapeutic benefit in this age group, and to develop suitable
formulations, even if the usage is likely to be small.
Id.
317. Id. The Guideline for Children explains that
Adults who participate in clinical trials and who understand the issues involved
in giving their informed consent, accept and share the risk of injury, although
in practice serious damage to trial subjects is rare. Children are legally depen-
dent on their parents/guardians who take the legal responsibility for their
welfare and safety, and fully informed consent should be obtained from the
legal guardian in iccordance with national legislation.
Id.
318. See id. (stating that "fully informed consent should be obtained from the legal
guardian in accordance with national legislation").
319. See id. (mandating that "[c] hildren should be fully informed about the trial in
language and terms which they are able to understand and, if able, should personally
sign and date the written informed consent.").
320. See id. (stating that "[t]he child should be made aware of his/her rights to
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distinction between therapeutic and non-therapeutic trials when
conferring the right to refuse participation.2 1
The Guideline for Children also specifically addresses the
issue of risk.3 22 The document first delineates the physical dif-
ferences between children and adults, as well as differences be-
tween children of different ages3 23 that necessitate separate
clinical trials utilizing pediatric subjects.3 24  It thoroughly de-
scribes hazards that are specific to different age groups that may
affect risk assessment.2 5 The CPMP then suggests ways to design
protocols to minimize risks to subjects. 326
The Guideline for Children also provides instructions for
testing medicines on children that may also be used in adults.3 2 7
According to the EU GCP, medicines should first be tested in
adults and then in children, unless the treatment is designed for
a childhood-specific illness.328 Once it is determined that the
trial can be conducted in children, the Guideline for Children
then describes which methods that are appropriate for pediatric
trials.3 29 As a whole, the Guideline for Children places great em-
decline to participate. The child's wish to be withdrawn from a study must be
respected.").
321. Id.
322. See id. arts. 1.2,1.3, 1.4 (discussing issues including Scientific Considerations,
Need to Minimise Risks, and Need to Minimise Distress).
323. See id. (detailing physical differences between children of different age
groups).
324. See id. art. 1.2 (specifying pharmokinetic, pharmacodynamic, and pathologi-
cal differences between adults and children, and differences caused by process of
growth and development).
325. See id. art. 2 (classifying children by age and maturity).
326. See id. art. 1.3 (explaining need to minimize risks). This article suggests that a
drug should first be tested on animals, then adults, and then on older children before
testing on younger children. Id. 1.3 (a). Article 1.3 (b) also suggests that the trial
should use the minimum numbers of subjects necessary to be statistically significant. Id.
1.3 (b). Article 1.4 mandates that investigators should stop a trial immediately if any
dangers arise in the research. Id. 1.4. Finally, the researchers should prepare emer-
gency protocols in case a trial becomes dangerous. Id. 1.3 (d).
327. See id. art. 4 (explaining that medicines that treat childhood specific diseases
may be tested first in children, but for other drugs, adult studies must be used to gather
relevant safety and toleration information before testing in children).
328. Id. art. 4.1. Article 4.1 states, "[ihf a product is being developed initially for
the treatment of a childhood-specific illness, the clinical development may start in chil-
dren before any prior adult exposure. In other circumstances, relevant safety and toler-
ation data from previous adult exposure is needed before proceeding with studies in
children." Id.
329. See id. art. 5.1.2 (specifying that tests on small blood volumes, urinalysis, and
saliva are appropriate). Protocols should be designed with four main considerations in
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phasis on looking to the child's maturity level to determine the
appropriate level of risk and informed consent.330 Although the
Guideline for Children may be helpful to investigators, as with
other CPMP guidelines, it is not binding.31
3. Japan
As the primary non-Western participant in the ICH, Japan's
cultural differences are reflected in its human research regula-
tions.3 2 Many of these differences result from a perspective on
the doctor-patient relationship that is unique among other par-
ties. Commentators state that, historically, the Japanese doc-
tor-patient relationship has been very paternalistic, making in-
formed consent a low priority among Japanese physicians.334 In
recent years, however, this relationship has changed, with gov-
ernment officials placing a greater emphasis on informed con-
sent.335 This shift in attitudes, along with the need to produce
internationally acceptable pharmaceutical exports, has played a
large role in fostering Japanese acceptance of the ICH GCP pro-
visions.3 36
mind: the therapeutic class of the trial, the clinical situation, the child's maturity level,
and the trial's objectives. See also id. art. 5.2 (stating that trial "[p]rotocols should be
adapted to: (a) the therapeutic class; (b) the clinical situation; (c) the stage of maturity
of the child; and (d) the proposed objectives of treatment.")
330. See id. art. 2 (using child's maturity to guide development of clinical study).
331. See C.A. Teijgeler, The Role of the CPMP in the EEC, in INTERNATIONAL
MEDICINES REGULATIONS: A FORWARD LOOK TO 1992 207, 213 (S.R. Walker & J.P. Grif-
fin, eds. 1989) (explaining that CPMP guidelines and other recommendations are not
binding).
332. See generally George J. Annas & Frances H. Miller, The Empire of Death: How
Culture and Economics Affect Informed Consent in the U.S., the UK, and Japan, 20 AM. J.L. &
MED. 357, 372-73 (1994) (describing differences between Japanese culture and Western
culture that create divergent views and legislation on informed consent and other
health care issues).
333. See Michael Hoffman, Deadly Doctors, MAINICHi DAILY NEws, Oct. 19, 1997, at
BI 1 (stating that doctor-patient relationships in Japan are completely different from
Western doctor-patient relationships).
334. See Annas & Miller, supra note 332, at 373 (explaining that concept of in-
formed consent was only introduced in Japan in 1970s, and is not yet accepted).
335. See Robert Leflar, Informed Consent and Patients' Rights in Japan, 33 Hous. L.
REv. 1, 10 (1994) (noting results of January 1990 meeting of Japan Medical Associa-
tion's Bioethics Roundtable that concluded that informed consent is necessary to trust-
ing doctor-patient relationship).
336. See id. at 76 (explaining that primary motivation behind Japanese acceptance
of ICH GCP was that Japan's failure to meet basic ethical standards as prescribed by
Western countries impeded its pharmaceutical industry's ability to sell drugs in interna-
tional markets).
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a. The Emerging Concept of Informed Consent in
Japanese Medicine
Even though Japan has made great strides in medical ethics
in recent years, the concept of bioethics is still relatively new to
Japan.33 v In the past, many Japanese doctors refused to disclose
important information to patients regarding the severity of their
medical conditions, causing some patients to ignore prescrip-
tions for medications and skip critical follow up visits. 338 These
physicians did not withhold information out of malice for their
patients; rather, one scholar noted that this practice resulted
from a widely held belief that informing a patient of serious ill-
ness would be cruel and would hinder the patient's recovery by
causing him or her to give up hope.339
This failure to give patients relevant information also ex-
tended to prescription drugs.340 Patients were prescribed medi-
cations routinely without receiving any explanation why they
were taking the drug, what risks the medication posed, and what
precautions they should take while using the medication.341
Alarmingly, this practice was common for experimental drugs, as
well as drugs that had already been approved. 42
Recently, however, there has been greater support for a
Western concept of informed consent in Japan. 343 A current
337. See (Seimi-Rinri)/Bioethics, DAILY YoMIuIu/YoMIuRu SHIMBUN, Feb. 20, 1997,
available at 1997 WL 9499757 (explaining that concept of bioethics is new to Japan and
that it has been uniquely shaped by Japan's cultural values and traditions).
338. See Derek Kroft, Informed Consent: A Comparative Analysis, 6J. INT'L L & PRAc.
457, 473 (1997) (explaining facts of leading informed consent case in Japan, Makino v.
The Red Cross Hospital, 1325 Hanji 203, 31 WAHBURN 455 (1992)). In Makino, the
doctor never informed his patient that he suspected that she had cholecystic cancer. Id.
The patient subsequently cancelled follow up appointments with the doctor, unaware
of the severity of her condition, and died several months later. Id.
339. See Leflar, supra note 335, at 21, 22 (stating that many doctors believe that
disclosing this type of information to patients would be medically and ethically irre-
sponsible, and contrary to their obligation to preserve patients' lives).
340. See id. at 27 (noting that another example of cultural paternalism in Japanese
medicine occurs in prescribing drugs).
341. See id. (explaining that often doctors neglected to explain drugs' purpose,
risks, or cautions for use).
342. See id. (stating that physicians withhold information with experimental as well
as standard drugs).
343. See Kroft, supra note 338, at 474-75 (mentioning that although doctors have
discretion in determining how much information to give patients, pressure is mounting
to make Japanese standards of informed consent more closely conform to those of
United States); see also Kyoko Imamura, A Critical Look at Health Research in Japan, LAN-
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poll conducted by a Japanese newspaper revealed a significant
increase in the number of respondents who wished to be fully
informed in medical situations.3 44 The numbers favoring disclo-
sure were even higher among respondents between the ages of
twenty and thirty.3 4
5
Public opinion, economic pressure, and several embarrass-
ing and fatal drug approvals3 46 influenced the Japanese govern-
ment to implement major changes in human research regula-
tions . 47  To facilitate this process, the Japanese Ministry of
Health and Welfare ("MHW") appointed an advisory committee
to formulate recommendations for revising clinical trial regula-
tions.148 In 1985, the advisory committee issued its report.3 49 Ja-
pan adopted its first Good Clinical Practice standards ('Japanese
CET, July 31, 1993, at 281 (explaining that even though many Japanese "appreciate the
stabilising influence of a powerful figure such as a physician ... people are now willing
to shed some of this dependence on medical authority, as shown by increasing pressure
for informed consent.").
344. See Survey: 80% Favor Law on Medical Disclosure, YoMlUIu SHIMBUN/DAILYYOMI-
uR, July 4, 1999, available at 1999 WL 17755311 (stating that 82% represents highest
approval rating since this survey was first conducted in 1987).
345. See id. (reporting that 87% of respondents in their 20s wanted to be informed
if they had cancer, as opposed to 72% in 1995).
346. See Michelle D. Miller, The Informed Consent Policy of the International Conference
on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use:
Knowledge Is the Best Medicine, 30 CORNELL INT'L L.J. 203 222 (1997) (describing
Sorivudine scandal). Sorivudine was an anti-viral drug that was released in the Japanese
market despite being rejected in Europe for causing death in chemotherapy patients,
and despite three patients and many animals that died in clinical trials. Id. Sixteen
people died when this drug was released on the market and many others were injured.
Id.
347. See generally, Anticancer Drugs: Primarily Led by Increase in Metabolic Protagonists,
PHRAJAPA N, Nov. 13, 1995, available at 1995 WL 10665757 (indicating that Sorivudine
scandal sparked greater efforts to obtain informed consent).
348. See Leflar, supra note 335, at 76 (explaining that Japanese Ministry of Health
and Welfare ("MI-LW") appointed prestigious committee to study clinical trial revision
in Japan).
349. See K Uchida, Future Perspectives of Regulations in Japan, in INrERNATIONAL
MEDICINEs REGULATIONS: A FORWARD LOOK TO 1992 173, 179 (S.R. Walker & J.P. Grif-
fin, eds., 1989) (explaining that MHW issued GCP proposal relating to investigational
drug trials, including: requiring that ethical aspects be considered when conducting
clinical trials; requiring contracts between investigators and institutions; requiring that
institutions be properly equipped to deal with trial and any emergencies that may arise;
that IRBs review trials in all institutions; that proper records must be kept; and that
investigators must "explain the details of a clinical trial to each subject and obtain con-
sent based on the subject's free will."). The report also defines the sponsor's responsi-
bilities, including the duty to monitor the trial, the investigator's responsibilities, and
the MHW's right to inspect and verify all trial results. Id.
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GCP"), based on the MHW advisory committee's recommenda-
tions, in 1989.50
Even after these regulations were adopted, many Japanese
physicians appeared to be unaware that the Japanese GCP even
existed,35 ' and many IRBs continued to approve trials blindly. 52
Some surveys, however, indicate that Japanese researchers have
begun to require written informed consent from their test sub-
jects.53 The growing awareness of the importance of informed
consent, along with continued abuses, led to criticisms of the
first Japanese GCP,35 4 and its revision in accordance with the
ICH GCP.
355
b. The New Japanese GCP
To remedy the old Japanese GCP's deficiencies and address
the growing concerns of the Japanese public, the MHW released
a revised version of the Japanese Good Clinical Practice Guide-
lines in April of 199756 ("New Japanese GCP"). Unlike the
original Japanese GCP, the NewJapanese GCP mandates that in-
vestigators obtain written informed consent3 58 from their pa-
350. See Leflar, supra note 335, at 76 (explaining that MHW waited for resistance
expressed by non-exporting Japanese drug manufacturers to settle down before issuing
original GCP in October 1989).
351. See id. at 80 (citing Nagoya Bar Association survey conducted in 1992-93, sug-
gesting that 23% ofJapan's physicians were unaware that GCP existed and another 24%
had not read them).
352. See id. at 80 (stating that serious IRB examination of research trials "appears
to be the exception rather than the rule").
353. See Necessity of Written Informed Consent Deemed High by Investigators, PHARMA JA-
PAN, June 24, 1996, available at 1996 WL 10082891 (discussing results of one study indi-
cating that 72.9% of investigators wanted written informed consent, compared with
60.5% of IRB members in 1994 and 48.9% of investigators in 1995).
354. See Ministry To Tighten Drug-Testing Policies, DAILY YOMIU/YoMiuRi SHIMBUN,
Mar. 21, 1997, available at 1997 WL 10099146 (explaining that continued abuses led
MHW to believe that Japanese GCP is too ambiguous).
355. See GCP Guidelines Agreed on, JAPAN CHEM. WK., May 22, 1996, available at 1996
WL 8148615 (stating that after new ICH-GCP Guidelines were adopted, Japanese au-
thorities took steps to conform Japanese GCP to ICH-GCP).
356. See JAPAN's NEw GCP AND OTHER RULES ON CLINiCAL TRIALS, PART III 2 (Re-
view Assessing Group, et al. eds., 1999) [hereinafter JAPAN's NEw GCP AND OTHER
RULES] (explaining thatJapanese GCP was introduced in April 1997 and became effec-
tive in 1998).
357. Id.
358. See id. art. 52 (explaining informed consent requirements). Article 52 para-
graph 3 states that if the subject cannot read, the subject can give verbal consent in the
presence of a witness who is not affiliated with the researchers. Id. art. 52.3.
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tients. 359 Another major change in the New Japanese GCP is
that each research facility should have an IRB that includes
members who are not affiliated with the research institution.36 °
Generally, the New Japanese GCP, like the EU GCP, is based on
the principles outlined in the Helsinki Declarations.361
Under the NewJapanese GCP, almost every research institu-
tion is required to have an IRB. 3 6 2 The IRB is charged with con-
359. SeeJAPAN's NEW GCP AND OTHER RULES, supra note 356, at 2 (listing primary
objections to written informed consent as being: "(1) that the notion of a contract was
foreign to most Japanese, (2) that the act of signing (or sealing), which is rarely per-
formed in daily life, would cause prospective subjects unnecessary anxiety"). Many in-
vestigators also opposed the notion of written consent, stating that most patients would
take time to seek their relative's consent, and then return to tell the investigator that
they will not participate. Id.
360. See id. art 28 (describing IRB composition). According to Article 28 of New
Japanese GCP, the IRB must meet the following qualifications:
(1) Being capable of fully reviewing the proposed clinical trial from the
ethical and scientific viewpoints;
(2) Being comprised of at least five members;
(3) Having, as its member(s), a person or persons other than, and be-
sides, those who have an expert knowledge in medicine, dentistry,
pharmacy, health care, or clinical trials [besides the member(s) de-
scribed in (4)];
(4) Having, as its member(s), among others, a person or persons disin-
terested in the medical institution.
Id. The Pharmaceutical Affairs Bureau ("PAB") Notification, On Application of Guide-
line for Good Clinical Practice, also notes, however, that "[tlhe IRB may invite non-
members with expertise in relevant special areas for assistance." See On Application of
Guideline for Good Clinical Practice (PAB/PCD Notification No. 445; PAB/SD Notifi-
cation No. 8), May 29, 1997, art. 28 [Explanation] para. 6 [hereinafter On Applica-
tion].
361. On Application, supra note 360, at chap. 1 para. 2(1). Chapter 1, paragraph
2, section 1 states, "[c]linical trials should be conducted in accordance with the ethical
principles that have their origin in the Declaration of Helsinki, and the standards for
the conduct of clinical trials on drugs established under the Ordinance (hereinafter
referred to as "the GCP')." Id.
362. NEW JAPANESE GCP, supra note 230, art. 27. Article 27 states,
The heads of medical institutions shall organize an institutional review board
for each institution to have the board review and deliberate on whether it is
appropriate to conduct a clinical trial and on other matters relevant to the
clinical trial. When it is impracticable to organize an institutional review
board because the medical institution is small in scale or of any other reason,
however, the relevant institutional review board may be substituted by any of
the following alternatives.
(1) A joint institutional review board organized by the head of the medi-
cal institution in collaboration with heads of other medical institu-
tions.
(2) An institutional review board organized by a juridical person pursu-
ant to Article 34 of the Civil Law (Law No. 89, 1896).
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ducting both preliminary and continuing ethical and scientific
review of the protocol,363 paying special attention to vulnerable
subjects.364 Although the IRB must review the ethical and scien-
tific validity of the trial, the New Japanese GCP does not specifi-
cally make them responsible for monitoring whether appropri-
ate informed consent has been obtained. 65 The Pharmaceutical
Affairs Bureau ("PAB") Notification on Application, however,
(3) An institutional review board organized by an academic organization
composed of health care professionals.
(4) An institutional review board organized by the heads of other medi-
cal institutions (excluding cases specified in Item 1).
Id.
363. Id. art. 32. Article 32 states that
the institutional review board shall review the ethical and scientific appropri-
ateness of the clinical trial and state its opinion in writing as to whether it is
appropriate to conduct the clinical trial at the medical institution on the basis
of the following documents.
(1) The documents specified in the items of Article 10.
(2) Documents concerning subject recruitment procedures.
(3) Documents describing information specified under Article 7, Para-
graph 5, and other information important for the proper conduct of
the clinical trial.
(4) Current curriculum vitae of each prospective investigator, etc.
(5) Other documents the institutional review board considers necessary.
Id.; see On Application, supra note 360, art. 32 2 (C), (D) (stating that IRB must also
examine sample informed consent forms and written information sheets).
364. See On Application, supra note 360, art. 32, para. 1 (stating that "[t]he IRB
should safeguard the rights, safety, and well-being of all subjects. Special attention
should be paid to clinical trials that may include vulnerable subjects"). Paragraph 7
states that
[w]hen a non-therapeutic trial without anticipated direct clinical benefit to
the subject carried out with the consent of the subject's proxy consenter [(see
Article 7, Paragraph 2) (7-2-3)] is proposed, the IRB should ensure that the
submitted protocol and other documents adequately address relevant ethical
concerns and comply with Article 7, Paragraph 2 (7-2-3) (4-2-8). The docu-
mented approval of the IRB should specifically state that the IRB approves
that such subject is to be enrolled in the trial
Id. at para. 7. The term "vulnerable subjects" is defined in the Central Pharmaceutical
Affairs Bureau ("CPAC") GCP under Advice Made to the Minister by the CPAC, as
Individuals whose willingness to volunteer in a clinical trial may be unduly
influenced by the expectation, whether justified or not, of benefits associated
with participation, or of a retaliatory response from senior members of a hier-
archy in case of refusal to participate. Examples are .. .minors and those
incapable of giving consent.
Advice Made to the Minister by CPAC, CPAC Notification No. 40, dated Mar. 13, 1997,
arts. 2-14.
365. NEWJAPANESE GCP, supra note 230, art. 32. The PAB Notification On Appli-
cation, however, places some responsibility for ensuring that all subjects have consented
in writing on the sponsor. On Application, supra note 360, art. 21, para. 4.
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states that the IRB may request that more information be added
to the subject informed consent form when necessary to protect
the patient's rights.1
66
Section four of the New Japanese GCP discusses informed
consent requirements. 67 This section outlines the requirements
surrounding subjects who are incapable of giving legal con-
sent.3 68 Although section four does not allow for any type of de-
366. See On Application, supra note 360, art. 32, para. 6 (explaining that "[t]he
IRB may request more information than is required to be included in the written infor-
mation [see Article 51 (7-3) ] be given to the subjects when, in the judgment of the IRB,
the additional information should add meaningfully to the protection of the human
rights, safety and/or well-being of the subjects").
367. NEwJAPANESE GCP, supra note 230, art. 51. The specific requirements for the
informed consent form are enumerated in article 51. The requirements under this
paragraph include explanation of the following items:
(1) That the clinical trial involves research
(2) Objectives of the clinical trial
(3) The name, title and address of the investigator to contact
(4) Trial procedures
(5) Anticipated benefits of the investigational products and anticipated
disadvantages to the subject
(6) Matters concerning other therapeutic measures
(7) Duration of participation in the clinical trial
(8) That the subject may withdraw from the trial at any time
(9) That subject's refusal of or withdrawal from participation in the trial
does not cause any disadvantage to him or her
(10) That the monitors, the auditors, and the institutional review board
are given access to the relevant source documents on condition that
confidentiality of the subject is fully secured
(11) That privacy of the subject is kept
(12) The office of the medical institution to contact in the event of trial-
related injury
(13) That necessary treatment is available to the subject in the event of
trial-related injury
(14) Matters regarding compensation in the event of any trial- related
injury
(15) Other necessary matters concerning the clinical trial.
2. The written information shall not include any language which causes the pro-
spective subject to waive or to appear to waive any legal rights, or any language
which releases or lightens or appears to release or lighten the sponsor, the med-
ical institution or the investigators etc. from their liabilities.
3. Wording and expressions in the written information should be as plain as possi-
ble.
Id.
368. Id. art. 50. Article 50 states that
1. Investigators etc. shall beforehand explain the content of the clinical
trial and other trial-related matters utilizing appropriate written infor-
mation to each prospective subject to obtain his or her informed con-
sent in writing to participate in the trial.
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cision-making by the child or any other incompetent subjects,369
a PAB Notification to the Department of Health.7 ° ("Notifica-
tion on Enforcement"), provides that incompetent subjects can
participate in the decision-making process."' The Notification
on Enforcement states that investigators should obtain the in-
competent subject's written consent to the extent permitted by
the subject's cognitive abilities.3 72 The Notification on Enforce-
ment also states that investigators should not enroll any subject
in a trial who cannot give informed consent unless the trial will
benefit the subject.3 73 There is, however, an exception to this
general rule, as subjects who cannot give consent can be used in
a trial if their participation is deemed necessary.37 4 Article seven
elaborates on this exception, stating that persons who cannot
give legal consent can be enrolled in a non-therapeutic clinical
trial if the investigator submits documentation that these sub-
jects are needed for the trial's success, 75 and that the risk is min-
2. A subject incapable of giving consent may be enrolled in a trial on the
consent of a person to act as a proxy consenter on behalf of the sub-
ject, notwithstanding the provisions of the preceding paragraph.
3. When a proxy consenter's consent is obtained pursuant to the preced-
ing paragraph, the investigators etc. shall prepare a record of the con-
sent and the relation of the proxy consenter to the subject.
Id.
369. See id. (stating that researchers only have to obtain proxy consent for subjects
who are incapable of giving informed consent).
370. On Enforcement of MHW Ordinance on Good Clinical Practice, PAB Notifi-
cation No. 430, Mar. 27, 1997 [hereinafter Notification on Enforcement].
371. See id. para. 34(B) (stating that "[e]ven when the subject is enrolled in the
clinical trial on the consent of a person to act as the proxy consenter on behalf of the
subject pursuant to Paragraph 2, the investigator shall explain the clinical trial to the
subject dependent on his or her ability to understanding (sic.), and, whenever possible,
obtain his or her informed consent in writing").
372. Id.
373. See id. para. 4 (stating that "[t]he investigators etc. shall not enroll any subject
incapable of giving consent to participation in a clinical trial in which no clinical bene-
fits of the investigational products can be anticipated in the subject, notwithstanding
the provisions of Paragraph 2, excluding cases stated under Article 7, Paragraph 2").
374. See NEw JAPANESE GCP, supra note 230, art. 44.2 (stating, in pertinent part,
that "[i] nvestigators etc. shall select a prospective trial subject respecting the following
principles .... (2) Any subject incapable of giving consent shall not be selected unless
it is inevitable to enroll him or her as a subject in the clinical trial").
375. See id. art. 7.2.1 (stating that where investigator wishes to use subjects who are
not able to give competent consent, investigator must include in protocol
"[e]xplanation on reasons why subjects whose consent pursuant to Article 50, Para-
graph 1 is expected to be difficult to obtain, have to be enrolled in the clinical trial").
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imal or non-existent. 76 Although the term minimal risk is not
defined in Article 7, or in the NewJapanese GCP's glossary,37 7 it
is briefly discussed in the Notification on Enforcement, which
states that minimal risk occurs when the negative mental and
physical impact on the subject is low, and that researchers
should try to avoid such risks.3 7 8
II. THE INTERNATIONAL CONFERENCE
ON HARMONISATION
The ICH was created to deal with specific problems caused
by the globalization of the pharmaceutical industry and the do-
mestic nature of existing pharmaceutical regulations and licens-
ing.179 In furtherance of obtaining these goals, the ICH adopted
the ICH Guidelines for Good Clinical Practice on May 1, 1996,
to address practical and ethical concerns surrounding human re-
376. Id. art. 7.2.2. The investigator must also provide an "[e]xplanation on how
the potential risk incurred to the subject, if at all, is minimal." Id.
377. Id. art. 7, 2.
378. See Notification on Enforcement, supra note 370, at chap. 2, para. 5. This
chapter states that "[t] he phrase 'how the potential risk incurred to the subject, if at all,
is minimal' used in Item 2 of the same paragraph means that 'the potential risks in the
subject are low and that an (sic.) negative impact physically and mentally on him or her
is minimal by efforts made to avoid them.'" Id. The requirements are further ex-
plained in On Application, at Article 7, paragraph 2. On Application, supra note 360,
art. 7, para. 2. This document explains that
Non-therapeutic trials may be conducted in subjects whose consent is difficult
to obtain, with consent of their proxy consenters provided the following con-
ditions 1) to 4) are fulfilled. Such trials, unless an exception is justified,
should be conducted in patients having a disease or condition for which the
investigational product is intended. The investigator or the subinvestigator
should particularly closely monitor the subjects in these trials and withdraw
them if they appear to be unduly distressed.
(1) The objectives of the clinical trial can not be achieved through a
trial in subjects who can give consent personally.
(2) The foreseeable risks to the subjects are low.
(3) The negative impact on the subject's well-being is minimized
and low.
(4) The approval of the IRB is sought expressly on the inclusion of
such subjects based on the consents of their proxy consenters,
and the documented approval should expressly indicate the
IRB's approval on the inclusion.
Id.
379. See A Brief History of ICH (visited Feb. 8, 2000) <http://www.ifpma.org/
ich8.html> (on file with the Fordham International Law Journal) (explaining that pharma-
ceutical regulation remained national, while pharmaceutical industry had international
scope).
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search.380  Recently, one of the ICH Expert Working Groups
("EWGs") developed the Draft Consensus Guideline on Clinical
Investigation of Medicinal Products in the Pediatric Popula-
381tion, to deal with the unique issues that are raised when con-
ducting research on children.3 8 2
A. History of the ICH
In the past, differences between domestic pharmaceutical
regulations forced pharmaceutical companies to engage in ex-
pensive, time-consuming, and repetitive experimental trials to
gain international market acceptance.38 3  This repetition re-
sulted in increased research and development costs, as well as an
overall increase in the cost of health care, and delays in market-
ing life saving treatments around the world. 3 4 The ICH's pri-
mary goal is to ensure that high quality, safe, and effective
medicines were developed and registered in the most cost-effec-
tive manner. 5 Its members aim to diminish clinical trial dupli-
cation without compromising consumer safety.
3 86
The need to harmonize pharmaceutical regulations was first
recognized by the European Community.38 7 Simultaneous ef-
380. International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use, ICH Harmonised Tripartite Guideline
for Good Clinical Practice, (updated May 1, 1996) <http://www.ich.org> (on file with
the Fordham International Law Journal) [hereinafter GCP]. "Good Clinical Practice" is
defined in the Glossary of the ICH GCP as "[a] standard for design, conduct, perform-
ance, monitoring, auditing, recording, analysis, and reporting of clinical trials that pro-
vide assurance that the data and reported results are credible and accurate and that the
rights, integrity, and confidentiality of trial subjects are protected." Id. art. 1.24.
381. See DRAr GUIDELINE ON PEDIATRIC TRLs, supra note 19 (explaining that
goals of this document include safe, timely, efficient, and ethical pediatric trials).
382. Id.
383. See A Brief History of ICH, supra note 379 (explaining that varying national
regulations caused repetition of costly and time-consuming testing procedures).
384. Id.
385. See Statement by the ICH Steering Committee Tokyo, October 1990, (visited Feb. 8,
2000) <http://www.ifpma.org/ich7.html> (on file with the Fordham International Law
Journal) (stating that parties at this meeting "reaffirmed their commitment to increased
international harmonisation, aimed at ensuring that good quality, safe and effective
medicines are developed and registered in the most efficient and cost-effective man-
ner.").
386. See id. (stating that harmonization efforts "are pursued in the interest of the
consumer and public health, to prevent unnecessary duplication of clinical trials in
humans and too minimise the use of animal testing without compromising the regula-
tory obligations of safety and effectiveness").
387. See Initiation oflCH (visited Feb. 8, 2000) <http://www.ifpma.org/ich8.html>
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forts at harmonization led the United States, Japan, and Europe
to form the ICH at the WHO Conference on Drug Regulatory
Activities ("ICDRA") in Paris, in 1989.188 The International Fed-
eration of Pharmaceutical Manufacturers Association ("IFPMA")
also participated in the ICH in order to work with the pharma-
ceutical industry to create a set of common guidelines. 389 Today,
the six sponsors of the ICH include the European Commission,
the European Federation of Pharmaceutical Industry Associa-
tions, the Japanese MHW, the Japanese Pharmaceutical Manu-
facturers Association, the U.S. FDA, and the U.S. Pharmaceutical
Research Manufacturers of America.390  These entities partici-
pated in the first ICH Conference in Brussels in April 1990.391
At the Brussels conference, the parties to the ICH decided
that the three criteria to be considered for drug approval should
be safety, quality, and efficacy. 92 Topics based on these criteria
would be examined by separate EWGs. 93 These topics were
eventually subdivided into narrower categories of review.394 As a
result, new topics considered for regulation are subjected to a
structured, multi-leveled process for developing new guide-
lines.395
(on file with the Fordham International Law Journal) (stating that European Community
pioneered movement toward harmonization in 1980s).
388. See id. (stating that after bilateral negotiations, United States, European
Union, and Japan began to lay groundwork for ICH at ICH and WHO Conference on
Drug Regulatory Activities in Paris in 1989 ("ICDRA")).
389. See id. (explaining that International Federation of Pharmaceuticals Manufac-
turers Association ("IFPMA") was asked to join ICH to discuss "joint regulatory-industry
initiative on international harmonisation").
390. See International Conference on Harmonisation; Draft Documents on Essen-
tial Documents for the Conduct of a Clinical Study, 60 Fed. Reg. 42948 (1995) (listing
parties involved in ICH).
391. See Initiation of ICH, supra note 387 (noting that first meeting was hosted by
European Federation of Pharmaceutical Industry Associations in Brussels in 1990).
392. See The Early Meetings (visited Feb. 8, 2000) <http://www.ifpma.org/
ich8.html> (on file with the Fordham International Law Journal) (stating that new topics
for consideration "would be divided into Safety, Quality and Efficacy to reflect the three
criteria which are the basis for approving and authorising new medicinal products").
393. See ICH Expert Working Groups, (visited Nov. 5, 1999) <http://www.ich.org/
ich3.html> (on file with the Fordham International Law Journal) (explaining that EWG
has representatives from each entities, and meet at same time as Steering Committee to
report on EWG's progress).
394. See ICH Topics and Guidelines (visited Feb. 9, 2000) <http://www.ifpma.org/
ich5.html> (on file with the Fordham International Law Journal) (listing narrower catego-
ries of review including stability testing, carcinogenicity, good clinical practice, medical
terminology, and genotoxicity).
395. See The ICH Process for Harmonisation of Guidelines (visited Feb. 8, 2000) <http:/
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B. Guidelines for Good Clinical Practice
The Draft Guidelines for Good Clinical Practice, prepared
by the Efficacy EWG, were first made available for public com-
ment on May 9, 1995.396 The standards embodied in this docu-
ment reflected the standards enunciated in Helsinki IV, as well
as the regulations of the three regulatory entities, and Australia,
Canada, the Nordic Countries, and the WHO.3 19  The ICH
GCP's sought to coordinate standards for designing, recording,
and reporting information from pharmaceutical trials involving
human subjects, and to protect the rights and safety of trial sub-
jects.398 It was the ICH's hope that this document would influ-
ence not only the countries that are direct participants in the
ICH, but also the standards of Australia, Canada, the Nordic
countries, and the WHO399 in formulating standards for all types
of human research.4 °°
The finalized ICH GCP was approved by the Steering Com-
mittee on May 1, 1996.401 Like the Helsinki Declarations, the
ICH GCP states that the anticipated benefits of a trial should
/www.ifpma.org/ich4.html> (on file with the Fordham International Law Journal) (ex-
plaining ICH procedure). New topics considered for harmonization are selected by the
Steering Committee based on Concept Papers that are submitted to it by the entities.
Id. Once the Steering Committee chooses a topic, they select an EWG to formulate a
draft guideline on that topic. Id. These draft guidelines are then returned to the Steer-
ing Committee, who distributes the draft to the three regulatory agencies for consulta-
tion in accordance with those countries' individual processes. Id. These comments are
then returned to the Regulatory Rapporteur, who, in consultation with regulatory ex-
perts, incorporates any necessary changes. Id. If changes are significant, then the draft
may be recirculated for another round of consultation. Id. The Rapporteur then
prepares a final draft of the document that must first be approved by the EWG, and
then by the Steering Committee. Id. After the final draft is discussed and approved by
the three regulatory parties, the process is complete when the countries adopt the regu-
lations into national law or regulations. Id.
396. See International Conference on Harmonisation; Draft Documents on Essen-
tial Documents for the Conduct of a Clinical Study, 60 Fed. Reg. 42948 (1995) (noting
that Steering Committee agreed to release Draft ICH GCP on May 9, 1995 for public
comment).
397. Id. at 42498.
398. See id. (stating that ICH GCP was designed to "provide a unified standard for
designing, conducting, recording, and reporting trials that involve the participation of
human subjects.").
399. See id. (stating that the guidelines are to influence regulations of Australia,
Canada, EU, Japan, Nordic Countries, United States, and WHO).
400. Id. at Introduction. The Introduction to the Draft GCP states that "[t]he
principles established in this Guideline should also be applied to other investigations
that involve therapeutic intervention in, or observation of, human subjects." Id.
401. ICH GCP, supra note 12.
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justify its risks.4 °2 Similarly, the ICH GCP states that preserving
the research subject's rights and safety should prevail over the
interests of society,40" and that all pharmaceutical trials should
be supported by prior laboratory testing.414
Also, as with the Helsinki Declarations, the ICH GCP states
that all trials must be supervised by an IRB, or an Independent
Ethics Committee ("IEC").4°5 The ICH GCP recommends that
the IRB/IEC be composed of at least five members, and that one
member is primarily interested in a non-scientific field, one
member is not affiliated with the institution, and that only mem-
bers who are not associated with the trial investigator may
vote. 406 The IRB/IEC may, at its election, invite outsiders with
402. Compare id. art. 2.2 (stating that "[b]efore a trial is initiated, forseeable risks
and inconveniences should be weighed against the anticipated benefit for the individ-
ual trial subject and society. A trial should be initiated and continued only if the antici-
pated benefits justify the risks."), with HELSINKI V, supra note 157, at art. 1.4 (stating
"[b]iomedical research involving human subjects cannot legitimately be carried out un-
less the importance of the objective is in proportion to the inherent risk to the sub-
ject.").
403. ICH GCP, supra note 12, art. 2.3. Article 2, paragraph 3 states, "[t]he rights,
safety, and well-being of the trial subjects are the most important considerations and
should prevail over the interests of society." Id.
404. Id. art. 2.4. Although this section does depart from the past requirements of
the Code and Helsinki Declarations that state that animal testing should be carried out
prior to human trials, Article 2.4 does require that "[a]vailable nonclinical and clinical
information on an investigational product should be adequate to support the proposed
clinical trial." Id.
405. Compare id. art. 2.6 (stating that "[a trial should be conducted in compliance
with the protocol that has received prior institutional review board (IRB)/independent
ethics committee (IEC) approval/favourable opinion"), with HELSINKI V, supra note
157, art. 1.2. Helsinki V mandated that
The design and performance of each experimental procedure involving
human subjects should be clearly formulated in an experimental protocol
which should be transmitted for consideration, comment and guidance to a
specially appointed committee is in conformity with the laws and regulations
of the country in which the research experiment is performed
HELSINKI V, supra note 157, art. 1.2.
406. ICH GCP, supra note 12, at 3.2.1. Article 3.2.1 states that the IRB/IEC
should consist of a reasonable number of members, who collectively have the
qualifications and experience to review and evaluate the science, medical as-
pects, and ethics of the proposed trial. It is recommended that the IRB/EIC
should include:
(1) At least five members.
(2) At least one member whose primary area of interest is in a nonscien-
tific area.
(3) At least one member who is independent of the institution/trial site.
Only those IRB/IEC members who are independent of the investiga-
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specialized expertise to assist in its evaluations.4 °7
The IRB/IEC's primary responsibility is to ensure that the
trial subjects' rights and safety are protected."' It is also incum-
bent on the IRB/IEC to ensure that the investigator is quali-
fied,409 and to conduct ongoing review of the trial.410 The IRB/
IEC must also supervise obtaining informed consent from sub-
jects,4 1 and ensure that there is no coercion involved in subject
solicitation. 2
Under the ICH GCP, informed consent should be obtained
from subjects in accordance with the Helsinki Declarations, ap-
plicable regulations of the jurisdiction where the trial is being
conducted, and the ICH GCP.4 13 The ICH GCP places primary
responsibility for compliance with these guidelines on the IRB/
IEC.4 14 The informed consent form must be submitted to the
IRB/IEC for approval prior to use and it must be updated if new,
tor and the sponsor of the trial should vote/provide opinion on a
trial-related matter.
Id.
407. See id. art. 3.2.6 (stating that "[a]n IRB/IEC may invite nonmembers with ex-
pertise in special areas for assistance") (emphasis added).
408. See id. art. 3.1.1 (stating that "[a]n IRB/IEC should safeguard the rights,
safety, and well-being of all trial subjects. Special attention should be paid to trials that
may include vulnerable subjects.").
409. See id. art. 3.1.3 (directing that "[t]he IRB/IEC should consider the qualifica-
tions of the investigator for the proposed trial, as documented by a current curriculum
vitae and/or by any other relevant documentation the IRB/IEC requests.").
410. See id. art. 3.1.4 (providing that "[t]he IRB/IEC should conduct continuing
review of each ongoing trial at intervals appropriate to the degree of risk to human
subjects, but at least once per year.").411. See id. art. 3.1.5 (stating that IRB may "request more information than is out-
lined in paragraph 4.8.10 be given to subjects when, in the judgment of the IRB/IEC,
the additional information would add meaningfully to the protection of the rights,
safety, and/or well-being of the subjects.").
412. See id. art. 3.1.8 (stating that "[t]he IRB/IEC should review both the amount
and method of payment to subjects to assure that neither presents problems of coer-
cion or undue influence on the trial subjects. Payments to a subject should be prorated
and not wholly contingent on completion of the trial by the subject.").
413. Id. art. 4.8.1. Section 4.8.1. states
In obtaining and documenting informed consent, the investigator should
comply with the applicable regulatory requirement(s), and should adhere to
the GCP and to the ethical principles that have their origin in the Declaration
of Helsinki. Prior to the beginning of the trial, the investigator should have
the IRB/IEC's written approval/favourable opinion of the written informed
consent form and any other written information to be provided to subjects.
Id.
414. See id. (describing IRB/IEC's responsibilities for reviewing informed consent
forms).
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relevant information pertaining to the trial is discovered. 415 The
informed consent form's wording is also regulated; it cannot
contain any statements that would operate to waive any legal
claims that the subject may have against the investigator, institu-
tion, or sponsor. 416 The informed consent form must be written
in layman's terms, and in a manner that is relatively comprehen-
sible to the subject or the subject's representative.417 Approved
informed consent forms must be signed and dated by the subject
or its legal representative.418 Prior to signing, however, the sub-
ject must be afforded the opportunity to question the investiga-
tor regarding the details of the trial and freely decide whether to
participate.41 9 Although Article Four states that trials should be
conducted on subjects who are capable of providing legal con-
415. Id. art. 4.8.2. Article 4, paragraph 8.2 states,
The written informed consent form and any other written information to be
provided to subjects should be revised whenever important new information
that may be relevant to the subject's consent. Any revised written informed
consent form, and written information should receive the IRB/IEC's ap-
proval/favourable opinion in advance of use. The subject or the subject's le-
gally acceptable representative should be informed in a timely manner if new
information becomes available that may be relevant to the subject's willingness
to continue participation in the trial. The communication of this information
should be documented.
Id.
416. Id. art. 4.8.4. Article 4, paragraph 8.4 states that
[n]one of the oral and written information concerning the trial, including the
informed consent form, should contain any language that causes the subject
or the subject's legally acceptable representative to waive or appear to waive
any legal rights, or that releases or appears to release the investigator, the
institution, the sponsor, or their agents from liability for negligence.
Id.
417. See id. art. 4.8.6 (stating that "[tihe language used in the oral and written
information about the trial, including the written informed consent form, should be as
non-technical as practical and should be understandable to the subject or the subject's
legally acceptable representative and the impartial witness, where applicable.").
418. See id. art. 4.8.8 (explaining that "[p]rior to a subject's participation in the
trial, the written informed consent form should be signed and personally dated by the
subject or the subject's legally acceptable representative, and by the person who con-
ducted the informed consent discussion.").
419. Id. art. 4.8.7. Article 4.8.7 states that
Before informed consent may be obtained, the investigator, or a person desig-
nated by the investigator, should provide the subject or the subject's legally
acceptable representative ample time and opportunity to inquire about details
of the trial and to decide whether or not to participate in the trial. All ques-
tions about the trial should be answered to the satisfaction of the subject or
the subject's legally acceptable representative.
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sent,4 2° it does list exceptions under which research may be con-
ducted in legally incompetent subjects.42 1
Although there is no article or section of the ICH GCP de-
voted exclusively to pediatric research subjects, the ICH GCP
does allude to children in various places in the document.4 22
Even though there are no distinct definitions of the words child
or minor in the ICH GCP Glossary, children are still classified as
a vulnerable population in the ICH GCP.425 When outlining the
IRB/IEC's responsibilities, the ICH GCP specifies that the IRB/
IEC should give special consideration to trials involving vulnera-
ble populations.424 Specifically, the IRB/IEC must ensure that
trial protocols recognize special ethical concerns involved in
these trials and to ensure compliance with local regulations.425
Minors receive the most attention in the article of the ICH
GCP that discusses informed consent.4 26 This article first pro-
vides proxy consent for all individuals who cannot give informed
420. See id. art. 4.8.13 (stating that except under specific circumstances, "a non-
therapeutic trial (i.e., a trial in which there is no anticipated direct clinical benefit to
the subject), should be conducted in subjects who personally give consent and who sign
and date the written informed consent form").
421. See id. art. 4.8.14 (explaining circumstances under which non-therapeutic tri-
als can be conducted in subjects who require consent of legally acceptable representa-
tives).
422. Id.
423. Id. art. 1.61. Article 1.61 defines vulnerable subjects as
Individuals whose willingness to volunteer in a clinical trial may be unduly
influenced by the expectation, whether justified or not, of benefits associated
with participation, or of a retaliatory response from senior members of a hier-
archy in case of refusal to participate. Examples are members of a group with
a hierarchichal structure, such as medical, pharmacy, dental, and nursing stu-
dents, subordinate hospital and laboratory personnel, employees of the phar-
maceutical industry, members of the armed forces, and persons kept in deten-
tion. Other vulnerable subjects include patients with incurable diseases, per-
sons in nursing homes, unemployed or impoverished persons, patients in
emergency situations, ethnic minority groups, homeless persons, nomads, ref-
ugees, minors and those incapable of giving consent.
Id. (emphasis added)
424. See id. at 3.1.1 (stating that "[s]pecial attention should be paid to trials that
may include vulnerable subjects").
425. See id. at 3.1.6 (stating that "[w]hen a non-therapeutic trial is to be carried out
with the consent of the subject's legally acceptable representative (see 4.8.12, 4.8.14),
the IRB/IEC should determine that the proposed protocol and/or other document(s)
adequately addresses relevant ethical concerns and meets applicable regulatory require-
ments for such trials.").
426. See id. art. 4.8 (discussing informed consent of trial subjects).
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consent.427 Despite this general rule, however, the ICH GCP
does provide that the subject must be informed to the extent
that he is able to understand.428 The subject should personally
sign and date the written informed consent form, if he or she is
able to do SO. 4 2 9
Although the ICH GCP includes the general proposition
that subjects who cannot give informed consent should not be
involved in non-therapeutic trials,430 it also specifies some situa-
tions where participation is permissible.431 Subjects who are in-
capable of providing informed consent may participate in non-
therapeutic trials under certain specific conditions.432 These
conditions include: (1) if a legal representative gives informed
consent, (2) if the risks and effect on the subject's well-being are
low, (3) if the trial complies with applicable law, and (4) if the
IRB/IEC specifically has approved including this group in the
trial.4 3 Under the ICH GCP, these trials should be closely moni-
427. See id. art. 4.8.5 (explaining that "[t] he investigator, or a person designated by
the investigator, should fully inform the subject or, if the subject is unable to provide
informed consent, the subject's legally acceptable representative, of all pertinent as-
pects of the trial including the written information and the approval/favourable opin-
ion by the IRB/IEC.").
428. See id. art. 4.8.5 (explaining requirements for obtaining consent from both
subject's representative and subject).
429. Id. art. 4.8.12. Article 4, section 8.12 states,
When a clinical trial (therapeutic or non-therapeutic) includes subjects who
can only be enrolled in the trial with the consent of the subject's legally ac-
ceptable representative (e.g., minors, or patients with severe dementia), the
subject should be informed about the trial to the extent compatible with the
subject's understanding and, if capable, the subject should sign and personally
date the written informed consent.
Id.
430. See id. art. 4.8.13 (explaining that non-therapeutic trials should be conducted
in subjects who are capable of providing informed consent).
431. See id. art. 4.8.14 (describing when minors can be used in non-therapeutic
trials).
432. See id. (describing conditions under which non-therapeutic research on chil-
dren may be conducted).
433. Id. Article 4, section 8.14 states that
Non-therapeutic trials may be conducted in subjects with consent of a legally
acceptable representative provided the following conditions are fulfilled:
(a) The objectives of the trial can not be met by means of a trial in sub-
jects who can give informed consent personally.
(b) The foreseeable risks to the subjects are low.
(c) The negative impact on the subject's well-being is minimized and low.
(d) The trial is not prohibited by law.
(e) The approval/favourable opinion of the IRB/IEC is expressly sought
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tored for signs of distress among research subjects, so that sub-
jects may be withdrawn if they demonstrate signs of undue dis-
tress.434
C. Draft Consensus Guideline on Clinical Investigation of Medicinal
Products in the Pediatric Population
In 1998, the Steering Committee appointed a new EWG to
deal with clinical investigation of medicinal products in children
("EWG on Pediatric Trials") .13 This EWG is charged with devel-
oping pediatric testing methods that will make it easier for phar-
maceutical companies to produce safer treatments for children,
and encourages clinical trials on pediatric groups.4"6 On Octo-
ber 7, 1999, the EWG on Pediatric Trials released its Draft
Guideline on Pediatric Trials for consultation and commentary
by ICH members.437 The goals of this document are to facilitate
timely, safe, efficient, and ethical studies of medicinal products
for use in pediatric populations and to increase the number of
medications that are licensed specifically for pediatric use.4 38
Although the Draft Guideline on Pediatric Trials is not intended
to be a comprehensive and exclusive document on pediatric
studies, it succeeds in covering a wide variety of topics, including
on the inclusion of such subjects, and the written approval/favour-
able opinion covers this aspect.
Such trials, unless an exception is justified, should be conducted in patients having
a disease or condition for which the investigational product is intended. Subjects
in these trials should be particularly closely monitored and should be withdrawn if
they appear to be unduly distressed.
Id.
434. See id. art. 4.8.14 (stating that subjects should be closely monitored and with-
drawn if they show signs of undue distress).
435. See ICH Web site, supra note 314, at Efficacy Topics (explaining that this
EWG's goal was to facilitate development of safe and effective medicinal products and
to help eliminate current difficulties encountered by companies that operate interna-
tionally).
436. Id. at Efficacy Topics, Ell, Clinical Investigation of Medicinal Products in
Children.
437. DRAFr GUIDELINE ON PEDIATRIC TRAis, supra note 19.
438. Id. art. 1.1. Article 1.1 states
The number of medicinal products currently labeled for pediatric use is lim-
ited. It is the goal of this guideline to encourage and facilitate timely pediatric
medicinal product development internationally. This guideline provides an
outline of critical issues in pediatric drug development and approaches to the
safe, efficient, and ethical study of medicinal products in the pediatric popula-
tion.
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general considerations for investigators when starting a pediatric
trial, timing, types of studies to be conducted, age categories,
and ethics.439
The Draft Guideline on Pediatric Trials begins by stating
general principles, including the idea that medicines be tested
in children of different ages before they may be prescribed gen-
erally.440 The general principles also state that drug studies for a
particular medicinal product should include pediatric groups
when the product is being developed for use in adults and will
have an anticipated use in children. 441 Finally, the general prin-
ciples state that great emphasis should be placed on the pediat-
ric trial subject's safety.4 4 2
The Draft Guideline on Pediatric Trials also addresses the
timing of pediatric trials.443 Article two, paragraph one provides
a list of factors to consider when determining whether to test
drugs on children.444 The most important of these factors is
whether the treatment to be tested will be used for a serious dis-
439. Id. art. 1.3. Article 1.3 states that
specific clinical studies issues addressed include: considerations when initiat-
ing a pediatric program for a medicinal product; timing of initiation of pediat-
ric studies during medicinal product development; types of studies
(pharmacokinetic, pharmacokinetic/pharmacodynamic (PK/PD), efficacy,
safety); age categories for studies; ethics of pediatric clinical investigation.
This guideline is not intended to be comprehensive; other ICH guidelines as
well as documents from regional regulatory authorities and pediatric societies
provide additional detail.
Id.
440. Id. art. 1.4. Article 1.4 explains that
Pediatric patients should be given medicines that have been appropriately
evaluated for their use. Safe and effective pharmacotherapy in pediatric pa-
tients requires the timely development of information on the proper use of
medicinal products in pediatric patients of various ages, and often of pediatric
formulations of those products. Major advances in formulation chemistry and
in pediatric study design ensure that this goal can be achieved.
Id.
441. See id. (stating that " [d ] rug development programs should include the pediat-
ric patient population when a product is being developed for a disease/condition in
adults and it is anticipated the product will be used in the pediatric population.").
442. See id. (stating that "[t] he ethical imperative to obtain knowledge of the ef-
fects of medicinal products in pediatric patients has to be balanced against the ethical
imperative to protect each pediatric patient in clinical studies. This responsibility is
shared by companies, regulatory authorities, health professionals, and society as a
whole.").
443. See id. art. 2.1 (discussing "issues when initiating a pediatric medicinal prod-
uct development program").
444. See id. art. 2.1 (stating that investigators should consider:
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ease that currently does not have an effective therapy.4 4 5 In situ-
ations where a medicinal product will not be used on pediatric
patients, the product does not have to be tested on children.446
Conversely, where a drug is being developed specifically for
a condition that is unique to children, the drug need not be
tested on adults if the results of such testing would be completely
irrelevant to pediatric populations, or if the study would expose
adults to inappropriate risk.44 7 Wherever possible, however, ini-
tial safety information should be obtained in studies on adult
subjects.448 Where a medicinal product is intended to treat a life
threatening illness occurring in both children and adults, testing
in children should occur simultaneously with adult studies, but
only after initial safety testing in adults.449 Where pediatric test-
ing is feasible in a particular situation, but none is conducted,
the sponsor must provide a detailed explanation of why there
are no pediatric trial results for that product.4 5 0 For drugs used
* the prevalence of the condition to be treated in the pediatric popula-
tion;
" the seriousness of the condition to be treated;
" the availability and suitability of alternative treatments for the condition
in the pediatric population, including the efficacy of those treatments,
and the adverse event profile (including any unique pediatric safety is-
sues);
" whether the medicinal product is novel or one of a class of compounds
with known properties;
" whether there are unique pediatric indications for the medicinal prod-
uct;
* the age ranges of patients likely to be treated with the medicinal prod-
uct;
" unique pediatric (developmental) safety concerns about the medicinal
product, including any non-clinical safety issues; and
" potential need for pediatric formulation development.
Id.
445. See id. (explaining that "[o]f these factors, the most important is the presence
of a serious disease without good current therapy. This situation suggests relatively ur-
gent and early initiation of pediatric studies.").
446. See id. (explaining that trials do not have to be conducted on children if using
product on children is clearly inappropriate).
447. See id. art. 2.3.1 (stating that some trials on medicinal products that treat dis-
eases that occur predominantly or exclusively in pediatric patients, must be initially
tested only in children, even in initial phases).
448. See id. art. 2.3.1 (explaining that "the entire development program will be
conducted in the pediatric population except for initial safety and tolerability data,
which will usually be obtained in adults").
449. Id.
450. See id. art. 2.3.2 (stating that where medicine treats serious or life threatening
illness in both adults and children, studies on children should commence early, after
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to treat less serious conditions, testing on pediatric populations
may begin later, or even after the drug is on the market for
adults, if there are safety concerns.45 1 If, however, the drug will
represent a major advance in treating pediatric patients, then
testing should begin in the earlier stages of product develop-
ment.
452
The next several sections of the Draft Guideline on Pediat-
ric Trials outline technical considerations, indicating how much
information may be extrapolated from adult studies, and that
certain types of trials should only be conducted in pediatric pa-
tients that are suffering from the disease that the medicine is
designed to cure.45 Next, the Draft Guideline on Pediatric Tri-
als explains that trials conducted on children may require
unique elements of trial design to measure factors such as pain
and other physical responses to treatment adequately.454 As with
the CPMP Guideline for Children, the Draft Guideline on Pedi-
atric Trials then divides children into five different age catego-
ries in order to address properly the biological and pharmaco-
logical factors that investigators must consider when planning re-
search trials.455
initial trials on safety and efficacy, and where pediatric testing is impossible, "lack of
data should be justified in detail").
451. See id. art. 2.3.3 (explaining that where drug is used to treat non-life-threaten-
ing illness, companies may wait longer to commence testing, but they must have plan
for how and when pediatric testing will be conducted).
452. See id. (stating that "[elven for a non-serious disease, if the medicinal product
represents a major therapeutic advance for the pediatric population, studies should
begin as early in development as possible, and the submission of pediatric data would
be expected in the application.").
453. See id. art. 2.4.1 (discussing pharmacokinetics and practical considerations for
conducting pharmacokinetic trials).
454. See id. art 2.4.2 (stating that "[t]he principles in study design, statistical con-
siderations and choice of control groups detailed in ICH 6,9, and 10 in general apply to
pediatric efficacy studies," but that researchers also have to be aware that certain ele-
ments must be adapted specifically for pediatric trials, like "[m]easurements of subjec-
tive symptoms such as pain").
455. See id. art. 2.5. (explaining that breaking pediatric population down into five
categories may help develop effective trial designs for each age group). This paragraph
separates children into five groups: pre-term newborn infants, term newborn infants,
infants and toddlers (28 days to 23 months), children (2-11 years), and adolescents (12
up to 16-18 years, depending on region where trial is conducted). Id. This paragraph
also discusses circumstances where division by age group is unnecessary, such as in
longer-term studies, where patients may move from one age group to another within
course of study. Id. In discussing adolescent age group, EWG placed particular empha-
sis on possible external factors that might effect the study, such as non-compliance,
particularly when trial may effect appearance, and subject's recreational use of non-
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The remainder of the Draft Guideline on Pediatric Trials
concerns ethical issues.456 Article two, paragraph six describes
pediatric populations as a vulnerable group requiring special
rights and safety protections.457 Here, the Draft Guideline on
Pediatric Trials states that every child subject should reap some
direct or indirect benefit from the trial, except as described in
the ICH GCP.458
The Draft Guideline on Pediatric Trials then discusses the
role of the IRB/IEC, stating that their responsibilities have been
set forth in the ICH GCP.459 The Draft Guideline on Pediatric
Trials does, however, state that all IRB/IECs that review pediat-
ric trials should include or consult with people who are knowl-
edgeable in pediatric ethical, clinical, and psychosocial issues.4 6 °
Furthermore, while subjects may be reimbursed for recruitment
expenses, researchers cannot offer coercive inducements, either
to the child or to the child's parents.461 Additionally, the group
selected for the study should represent the demographics of the
region or the disease being studied unless a good reason exists
for restricting the group of subjects. 4 6 2
The Draft Guideline on Pediatric Trials also discusses con-
sent.463 The Draft Guideline on Pediatric Trials requires that re-
searchers must always obtain full, informed consent from the
subject's parents in accordance with national or regional regula-
prescribed drugs. Id.; see also GUIDELINE FOR CHILDREN, supra note 51 (referring to clas-
sification by age and maturity level).
456. DRAfr GUIDELINES ON PEDIATRIC TRIALS, supra note 19, art. 2.6. Article 2.6 is
entitled "Ethical Issues in Pediatric Studies." Id.
457. See id. ("[t]he pediatric population represents a vulnerable subgroup. Special
measures are therefore needed to protect their rights and to shield them from undue
risk.").
458. See id. ("participants in clinical studies are expected obtain [sic] some direct
or indirect benefit from the clinical study except under very special circumstances as
discussed in ICH E-6 (GCP; section 4.8.14)).
459. See id. art. 2.6.1 ("[tlhe roles and responsibilities of IRB/IECs as detailed in
ICH E-6 are critical to the protection of study participants").
460. See id. ("[w]hen protocols involving the pediatric population are reviewed,
there should be IRB/IEC members, or experts consulted by the IRB/IEC, who are
knowledgeable in pediatric ethical, clinical, and psychosocial issues").
461. See id. art. 2.6.2 (explaining that subjects may be paid for reimbursement and
subsistence costs, but may not receive coercive financial or other inducements).
462. Id. Article 2.6.2 states that "[w]hen studies are conducted in the pediatric
population, an attempt should be made to include individuals representing the
demographics of the region and disease being studied, unless there is a valid reason for
restricting enrollment." Id.
463. Id. art. 2.6.3. Article 2.6.3 is entitled Consent. Id.
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tions.4 64 Additionally, the subjects themselves must be informed
about the study in a comprehensible manner. 46' The EWG spec-
ified that a child who is considered capable of providing assent
should be allowed to do so, and, if able, sign and date an in-
formed consent form.4 66 The child subject must also be in-
formed of his or her right to withdraw or refuse to participate in
the trial, and the child's wish not to participate must be
respected, unless participation is necessary for the child's well-
being.4 67 This section concludes by stating that, wherever possi-
ble, trials should be conducted in populations that are more
competent to give consent, than those that are less capable.468
Finally, the Draft Guideline on Pediatric Trials divides risk
into two separate categories, Minimizing Risk46 9 and Minimizing
Distress.47 0 The section on minimizing risk states that research-
ers must take every precaution to anticipate and reduce the risk
of physical injury resulting from participation.471 Researchers
must understand the level of toxicity of the drug studied, and
maintain a staff that is sufficiently trained and knowledgeable in
studying and treating pediatric patients.472 The trial should in-
464. See id. (explaining that because children are legally dependent on their par-
ents, "fully informed consent should be obtained from a legal guardian in accordance
with regional laws or regulations."). Researchers, however, do not have to obtain pa-
rental consent for children who are classified as mature minors or emancipated minors.
Id. Indeed, "[e]mancipated or mature minors (defined by local laws) may be capable
of giving autonomous consent." Id.
465. See id. (stating that "[a]ll participants should be fully informed about the
study in language and terms they are able to understand").
466. Id. Article 2.6.3 states that "[plarticipants should assent to enroll in a study
(age of assent to be determined by IRB/IECs). Participants of appropriate intellectual
maturity should personally sign and date either a separately designed written assent
form or the written informed consent." Id.
467. Id. Subjects must be made aware of their right to decline to participate in a
study or to withdraw at any time. Id. The right to withdraw must be respected, unless
"in the opinion of the investigator, parents, and IRB/IEC the welfare of the pediatric
patient would be jeopardized by their failing to participate in the study; the patient's
agreement or assent may be waived under such circumstances." Id.
468. See id. (stating that "[i]nformation that can be obtained in a less vulnerable,
consenting population should not be obtained in a more vulnerable population or one
unable to provide individual consent").
469. Id. art. 2.6.4.
470. Id. art. 2.6.5.
471. See id. art. 2.6.4 (stating that "[e]very effort should be made to anticipate and
reduce known hazards").
472. Id. This provision requires that
Investigators should be fully aware before the start of a clinical study of all
relevant pre-clinical and clinical toxicity of the medicinal product. Minimiz-
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clude the minimum number of participants and interventions
possible, and should be able to be stopped immediately should
an adverse reaction or hazard arise.4 7 3
The section of the Draft Guideline on Pediatric Trials enti-
fled Minimizing Distress recognizes pediatric subjects' emotional
and psychological vulnerabilities. 474 Article two, paragraph six,
section five states that to minimize subjects' distress level, all per-
sons involved in conducting the study should be experienced in
treating pediatric patients, and if a trial protocol was originally
used for a study on adult subjects, it should be redesigned for
use with children.475  This section then makes specific sugges-
tions designed to comfort children in the research environment,
such as using age-appropriate furniture, activities, and food,
minimizing the number of venipunctures and other invasive pro-
cedures, and always respecting the child's right to decline to par-
ticipate.476
ing risk in pediatric clinical studies requires that those conducting the study
be properly trained and experienced in studying the pediatric population, in-
cluding the evaluation and management of potential pediatric adverse events.
Id.
473. See id. (expressing that "every attempt should be made to minimize the
number of participants, consistent with good study design, and the number of proce-
dures. Mechanisms must be in place to assure that a study can be rapidly terminated
should an unexpected hazard be noted").
474. See id. art. 2.6.5 (recognizing that "[r]epeated invasive procedures may be
painful or frightening").
475. See id. (suggesting that to reduce stress," [d] iscomfort can be minimized if the
studies are designed and conducted by investigators experienced in the treatment of
pediatric patients," and that "[p]rotocols and investigations should be specifically
designed for the pediatric population, (not simply re-worked from adult protocols and
approved by a competent and experienced IRB/IEC")).
476. Id. Article 2.6.5 states,
Practical considerations to ensure that participants' experiences in clinical
studies are positive, and to minimize discomfort and distress include:
* personnel knowledgeable and skilled in dealing with the pediatric pop-
ulation and its age-appropriate needs, including skill in performing pe-
diatric procedures;
* a physical setting with furniture, play equipment, activities, and food,
appropriate for age;
" conducting studies in a familiar environment such as the hospital or
clinic where they normally receive their care;
" use of approaches to minimizing discomfort of procedures, e.g. topical
anesthesia to place IV catheters;
* in-dwelling catheters rather than repeated venipunctures for blood
sampling;
" collection of some blood samples when routine clinical samples are ob-
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III. THE PARTIES TO THE ICH AND THE ICH STEERING
COMMITTEE SHOULD ADOPT THE PROTECTIONS SET
FORTH IN THE DRAFT GUIDELINE ON PEDIATRIC TRIALS
WITH SOME MODIFICATIONS
The Draft Guideline on Pediatric Trials takes definite steps
toward clarifying the ICH GCP in areas that address the unique
requirements of working with children. Although specific guide-
lines for pediatric research should eventually be adopted at a
broader international level, the ICH's limited membership and
partnership with non-governmental entities makes it an appro-
priate place to start refining the current international regulatory
scheme.477 Eventually, the parties to the ICH and the ICH Sec-
retariat should adopt the Draft Guideline on Pediatric Trials,
with some modifications, because it will provide necessary clarifi-
cation on issues arising in pediatric research.
A. The ICH Is a Good Place To Start Improving Pediatric
Medical Research Regulations
The ICH provides a good forum to begin refining pediatric
medical research regulations. Unlike some of the other interna-
tional organizations that have addressed this topic,47 the ICH
has a limited number of participants, making it easier for the
parties to agree on issues of greater specificity.4 7 9 Moreover, cur-
rent regulations in the United States, Europe, and Japan do not
differ from each another dramatically: all three entities cur-
rently have regulations limiting the level of risk in pediatric trials
to low or minimal,4"' and all allow for the child subject's involve-
ment in research participation decisions.481 Due to these simi-
larities on fundamental issues, none of the participants would
mined... [t]he participant's right to refuse further investigational pro-
cedures must be respected.
Id.
477. See supra note 169 and accompanying text (describing consultation process
for CIOMS/WHO Guidelines).
478. Id.
479. See supra note 97 and accompanying text (describing cultural differences im-
peding international human research regulation).
480. See supra notes 290-97, 322-26, 376-78 and accompanying text (describing
U.S. regulations on risk, CPMP Guideline for Children on risk, and New Japanese GCP
on risk).
481. See supra text accompanying notes 249-72, 319-20 367-75 (describing U.S.,
CPMP Guideline for Children, and Japanese GCP regulations on assent).
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need to incorporate new standards that are completely foreign
to their current regulations.
Additionally, because the pharmaceutical industry is an ac-
tive participant in the ICH, the ICH GCP and other ICH docu-
ments have great potential to effect research positively, in a way
that national regulations and current international documents
have not. Although past international guidelines have included
input from the medical community, 4 2 many national regula-
tions, such as those in the United States, do not apply to pri-
vately funded research.483 Because the pharmaceutical industry
sponsors the majority of privately funded research on human
subjects, 48 4 its participation in creating guidelines that it would
agree to follow, is crucial.
Finally, the ICH's overriding goal is creating and marketing
safe, effective medications, in the most efficient manner possi-
ble.48 5 In this process, however, the ICH must not only focus on
the physical needs of patients, but also on the research subjects'
psychological state and liberty interests, a point that has been
reiterated throughout international human research guide-
lines.4 6 The ICH must defend these basic principles with re-
spect to pediatric subjects.
B. Despite Some Weaknesses, the Draft Guideline on Pediatric Trials
Takes Significant Steps To Improve the Standards for
Pediatric Research Set Forth in the ICH GCP
The ICH GCP was insufficient to protect the safety and lib-
erty interests of pediatric patients adequately. Specifically, its
provisions on informed consent and level of risk are too vague
and are in need of clarification. Additionally, the ICH GCP does
not contain special requirements for IRBs that review pediatric
trials. Doing so would improve local input into research proto-
482. See supra note 127, 169 and accompanying text (explaining medical commu-
nity's movement for new guidelines resulting in Helsinki Declarations), and CIOMS/
WHO inclusion of medical schools' opinions).
483. See supra note 243 and accompanying text (stating that U.S. regulations do
not apply to privately funded research).
484. See supra note 16 and accompanying text (indicating that pharmaceutical re-
search accounts for most research using human subjects).
485. See supra note 385 and accompanying text (explaining ICH goals).
486. See supra note 149 and accompanying text (explaining Helsinki II's provision
on subject's psychological state).
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cols by including IRB members that are competent and knowl-
edgeable on children's issues.
With regard to the child's involvement in research participa-
tion decisions, although the ICH GCP specified that the child
subject should be informed about the trial and give his consent
to the extent that he is able, it did not provide any guidance on
how to implement this requirement.4 "7 It neither explained
which factors the IRB or IEC should review when determining a
subject's capacity to provide consent or assent,488 nor did it dis-
cuss what type of information should be conferred upon the sub-
ject.4 89 It is important to clarify these guidelines, as ambiguity in
this area can result in many subjects being deprived of their
right to be included in the research participation decision. Sig-
nificantly, allowing a child to participate in making this decision
may contribute to a trial's success, as it may enhance the child's
willingness to cooperate in the study, as well as improving the
child's self esteem.49 ° In contrast, depriving a child of this input
may have significant negative implications for the child's future
opinion and trust of the medical community.491 Most impor-
tantly, involving the child in the research participation decision
is the best way to promote rights for pediatric subjects that are
already granted to all other research subjects in every interna-
tional guideline since the Nuremberg Code. The importance of
granting these rights to children has been affirmed by the inter-
national community's overwhelming support for the CRC, which
specifically grants children the right to participate in decisions
that effect their lives.492
The EWG on Pediatric Research took some steps to clarify
the ICH GCP's stance on informed consent in the Draft Guide-
line on Pediatric Trial's paragraph on consent. First, this para-
graph, like the U.S. regulations, uses the term assent, rather
487. See supra notes 426-29 and accompanying text (explaining ICH GCP's regula-
tions on assent).
488. Id.
489. Id.
490. See supra note 80 and accompanying text (explaining benefits of allowing
child subjects to contribute to research participation decision-making).
491. See supra note 82 and accompanying text (explaining opinions suggesting that
ignoring child's decision may result in future distrust of medical community and par-
ents)
492. See supra note 225 and accompanying text (stating that 191 countries ratified
CRC).
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than consent, to refer to the child's agreement to participate in a
trial.493 Using the term assent rather than consent will give the
ICH and the EWG on Pediatric Trials a specific term to define
and refer to that is distinct from the term used for competent
adults. 494 Additionally, the EWG on Pediatric Trials adopted the
CPMP's provision stating that a child's refusal to participate in a
study should be binding on the researcher,495 unless participa-
tion is necessary for the child's health or survival. This provision
shows respect for the child's liberty interests and autonomy, as
called for in the CRC, while protecting his health and safety.
Although the consent paragraph in the Draft Guideline for
Pediatric Trials helps to clarify some issues, there is still room for
improvement during the consultation period. Although the
EWG was correct in not adopting a strict age requirement for
assent 496 that may infringe on national sovereignty, the EWG
should provide more specific guidelines to help IRBs determine
which children are capable of providing assent. Like the provi-
sions for informed consent for adults, the Draft Guideline on
Pediatric Trials should be revised to include a list of the type of
information that should be provided to the pediatric participant,
subject to IRB review and revision, to enable him or her to give
adequate assent. Supplementing the text of the Draft Guide-
lines on Pediatric Trials with these provisions would make them
more practical and comprehensible for local IRBs and IECs.
The parties to the ICH would be also likely to accept these
new assent provisions. In the United States, multiple commenta-
tors have suggested that the provisions in the Common Rule re-
garding assent are too vague, allowing for vast differentiation be-
tween research institutions.497 Furthermore, clearer guidelines
on this subject may help to ameliorate some of the human rights
concerns expressed by some European countries, particularly
493. See supra notes 251-52 and accompanying text (explaining the difference be-
tween assent, permission, and consent in U.S. regulations).
494. See supra notes 463-67 and accompanying text (referring to consent provisions
of Draft Guideline on Pediatric Trials).
495. See supra note 320 and accompanying text (discussing CPMP's provision that
child's refusal to participate must be respected).
496. See supra note 84 and accompanying text (describing AAP suggestion that
children should be able to provide assent at age seven).
497. See supra notes 291-97 and accompanying text (describing critic's views of U.S.
regulations).
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Germany.498 Finally, although Japan has been historically hesi-
tant to address the issue of informed consent at all, recent
surveys499 and the New Japanese GCP and Notes on Enforce-
ment,5"' indicate that this country is ready for more progressive
guidelines in this area.
The ICH GCP also inadequately described the level of risk
to which children can be exposed in research trials. Although
the ICH GCP permits children to be involved in low risk non-
therapeutic research, unlike the U.S. Common Rule or the Bi-
omedical Convention, the term low risk not defined.0 1 This de-
ficiency is potentially very dangerous, as even in the United
States, which has defined the term minimal risk, there is great
disparity in how this phrase is interpreted. 0 2 By not defining
the term minimal risk at all, the ICH GCP left its interpretation
completely in the hands of local IRBs, which may be danger-
ous.
5 0 3
The EWG on Pediatric Trials takes significant steps to de-
fine this term more completely, similar to the CPMP Guideline
for Children. The Draft Guideline on Pediatric Trials thor-
oughly explains special physical risks for children of different
age groups and details means of minimizing both physical and
psychological strain on subjects. 504 As with the CPMP Guideline
for Children, as well as the Biomedical Convention, the Draft
Guideline on Pediatric Trials also gives concrete examples of
which trial methods are safe and which are unsafe for various
age groups.50 5 These provisions represent a significant improve-
ment over both the ICH GCP and other international docu-
498. See supra note 211 and accompanying text (describing German criticisms of
Biomedical Convention).
499. See supra note 344 and accompanying text (citing polls indicating new Japa-
nese attitudes toward informed consent).
500. See supra note 371 and accompanying text (explaining that New Japanese
GCP allows children to participate in research decisions).
501. See supra note 432 and accompanying text (citing ICH GCP's provision for
risk in nontherapeutic trials).
502. See supra note 295 and accompanying text (describing different interpreta-
tions of minimal risk).
503. See supra notes 1-9, 297 and accompanying text (describing problems of group
think and IRB members that are sympathetic to medical community)
504. See supra note 325 and accompanying text (citing Guideline for Children pro-
visions on risk).
505. See supra note 326, 204-06 and accompanying text (describing minimal risk
provisions in Guideline for Children and Biomedical Convention).
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ments for protecting pediatric subjects' physical and emotional
well-being."'
Even if the Draft Guideline on Pediatric Trials is accepted
with the changes proposed above, a great deal of discretion still
lies in the hands of the local IRBs who ultimately decide which
trials are acceptable and which are not. For this reason, the
EWG on Pediatric Trials was correct in adopting the AAP's sug-
gestion that IRBs who regularly review children's research proto-
cols should include or consult with pediatric experts.5 °7 To ame-
liorate logistical problems that may arise in small institutions, the
ICH GCP may adopt a provision similar to that of the New Japa-
nese GCP,5 °a which allows for one specialized IRB that would
provide opinions for protocols at several small institutions. Fi-
nally, the EWG on Pediatric Trials should require that IRBs re-
viewing protocols that will be conducted in developing countries
should include an anthropological or sociological expert to eval-
uate local customs and opinions on informed consent.50 9 This
scheme would help to further improve issues of ethnic diversity
addressed in the CIOMS/WHO Guidelines.510 Because IRBs are
crucial in determining which trials can be carried out on chil-
dren, it is of utmost importance that IRB members are exper-
ienced and knowledgeable in issues that are unique to pediatric
research and in local traditions.
CONCLUSION
The Draft Guideline on Pediatric Trials makes significant
progress in providing practical, comprehensive guidelines for in-
stitutions conducting research on children. Specifically, the
EWG on Pediatric Trials has made great progress in identifying
506. See supra note 68-70 and accompanying text (describing importance of consid-
ering psychological risks along with physical risks).
507. See supra note 259 and accompanying text (describing AAPs suggestion to in-
clude pediatric experts on IRBs).
508. See supra note 362 and accompanying text (citingJapanese GCP provision that
states that small institutions can have shared IRBs).
509. See supra notes 97, 168 and accompanying text (describing cultural differ-
ences in concepts of informed consent and CIOMS/WHO requirement that IRBs re-
viewing trials in developing countries should include member familiar with local cus-
toms and traditions).
510. See supra note 97 and accompanying text (explaining that CIOMS/WHO
Guidelines addressed issues regarding trials in developing countries and that cultural
differences effect attitudes on informed consent).
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and describing special physical and psychological risks for inves-
tigators and IRBs to consider when reviewing pediatric studies.
The Draft Guideline on Pediatric Trials could, however, be im-
proved in the areas of informed consent and IRB membership.
With regard to informed consent, the EWG should provide
clearer guidelines for determining which children are capable of
providing assent as well as what information should be provided
to these children. The EWG should also mandate, instead of
merely suggest, that IRBs that review pediatric protocols should
include pediatric specialists. By implementing these provisions,
along with the existing draft guidelines on risk, the ICH will be
able to end some of the injustices that have plagued pediatric
research, protect pediatric subjects' rights in the future, and
meet their goal of producing safe, effective medications in the
most efficient manner possible.
